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Kurzzusammenfassung 
Das humane Zytomagalovirus (HCMV) ist weit verbreitet, und mehr als die Hälfte der 
Bevölkerung in den entwickelten Ländern und fast die gesamte Bevölkerung in den 
Entwicklungsländern ist mit dem Virus infiziert. Es ist somit eines der erfolgreichsten und am 
weitesten verbreiteten humanen Pathogene. Obwohl sehr viel Arbeit und Energie in die 
Erforschung des Viruses investiert wurden, sind sehr viele Fragen bezüglich seiner Biologie noch 
immer offen, welches teilweise durch sein für Viren riesiges Genom und damit einhergehende 
immense Kodierungskapazität und Komplexität erklärt werden kann. Ein großer Teil der vom 
Virus kodierten Proteine sind bisher noch nicht funktionell charakterisiert worden, allerdings 
haben vorhergehende Studien gezeigt, dass nur eine Minderheit aller CMV Proteine essentiell für 
die virale Replikation sind, wohingegen die überwältigende Mehrheit der viralen open reading 
frames (ORFs), besonders in den terminalen Regionen des Genoms, für Proteine kodieren, deren 
Aufgabe es ist, dem Wirtsimmunsystem entgegen zu wirken. Das Virus ist durch Millionen von 
Jahren von Ko-evolution so gut an den Wirt angepasst, dass das Überstehen der Infektion und die 
Beseitigung des Virus durch das Immunsystem dem Wirt keinen Schutz gegen Reinfektion 
verleihen. Wegen dieser langen Ko-evolution sind CMVs, isoliert von verschiedenen Spezies, 
außerdem ausgesprochen speziesspezifisch und HCMV kann keine Versuchstiere infizieren. 
Deshalb müssen die Zytomegalievieren der entsprechenden Versuchstiermodelle als Modell 
System für in vivo Studien verwendet werden. In dieser Studie präsentieren wir eine umfassende 
Charakterisiereng des Rhesus-Zytomegalovirus (RhCMV), welches das am nächsten verwandte, 
verwendbare Model zur Untersuchung von HCMV darstellt. Zur genaueren Beschreibung des 
publizierten RhCMV BAC (bacterial artifical chromosom) (Stamm 68-1), welcher die Grundlage 
für alle hergestellten RhCMV Mutanten darstellt, wurde dieser von uns unter Einsatz von next-
generation sequencing (NGS) sequenziert und die kodierten ORFs mittels vergleichender 
Genomuntersuchungen neu bestimmt. Hierdurch waren wir in der Lage zu zeigen, dass dieses 
CMV deutlich größere Homologie zur humanen Variante hat als bisher angenommen, da sich die 
meisten ORFs ohne Homologie zu HCMV ORFs nicht bestätigen ließen. Darüber hinaus konnten 
wir nun, auf unseren vorherigen Studien zur Etablierung von RhCMV als viralem Vektor zur 
Entwicklung von T-Zell Vakzinen aufbauend, das neu annotierte RhCMV 68-1 Genom zur 
Konstruktion von mehreren Deletionsmutanten mit erhöhter in vitro und in vivo Attenuierung 
verwenden, um einen Impfvektor der zweiten Generation zu entwickeln. Das Ziel war, weiterhin 
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eine starke und andauernde Immunantwort, besonders gegen die eingefügten fremden Antigene, 
zu induzieren, aber zur gleichen Zeit eine reduzierte Pathogenität und Ausbreitung des Impfvektors 
zu erreichen. Unsere ersten Kandidaten waren die RhCMV Homologe des HCMV pp65 Proteins, 
pp65 a und b. Unglücklicher Weise führte eine Deletion dieser ORFs nicht zu einer erhöhten 
Sicherheit des Vektors. Ganz im Gegenteil, diese Mutante replizierte in vivo zu deutlich höheren 
viralen Genomkopien verglichen mit dem Wildtyp, die Deletionsmutante zeigte also eine höhere 
Virulenz verglichen mit dem parentalen Virus. Dieser Unterscheid lässt sich höchstwahrscheinlich 
mit der Abwesenheit von pp65 spezifischen CD8+ T-Zellen nach Infektion mit der Mutante 
erklären. pp65 ist das Hauptantigen für T-Zellen, und die Mehrheit der CMV spezifischen T-Zellen 
erkennen Epitope dieses Proteins. In Abwesenheit von pp65 spezifischen T-Zellen in der frühen 
Phasen der Infektion ist es dem Immunsystems des Wirtes unmöglich die virale Replikation zu 
kontrollieren und die Deletionsmutants kann ungehemmt replizieren. Ein weiterer potentieller 
Kandidat für einen attenuierten RhCMV Vektor war ein anderes wichtiges Tegumentprotein, pp71, 
ein Protein, welches in der Evasion der intrinsischen Immunantwort eine Rolle spielt, indem es die 
in den PML-bodies enthaltenden Proteine Daxx, Bcl-AF1, Rb und ATRX degradiert. Diese 
Mutante zeigte eindeutig höhere Attenuierung verglichen mit der pp65 Deletionsmutante und 
unsere in vivo Resultate deuten an, dass, obwohl dieses Virus eine sehr starke T-Zell Antwort 
gegen die eingefügten SIV Antigene induziert, es nicht von den geimpften Affen im Urin 
ausgeschieden wird und dass es auch nicht von einem CMV-positiven auf einen naiven Rhesus 
Makaken mittels adoptivem Leukozyten Transfer übertragen werden kann. All diese Ergebnisse 
implizieren pp71 als vielversprechenden Kandidaten für die Entwicklung eines auf attenuiertem 
HCMV basierenden HIV-Impfstoffs für klinische Studien in der näheren Zukunft. 
 
Schlagworte: 
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Abstract 
Human cytomegalovirus (HCMV) infects half of the population in the developed world and nearly 
every person of the developing world, making it one of the most successful and widespread human 
pathogens. Although a lot of research has been conducted to unravel the biological properties of 
this virus, there is still a lot of work to be done given the high complexity of the virus due to its 
huge genome size and coding capacity. While most virally encoded proteins have not been 
functionally characterized or properly mapped, it is nevertheless apparent that only a minority of 
all CMV proteins are essential for viral replication in vitro. However, most viral open readings 
frames (ORFs), especially in the terminal regions of the genome, encode for proteins involved in 
evading the host adaptive and innate immune systems. This results in a universal inability of the 
infected host to clear the virus despite ongoing immunological responses directed at CMV as well 
as no protective immunity against re-infection. These immune evasion mechanisms are the product 
of millions of year of virus-host coevolution that have additionally resulted in tight species 
specificity that thoroughly precludes infection of non-host species and complicates in vivo studies. 
Here we further characterize the rhesus cytomegalovirus (RhCMV) as the closest, usable in vivo 
model presently available for understanding HCMV. We resequenced the RhCMV strain 68-1 
BAC and re-annotated the entire genome using comparative genomics. By doing so, we were able 
to show that this CMV shows substantially higher homology to the human version than previously 
assumed, because most ORFs without homologues in HCMV could not be confirmed by our 
system. Furthermore, given our previous work establishing RhCMV as a delivery vector for the 
development of T-cell vaccines, we now used our newly annotated genome of RhCMV 68-1 to 
construct several deletion mutants with increasing in vitro and in vivo attenuation with the goal to 
create a 2nd generation vaccine vector that retains high and long lasting immunogenicity, especially 
against the inserted foreign antigens, but at the same time shows reduced pathogenicity and spread. 
Our first deletion candidates, the RhCMV homologues of HCMV pp65, RhCMV pp65 a and b, 
did not achieve the goal of superior safety. On the contrary, the virus replicated in vivo to 
significantly higher viral copy number compared to the WT, describing the first observed case in 
RhCMV where a deletion mutant showed higher virulence than the parental virus. This increase is 
most likely connected to the absence of pp65 specific CD8+ T-cells in the deletion mutant. Pp65 
is the major T cell antigen and the majority of CMV specific T-cells are directed against this very 
protein, underlying its importance for the generation of a strong anti-CMV immune response and 
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explaining why the virus is more virulent in the absence of pp65 specific T-cells early in infection. 
Our second deletion candidate was another important tegument protein, pp71, a protein involved 
in intrinsic immune evasion through degradation of the PML-body associated proteins DAXX, 
Bcl-AF1, Rb and ATRX. This virus showed substantially higher attenuation than the pp65 deletion 
mutant and our in vivo results indicate that although the virus induces a very strong T-cell response 
against the inserted SIV antigens, it is not shed in the urine of vaccinated monkeys and cannot be 
transferred to CMV naïve animals by adoptively transferring leukocytes from a vaccinated 
monkey. All these results imply pp71 as a promising potential candidate for the development of 
an attenuated HCMV based HIV-vaccine for clinical trials in the foreseeable future. 
 
Key words: 
Cytomegalovirus, CMV, Rhesus macaques, Vaccine, Vectors 
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Extended Summary 
1. General Introduction 
1.1 Herpesviruses 
Herpesviruses form the family herpesviridae within the order herpesvirales, an order of large 
double stranded DNA viruses with a broad host spectrum ranging from molluscs 
(malacoherpesviridae) over fish and amphibians (alloherpesviridae) to birds, reptiles and 
mammals (herpesviridae), including humans [1, 2] (for a recent review see [3]). The origin of the 
family is not fully certain, but genetic similarities point to a relationship with the order 
caudovirales, a diverse order of double stranded DNA bacteriophages, indicating that the earliest 
ancestors of herpesviruses might have evolved more than 2 billion years ago [4, 5]. 
 
 
Fig.1: Cladogram depicting relationships among viruses in the order Herpesvirales, based on the conserved 
regions of the terminase gene. The Bayesian maximum-likelihood tree was rooted by using bacteriophages T4 and 
RB69. Numbers at each node represent the posterior probabilities (values >90 shown) of the Bayesian analysis. (Figure 
taken from Michel et al., Emerg Infect Dis 16(12), 1835-1843 (2010) [6]). 
 
The herpesviridae can be further subdivided into 3 subfamilies, the alpha-, beta- and 
gammaherpesvirinae, which in turn are each made up of 4 genera. All in all, there are 8 known 
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human herpes viruses (HHV1 – HHV8) to date, members of which can be found in all subfamilies. 
These subfamilies show significant differences in cell tropism, latency and pathogenesis, whereas 
the genome organization, general virion composition and appearance and the core proteins are 
largely conserved throughout the entire family. With a genome size ranging from 124 – 230 kb in 
length [7], herpesviruses contain some of the largest viral genomes for eukaryotic viruses and are 
surpassed only by some members of the nucleocytoplasmic large DNA viruses (NCLDVs, e.g. 
pox- or mimiviridae) and white spot syndrome virus (WSSV) a member of the family nimaviridae 
[8]. The genome exists as a monopartite, linear, dsDNA, made up of repeated sequences in direct 
or inverted orientation separated by non-repeated (unique) segments. For most alpha- and beta-
herpesviruses, the genome structure presents in the classical herpesviral form with two unique 
regions (UL, unique long) and (US, unique short) divided by terminal and internal repeats, whereas 
the genome of gammaherpesviruses contains variable numbers of internal repeats [9]. 
 
 
Fig.2: Herpesvirus genomes. Large genetic repeat sequences are boxed. Direct repeat DNA sequences are shown in 
blue, indirect repeat DNA sequences are shown in red; UL (long unique region); US (short unique region). The genome 
of HSV and CMV have two sections, the unique long (UL) and the unique short (US), each of which is bracketed by 
two sets of inverted repeats of DNA. The inverted repeats facilitate the replication of the genome but also allow the 
UL and the US regions to invert independently of each other to give four different genome configurations or isomers. 
VZV has only one set of inverted repeats and can form two isomers. EBV exists in only one configuration with several 
unique regions surrounded by direct repeats. (Figure taken from Prof. Dr. Gehan Aly El-Sherbeny, Part (3): Medical 
Virology, Chapter (10) Laboratory Diagnosis of Viral Disease, 
http://dc231.4shared.com/doc/1OJVQm4w/preview.html). 
 
The orientation of the unique segments within the genome is variable, and during the viral 
genome replication, up to 4 different isomers can be produced. Depending on the virus these 
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different isomers can be produces in equal (e.g. HSV-1) (stoichiometric) or varying (e.g. VZV) 
ratios [10-15]. The members of this viral family form enveloped virions of spherical to 
pleomorphic appearance which are 150-200 nm in diameter. The envelope contains numerous 
glycoproteins necessary for budding and entry and surrounds a capsid with T=16 icosahedral 
symmetry consisting of 162 capsomers [16] and a layer of an amorphous mixture of proteins called 
the tegument separating the envelop and the capsid [17]. All in all, these virions are a highly 
intricate structure comprising potentially more than 60 different structural proteins [18]. 
 
 
Fig.3: Structure of a herpesviral particle. (Figure taken from the from ExPASy’s web-resource ViralZone, 
subsection Herpesviridae, http://viralzone.expasy.org/all_by_species/176.html). 
 
Herpesviruses have co-evolved with their respective hosts for millions of years, maybe even 
since the evolution of their host species, so they show a high degree of species specificity and 
zoonotic infection are rare [19-21]. 
 
1.2 HHV5 (human cytomegalovirus, HCMV)  
The prototypic member of the β-herpesvirus subfamily is HHV5, commonly known as the human 
cytomegalovirus (HCMV). This virus is highly widespread reaching seroprevalence levels of 
around 50% in the United States [22] and close to 100% in the developing world [23, 24]. 
Seroprevalence increases with age, and more that 90% of tested individuals aged 80 or older in the 
US are CMV positive [25]. 
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Fig.4: CMV disease mechanisms. In addition to CMV antigenemia, a common indicator of active infection, examples 
of end CMV organ disease commonly occurring in AIDS patients and in transplant recipients are shown. Image 
credits: antigenemia, pp65+ cell in a leukocyte cytospin preparation (M. Boeckh); retinitis, ophthalmoscopic view of 
retinal hemorrhage and inflammation (E. Chuang); ependymitis, periventricular inflammation detected by MRI (left; 
reproduced from Drew and Bates: Cytomegalovirus. In: Sexually Transmitted Diseases, Holmes K., Sparling P., 
Mardh P.A. et al. (Eds). McGraw-Hill Professional, New York, NY, 313-326 (1999) [26] with permission from 
McGraw Hill) and postmortem brain specimen (right; C. Marra); hepatitis, microabscesses associated with CMV 
hepatitis (A. Limaye); esophagitis, endoscopic view of shallow esophageal ulcers (G. McDonald); colitis, deep ulcer 
in a colonic biopsy (G. McDonald); pneumonia, chest CT scan of CMV pneumonia (M. Boeckh). (Figure taken from 
Boeckh and Geballe, J Clin Invest 121(5), 1673-1680 (2011) [27]). 
 
While the primary infection is generally asymptomatic, some patients can present with 
mononucleosis-like clinical symptoms, including fatigue, fever and myalgia [28, 29]. The threat 
this virus poses is not to the fully immunocompetent, but to individuals with an 
immunocompromised immune system like AIDS patients and transplant recipients. Here the 
symptoms are significantly more severe and can include retinitis even as severe as to cause 
blindness, pneumonia, diarrhea, ulcers in the digestive tract, hepatitis, encephalitis, behavioral 
changes, seizures and coma [27]. Complications resulting from these symptoms can be fatal [30, 
31]. Additionally, the virus poses a severe threat to transplant recipients, because primary CMV 
infection or CMV re-activation from either the patient or the transplant can lead to graft rejection 
[32]. Another group of immunocompromised individuals that are at high risk of suffering from 
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severe consequences from CMV infection are neonates. Here, the virus is the leading 
environmental cause of childhood hearing loss, the most common sequelae following congenital 
CMV infection [33-35], accounting for approximately 15%-21% of all hearing loss at birth in the 
United States [36, 37]. CMV-related hearing does not manifest immediately after birth, and 
children with potential congenital CMV infection have to be continually monitored for progressive 
or late-onset hearing defects. Additionally, congenital CMV infection is as common a cause of 
serious developmental disability as are Down syndrome and neural tube defects [38]. Given that 
Cytomegalovirus (CMV) is one of the most frequently transmitted intrauterine infections, 
detectable in an estimated 0.64%-0.70% of live births worldwide [39, 40], the number of families 
impacted by this virus is enormous and the cost put on the US health care system astronomical, 
estimated to be upwards of 2 billion dollars annually [41]. Given the hardship caused by the virus, 
it is not surprising that the Institute of Medicine (IOM) of the National Academy of Sciences 
(USA) has declared the development of a CMV vaccine the highest priority in 1999 [42], but so 
far none of the multiple studies performed resulted in the successful development of an effective 
vaccine candidate [43-56]. 
 
1.3 Cell Entry and Gene Expression  
The viral lifecycle of the cytomegalovirus begins with the attachment to the target cell via the 
glycoproteins on the viral membrane. Multiple glycoproteins are involved in this step and the exact 
details are still elusive [57]. The same is true for the actual receptor the virus uses to enter the host 
cell. Multiple different proteins have been proposes as CMV receptors and the downregulation of 
many of these candidates indicated a role in virus entry as the amount of virus that was able to 
enter the cell was significantly diminished in these cells compared to control cells, but virus entry 
was not completely abrogated, identifying the proteins as potential co-receptors, but not as the 
main receptor for virus entry [58-63]. This situation is complicated by the fact that the virus seems 
to employ seperate strategies to enter different cell types. Whereas a complex formed by the 
glycoproteins gH/gL/gO together with gB is needed for entry into fibroblasts through attachment, 
receptor binding and subsequent membrane fusion [64-66], the mechanism by which the virus 
enters endothelial cells utilizes a pentameric complex made up of gH/gL/UL128/UL130/UL131A 
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to attach to the target cell and enter it by receptor mediated endocytosis and subsequent membrane 
fusion of the viral membrane with the endosome [60, 65, 67]. In either case, the virus enters the 
cell and the viral capsid and tegument are released into the cytoplasm [64]. Multiple early immune 
evasive functions are connected to the tegument proteins that are brought into the infected cell by 
the virus, so the release of the viral tegument represents an immediate early viral step to avoid 
detection by manipulating the host’s intrinsic immunity [68]. After the capsid is released into the 
cytosol, it is further transported along microtubules to the nucleus, where the viral DNA is injected 
through the nuclear pore [69, 70], and viral gene expression can occur. In all herpesviruses, gene 
expression is a highly regulated process in which the viral genes are expressed in three subsequent 
cascades (Immediate Early (IE, α), Early (E, β) and Late (L, γ)). The immediate early genes are 
the first genes to be expressed. Their expression is amplified by tegument proteins brought into 
the cell within the virion, but not solely dependent on them [71-73]. The IE genes have multiple 
functions including evading the innate immune response (see below), arresting the cell cycle at a 
point favorable for the viral replication [74-77] and, last but not least, transactivating the 
expression of the next stage of viral gene expression, expression of the E genes [78-83]. The E 
genes comprise the majority of the viral genes expressed throughout the lytic viral replication. 
Generally, the definition for an E gene is a gene that is not expressed without prior IE gene 
expression, but is not dependent on viral DNA replication like L genes [84]. Functionally E genes 
are highly diverse, and almost every nonstructural function known for herpesviruses is carried out 
by one or even multiple genes expressed with early kinetics. Additionally, genes involved in viral 
DNA replication will also be expressed with early kinetics, and the hereby initiated viral genome 
replication will in turn induce L gene expression [85, 86]. This last phase of viral genes expression 
can be subdivided into an early (E-L) and a late (L) phase (also termed γ1 and γ2). Most of the 
structural genes are expressed with late kinetics, and the assembly of new capsids will start in the 
nucleus at this point. These newly synthesized capsids, termed A capsids will mature to B capsids 
by incorporating the assembly protein (UL80.5), through which the viral DNA will be channeled 
into the immature capsid [87-92]. The now fully mature C capsid is exported by the nuclear egress 
complex through the nuclear membrane into the cytosol, where tegument proteins have 
accumulated [93, 94]. The capsid is coated in an inner and an outer layer of different tegument 
protein and further matures through the endoplasmic reticulum (ER). All viral glycoprotein 
expressed during viral replication have been synthesized into the ER and further mature through 
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the Golgi until they are anchored into trans-Golgi cisternae [95] or early endosomes [96-98]. When 
the virus now enters the ER, the immature capsids are transported through the ER and Golgi and 
the mature virions are enveloped in the trans-Golgi or the early endosomes from where they will 
be released through exocytosis [96].  
 
Fig.5: Life cycle of HCMV in a human cell. HCMV enters human cells either through direct fusion or through the 
endocytic pathway. The virus attaches to the cell via interactions between viral glycoproteins (e.g., gB and gH) and a 
specific surface receptor(s) (e.g., platelet-derived growth factor α), followed by the fusion of the envelope with the 
cellular membrane to release nucleocapsids into the cytoplasm. These nucleocapsids are translocated into the nucleus, 
where viral DNA is released. This initiates the expression of IE-1/IE-2 genes. Viral replication and maturation follow 
the stimulation and parallel accumulation of viral synthesis function. This process involves the encapsulation of 
replicated viral DNA as capsids, which are then transported from the nucleus to the cytoplasm. Secondary 
envelopment occurs in the cytoplasm at the endoplasmic reticulum (ER)-Golgi intermediate compartment. This is 
followed by a complex two-stage final envelopment and egress process that leads to virion release by exocytosis at 
the plasma membrane.  (Figure taken from Crough and Khanna, Clin Microbiol Rev 22(1), 76-98, (2009) [99]). 
 
1.4 CMV Latency 
Besides this lytic replication in which the virus will eventually kill the host cell, herpesviruses can 
also enter a latent phase in which the viral genome will persist in the host. The pattern of viral gene 
expression will shift substantially from genes that are highly expressed in lytic infection to specific 
latency associated genes expressed during latency [100]. All Herpesviruses have the ability to 
persist in their respective host for the entire lifetime of the host after primary infection [101], but 
the appearance, the location and extend of latency varies greatly between the different subfamilies. 
Whereas gammaherpesviruses enter latency shortly after infection of B cells [102-104], 
alphaherpesviruses will enter latency as efficiently in neurons like the trigeminal ganglia in case 
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of HSV-1 and VZV [105-107]. The Cytomegalovirus, the prototypical betaherpesviruse on the 
other hand, is thought to have a very different form of latency in which it infects monocytes, white 
blood cells produced in the bone marrow, that serve as precursors to macrophages and dendritic 
cells [108-110]. CMV is capable of infecting these cells, but it is not able to fully replicate in 
monocytes and to produce virus progeny, so the viral genome is maintained as an episome in the 
infected cell and the virus remains latent. When these infected monocytes are activated and mature 
to macrophages, the cells become fully permissible to lytic viral replication and the virus 
reactivates and produces new infectious viral particles, so the infected monocytes serve as a 
reservoir for constant viral re-activation [111, 112]. Although a change in gene expression patterns 
has not been reported in this instance, CMV does express genes that will be preferentially 
expressed during latency as was shown for a clinical isolate of CMV infecting CD34+ stem cells 
[113-116]. In this experiment, the expression pattern changed towards the expression of UL133–
UL138, genes encoded in the viral ULb’ region, a region not present in some fibroblast adapted 
strains of HCMV like AD169. This constant switch between lytic replication and latency is a 
characteristic and important feature for all herpesviruses, because it characterizes their biological 
niche as opportunistic pathogens. 
 
1.5  Immune evasion by Cytomegalovirus 
The development of an effective CMV vaccine proved to be more challenging than initially 
assumed due to the fact that even a pre-existing primary CMV infection does not confer protective 
immunity against re-infection, not against the same clade, the same strain or even the same isolate 
[117-120]. This interesting phenomenon severely complicates the creation of an effective vaccine, 
because if successfully fighting the infection does not generate protective immunity, how can an 
attenuated life virus or a subunit vaccine change this outcome? The reason for not establishing a 
sufficient immune response to avoid reinfection is even more curios given that the virus will indeed 
induce a very strong B- and T-cell response [121, 122], but although up to 10% of all T-cells in an 
individual can be directed against various CMV epitopes [121], it still does not prevent re-infection 
or re-activation. This can lead to individuals being infected by multiple strains of CMV either 
simultaneously or seqeuentially, something that has been observed not only in humans [117-120], 
but also in wild mice infected with multiple strains of MCMV [123]. After decades of research the 
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explanation for the efficient evasion of the host immune system by the virus was found in dozens 
of viral genes expressed during the viral life cycle, directed against every single aspect of the 
immune response to insure viral survival and persistence [124]. Although all herpesviruses encode 
for immune evasion genes, many of these genes are encoded in the terminal regions of the viral 
genome. Whereas the genes encoded in the central part of the genome in a given herpesvirus show 
fairly well conservation not only between members of the same subfamily but to a certain degree 
even between all herpesviruses [125] this does not hold true for viral proteins encoded in the 
terminal regions of the genome. These genes are mostly virus specific and are not conserved even 
throughout members of the same subfamily. As a result of this, every single member of the 
herpesvirus family encodes for its own set of viral immune evasion genes. 
 
1.5.1 Evasion of the innate immune response 
One of the earliest steps for the host to fight entering viruses is the innate immunity, a collection 
of broad, pathogen unspecific defense mechanism. These defense mechanisms are triggered by the 
pathogen either by interacting with a pattern recognition receptor (PRR) on the cell surface, like 
certain toll like receptors (TLRs), or by triggering a response by engaging an intracellular toll like 
receptors receptor or other intracellular receptors like MDA-5 and RIG-I [126]. All these receptors 
will recognize pathogen-associated molecular patterns (PAMPs) including DNA, RNA, 
Glycoproteins or LPS, so that the entire range of potential pathogen trying to infiltrate the cell will 
be detected by the cellular immunity [126]. Triggering a PRR will activate different, very intricate 
signaling cascades resulting in the activation of several pathways including the NF-κB-pathway 
[127], the IRF3- pathway [128] and eventually the JAK/STAT-pathway [128], all leading to the 
specific expression of cellular genes with anti-viral, anti-microbial or pro-inflammatory activity. 
Furthermore, some of the proteins synthesized by the cell in response to the detection of an 
infecting pathogen will be secreted and can signal in either an autocrine- or paracrine fashion to 
alert the neighboring cells and to attract different cells of the immune system [129]. 
This unspecific arm of the immune system is essential for the host in controlling viral 
infections and pathogenesis. As can be shown in several in vivo models and in humans with certain 
mutations of the IFN receptors or associated signaling molecules, lack of an effective  interferon 
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response will lead to a higher susceptibility, and to more severe viral infections shown for various 
different herpes viruses [130-133]. On the other hand, pretreatment of cells with interferon will 
put the cells into an antiviral state, impairing the ability of the virus to replicate to high titers [134, 
135]. As a result of this finding, recombinant IFN α has been used therapeutically to successfully 
control HCMV-induced retinitis during AIDS [136] and to control viremia following congenital 
infections [137]. 
To activate the NF-κB-pathway, triggering a PRR will lead to the phosphorylation of IKK-
α and IKK-β, two serine/threonine protein kinase whose activation will in turn lead to the 
phosphorylation and subsequent ubiquitination of the IκB protein complex [138]. IκB binds to 
both NF-κB subunits and inhibits their nuclear localization [139]. Ubiquitination of IκB will result 
in its proteosomal degradation [138], allowing NF-κB to translocate into the nucleus and to induce 
the transcription of important chemokines and cytokines like IL6, IL8 and IFNβ, all involved in 
activating and alerting other cell of the innate and adaptive immune system [140-144]. This protein 
expression is inhibited in the presence of HCMV, and further research revealed the immediate 
early protein 2 (IE2, IE86) was needed and sufficient for this blockage [145, 146], so HCMV 
developed a mechanism to efficiently undermine signaling through this important host defense 
pathway. 
NF-κB signaling can not only be inhibiting at its last step by inhibiting the synthesis of 
newly synthesized antiviral proteins, but also by interfering with cellular PRRs siganlling through 
the NF-κB-pathway. Protein Kinase R is an intracellular receptor activated by dsRNA which will 
be synthesized during transcription of complementary strands of the CMV genome. HCMV not 
only encodes for one, but two proteins (TRS1 and IRS1) with the capability to bind dsRNA. By 
hiding the dsRNA from the cellular receptor, the virus can ensure viral gene expression without 
triggering the PRR and alarming the innate immune response. TRS1 and IRS1 can substitute for 
the vaccinia virus (VV) RNA binding protein [147, 148], however, the role of these proteins in the 
context of HMCV infection has not been evaluated [149]. 
 Similar to the NF-κB-pathway, signaling through the IRF3-pathway also needs prior 
triggering of a PRR by the entering pathogen. The resulting phosphorylation cascade will lead to 
the phosphorylation of IRF3, which can now homodimerize and relocate to the nucleus where the 
dimer binds to its recognition site on the DNA, inducing the expression of a whole range of 
different proteins, including many with shown antiviral activity and the important cytokine IFNβ 
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[150]. Although reports exists describing HCMV pp65 as a potential inhibitor of IRF3 signaling 
[151, 152], these results were called into question, because the mutant virus used in both studies 
was a full deletion of the entire UL83 open reading frame effecting the expression of the upstream 
UL82 (pp71) ORF and resulting in an attenuated virus with significantly delayed gene expression 
[153]. A second pp65 deletion mutant with introduced stop codons instead of a full deletion did 
not inhibit IFNβ expression [153]. RhCMV on the other hand has been shown to effectively inhibit 
IRF3 phosphorylation, dimerization and nuclear localization completely abrogating any IRF3 
dependent signaling [148]. The viral protein for this phenotype has not been identified, but 
interestingly RhCMV is only capable to inhibit IRF3 signaling in rhesus fibroblasts, whereas 
human fibroblast infected with RhCMV show no inhibition of IRF3 nuclear localization or IRF3 
dependent gene expression (Malouli et al., unpublished data). 
 After the infected cell synthesizes IFNβ, either through the NF-κB- or the IRF3-pathway, 
this cytokine will be released from the cell where it can now signal either in a paracrine (to a 
different cell) or in an autocrine (to itself) fashion [144]. The interferon will bind the interferon-
α/β receptor (IFNAR), a cell surface protein that will bind all type I interferons and which is 
associated with the JAK1 and Tyk2 tyrosine kinases [144]. Upon ligand receptor binding, these 
two kinases autophosphorylate and phosphorylate the IFNAR, which will lead to the 
phosphorylation of two different Signal Transducer and Activator of Transcription (STAT) 
proteins, STAT1 and STAT2. Upon phosphorylation these two proteins dimerize and complex 
with IRF9 to form the ISGF3 (Interferon Stimulated Gene Factor 3) complex [144]. This protein 
complex relocates to the nucleus where it can bind to multiple ISRE (Interferon-Stimulated 
Response Element) promoters to induce the expression of interferon stimulated genes (ISGs) 
[144]. Like the genes expressed upon IRF3 signaling, many of these ISGs have proven antiviral 
activity [154], and successful JAK-STAT signaling transfers the cell into an anti-viral state [155]. 
This underlines the importance for CMV to inhibit JAK-STAT signalling, because if the virus was 
not inhibiting this signaling cascade, the infected cell would alarm all neighboring cells through 
the release of type I interferon rendering them less infectious and prepared for a potential infection. 
The human CMV immediate early protein 1 (IE1, IE72) can inhibit the binding of ISGF3 to the 
ISRE and by that block signaling through the JAK/STAT pathway [156]. The region of IE1 
responsible for this inhibition has been mapped, although different studies disagree about the exact 
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location of the active region [157, 158] and this function of IE1 is also conserved in RhCMV 
(Malouli et al, unpublished data). 
 Besides blocking of ISG synthesis by inhibiting the binding of the ISGF3 to the ISRE, 
CMV has developed multiple independent mechanisms to undermine signaling through the 
JAK/STAT pathway. Impaired Interferon signaling in cells infected with cytomegalovirus has 
been described independently by multiple groups [156, 159, 160], but different phenotypes 
explaining the compromised interferon response were found. Degradation [160-162] as well as 
absence of phosphorylation [160] has been described for many kinases and signaling molecules in 
the pathway, including JAK1, IRF9, STAT1 and STAT2. Interestingly, proteasome-dependent 
STAT2 degradation late in HCMV infection has been described for multiple different viral strains 
except HCMV Towne [161], but an explanation for this interstrain difference has not yet been 
found. Because the various signaling molecules and kinases are part of multiple independent 
JAK/STAT signaling pathways, degradation of single signaling molecules can effect stimulation 
by diffident cytokines. Type II interferon (IFNγ) induced JAK/STAT signaling through the IFNGR 
is also blocked by HCMV through the inhibition of phosphorylation and proteasomal degradation 
of multiple important players in the signaling pathway [162]. The viral proteins responsible for all 
the described phenotypes have not been identified so far. 
 Finally, there are two more described mechanisms utilized by the virus to derail the innate 
immune response. One involves the feedback loop that the JAK-STAT pathway has evolved in 
response to newly synthesized interferon that can signal in an autocrine fashion to restimulate the 
pathway. The pathway is negatively regulated by various cellular proteins [163], among them 
protein tyrosine phosphatases that will dephosphorylate proteins in the pathway, effectively 
shutting down the signaling. Lack of phosphorylation has been shown after HCMV infection and 
IFNγ stimulation [164] and the cellular tyrosine phosphatase SHP2 (Src homology region 2 
domain-containing phosphatase 2) has been shown to be involved in this phenomenon [164, 165]. 
What this implies is that HCMV evolves the capability to selectively activate the cellular tyrosine 
phosphatases SHP2 to manipulate IFN-induced phosphorylation of JAK1 and by that to diminish 
or shut down all JAK/STAT signaling pathways involving this kinase. 
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Fig.6: Herpesviruses encode proteins that help them to evade detection by pattern recognition receptors 
(PRRs). For example, the herpes simplex virus type 1 (HSV-1) proteins ICP34.5 and virion host shut-off protein (Vhs) 
prevent the recognition of viral nucleic acids by inhibiting autophagy and degrading viral RNA, respectively. 
Herpesviruses also inhibit signalling through PRRs using multiple mechanisms. Some are specific to individual PRRs; 
for example: HSV-1 ICP0 protein inhibits Toll-like receptor 2 (TLR2) signalling by stimulating the degradation of 
TLR adaptor molecules; and murine cytomegalovirus (MCMV) M45 protein inhibits the recruitment of receptor-
interacting protein 1 (RIP1) to DNA-dependent activator of IFN-regulatory factors (DAI). There are also more general 
mechanisms that target all PRRs; for example, human herpesvirus 8 (HHV8) ORF45 protein interacts with IFN 
regulatory factor 7 (IRF7) and inhibits its phosphorylation and nuclear translocation. Finally, several herpesvirus-
encoded proteins (such as HHV8 v-IRF3) inhibit transcription by interacting with nuclear factor-κB (NF-κB) and 
IRF3 and/or IRF7 in the nucleus. This prevents the interaction of these transcription factors with DNA, and the 
assembly of functional transcriptional complexes. (Figure taken from Paludan et al., Nature reviews. Immunology 
11(2), 143-154 (2011) [166]). 
 
 
1.5.2 Evasion of the intrinsic immune response 
The very first line of defense against any intracellular infection is always the intrinsic immunity. 
This immunity differs from the innate immunity, in that the proteins of the intrinsic immunity are 
constantly expressed and ready within a cell [167], whereas the expression of anti-viral interferon 
stimulated genes (ISGs) for instance, has to be induced after a given pathogen triggers a pattern 
recognition receptors (PRRs) like a toll like receptor [168, 169]. The best described members of 
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the intrinsic immunity have been found in connection with anti-HIV research, where cellular 
proteins like TRIM5α (Tripartite interaction motif five, splice variant α), a cellular protein capable 
of preventing retroviral uncoating, and APOBEC3G (Apolipoprotein editing complex 3 G), a 
cytidine deaminase that will randomly introduce cytidine to uracil nucleotide changes into the viral 
genome during retroviral reverse transcription leaving the resulting provirus inviable due to the 
multitude on nonsense mutations [170, 171], have been found to possess substantial antiviral 
activity. 
 In connection with herpesviruses, the part of the intrinsic immunity that has been shown to 
effectively inhibit viral propagation and spread is a protein complex that forms small dot like 
structure in the cellular nucleus, and that is known as ND10- or PML bodies [172, 173]. This 
protein complex consists permanently or transiently of more than 50 different cellular proteins 
[174], and many of them are involved in such diverse cellular functions as the DNA damage 
response, chromatin modification, the stress response, senescence, and protein stability, and there 
is growing scientific evidence linking ND10 function and protein modification with small 
ubiquitin-like modifier (SUMO) family members [173, 175, 176]. After intensive research, some 
of these proteins have been shown to directly interact with intruding viruses, including the 
promyelocytic leukaemia protein (PML), the small ubiquitin-like modifier 1 (SUMO1), the SP100 
nuclear antigen, the Death-associated protein 6 (DAXX) and ATRX, the protein responsible for 
alpha-thalassemia X-linked mental retardation when mutated [177]. The assembly of ND10-bodies 
is coordinated by sumoylated PML, and by SUMO interaction motif (SIM)-dependent interactions 
between PML and other sumoylated proteins [178], which in turn will lead to the recruitment of 
other important protein complex constituents like DAXX and ATRX [179-183]. These two 
proteins will locate to histones, where they are involved in chromatin modification functions. This 
is also the site were herpesvirus genomes are located immediately after infection and where virus 
transcription and DNA replication are initiated [184-190]. Experimental RNA knockdown of PML 
or DAXX or a combination of both proteins lead to a significantly increased HCMV of HSV-1 
replication [191-194], indicating why it is advantageous for CMV to disrupt ND10 bodies during 
infection [195-199]. The virus employs multiple strategies to ensure dispersal and degradation of 
the host proteins with intrinsic antiviral activity. PML and Sp100 will be dispersed and degraded 
by the immediate early protein 1 (IE1) [198-203], which will locate to PML bodies shortly after 
infection, whereas the immediate early protein 2 (IE2) will co-localize with CMV genomes 
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adjacent to ND10-bodies [204]. Additionally, the tegument protein pp71 interacts with Daxx, 
which leads to its dispersal and partial degradation [205-208]. Other ND10 body components 
directly affected by pp71 include ATRX [192], BclAF1 [209] and Rb protein family members 
[210]. Due to this importance of pp71 in degrading or delocalizing multiple proteins involved in 
anti-viral intrinsic immunity, it is not surprising that viral propagation and spread are substantially 
reduced in human fibroblasts after low MOI infection with an HCMV pp71 deletion mutant, given 
that the mutant virus is no longer able to ensure efficient viral DNA replication [211]. 
 
Fig.7: Activation of HCMV and HSV-1 viral gene expression. (A) Upon HCMV fusion and content delivery to the 
infected cell, the tegument protein pp71 binds to and induces the degradation of Daxx (1). This de-represses the viral 
MIEP and promotes the expression of the IE genes (2). IE1 disrupts the remaining PML-NB proteins by 
preventing/disrupting the SUMOylation status of PML, and possibly Sp100, further increasing IE gene expression (3). 
Both IE1 and IE2 negate the effect of HDACs by binding to and sequestering them away from viral promoters (4). 
Finally, the IE proteins can recruit BTM and TFs to early and late viral promoters to activate their respective genes 
(5). (B) Upon HSV-1 fusion and content delivery to the infected cells, the tegument protein VP16 binds to the cellular 
Oct1 and HCF proteins and targets to the viral IE promoter, where it displaces cellular H (1), and activates viral gene 
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expression by recruiting the BTM (2). ICP0 has multiple functions to activate subsequent viral gene expression, 
including dissociating HDAC complexes (3) and inducing the degradation of PML and Sp100 (4). ICP4 promotes the 
expression of early and late viral genes by recruiting BTM to targeted promoters (5). BTM: Basal transcriptional 
machinery; E/L: Early/late; H: Histones; HCF: Host-cell factor; HCMV: Human cytomegalovirus; HDAC: Histone 
deacetylase; HSV: Herpes simplex virus; IE: Immediate-early; MIEP: Major immediate-early promoter; PML: 
Promyelocytic leukemia; PML-NB: PML-nuclear body; TF: Transcription factor. (Figure taken from Saffert and 
Kalejta, Future Virol. 1;3(3):265-277 (2008) [212]). 
 
 
 
1.5.3 CMV evasion of natural killer (NK) cells 
One very important part of the innate immune response are natural killer (NK) cells, which can be 
classified as a heterologous group of CD3- and CD56+ cells and which represent about 15% of 
peripheral blood lymphocytes [213, 214]. As members of the innate immune response their activity 
is generally unspecific, but studies in mice indicated that an NK cell subset with immunological 
memory might exist [215, 216]. NK cells area activated in response to type I interferons and induce 
the lysis of malignant or virally infected cells, thereby containing the viral replication early in 
infection. Although they act at a very early stage of infection before B- or T-cells can mount an 
immune response, NK cells play a pivotal role in bridging the innate and adaptive immune 
response by regulating the development of the adaptive immunity [217, 218] through the secretion 
of cytokines and chemokines [219]. Unlike members of the adaptive immune response, NK cells 
do not detect pathogenic antigens through specific receptors but express a complex network of 
activation and inhibitory receptors that interact with different cellular molecules expressed on the 
target cell [220]. The overall combined stimulus transmitted through this signaling network 
determines the activation status of the NK cell and the fate of the target cell, and many pathogens 
have developed mechanisms to alter the signaling to NK cells in their favor to ensure their 
replication and survival. HCMV is a prime example of this as it encodes for multiple genes 
interfering with NK signaling and activation [221, 222]. 
 The need for viruses to interfere with NK cell activity becomes apparent when case studies 
of humans with NK cell deficiencies are considered [223, 224]. These patients suffer from 
numerous viral infections including multiple herpes viruses and similar effects were seen in 
patients suffering from immunodeficiencies with impaired NK cell numbers and function, where 
infections with HSV, VZV and CMV among others where frequent [225-227]. 
 The first set of activation receptors expressed on NK cells is a family of protein comprising 
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three members, NKp46, NKp40 and NKp30 [228]. Their cellular ligand is unknown, although 
several viral and tumor associated interaction partners have been identified [229]. One of them is 
the HCMV tegument protein pp65, which can interact with NKp30, leading to the dissociation of 
the linked CD3ζ from NKp30 and subsequently the inhibition of NK cell mediated killing [230]. 
A second important set of receptors are the killer immunoglobulin-like receptors (KIRs), 
the human homologues to the mouse Ly49 C-type lectin-like receptors. KIRs interact with specific 
allotypes of the classical (HLA-A, HLA-B and HLA-C) and nonclassical (HLA-G) human 
leukocyte antigen class I receptors and interaction of the target cell MHC class I with the NK-cell 
KIR will deliver either an activating or inhibitory signal depending on the KIR involved [231]. 
HCMV encodes for multiple proteins with structural homology to MHC-class I that can bind to 
inhibitory KIRs and prohibit NK cell activation. Furthermore, the HCMV protein UL18 can serve 
as a ligand for the leukocyte immunoglobulin-like receptor 1 (LIR-1), another related inhibitory 
NK cell receptor, which will also prevent NK cell activation [232, 233]. 
One last, very well described group, of NK cell receptors is a family of C-type lectins 
abundantly expressed on the cell surface of many lymphocytes. Members of this receptor family 
can deliver activating or inhibitory signals. For instance NKG2A binds to the non-classical HLA-
E molecule loaded with peptides derived from other HLA class I molecules. By doing so the NK 
cell is controlling for “missing self”, for the downregulation of MHC class I molecules during viral 
infection. If the level of MHC class I signal peptides presented on HLA-E goes below a certain 
threshold, then the inhibitory signal to the NK cell will not be strong enough anymore to prevent 
NK cell activation and the activated NK cell will lyse the target cell. HCMV has developed a very 
interesting mechanism to counter this immune defense. The virus encodes for a proteins (UL40) 
that contains a signal sequence with high homology to the HLA-A signal sequence, so that the 
UL40 signal sequence can be loaded onto HLA-E molecules instead of the HLA-A signal 
sequence, tricking the NKG2A receptor into believing that the cell is still expressing the classical 
MHC class I molecules at normal levels on the cell surface [234]. Even the viral proteins involved 
in CD8+ T-cell evasion do not interfere with the transport of the UL40 signal peptide loaded HLA-
E protein complex to the cell surface, so that even in the midst of a full blown lytic infection, the 
outer appearance of the cell to the inhibitory NKG2A receptor is still normal. 
Another member of the same NK cell receptor family is the highly expressed NKG2D 
protein, which forms a heterodimer with CD94 [235]. The ligands for the human version of this 
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receptor are a group of cellular proteins including MICA, MICB and the UL16 binding proteins 
ULBP1-6, all of which are upregulated during the cellular stress response in malignant cells or 
after viral infection [221, 222]. HCMV encodes for several proteins that will interfere with the 
expression of the NKG2D ligands of the cell surface of infected cells. UL16 can bind to MICB, 
ULBP1 and ULBP2, leading to the intracellular retention of these proteins [236, 237]. MICA is 
also retained in the same compartment, albeit by a different viral protein, UL142, a protein that 
was initially missed because it was lost during passage in HCMV laboratory strains like AD169 
[222, 238]. In addition to viral proteins, HCMV also encodes for a viral microRNA termed miR-
UL112 that can downregulate the expression of MICB leading to decreased binding of NKG2D 
and reduced killing by NK cells [239, 240]. 
 
Fig.8: MCMV and HCMV proteins interfere with expression of NKG2D ligands and host recognition of virally 
infected cells. (A) MCMV-encoded glycoproteins (shown in orange) inhibit the expression of mouse NKG2D ligands: 
m152 interferes with expression of all five members of the RAE-1 family, m145 prevents surface expression of 
MULT1, m155 causes degradation of H60, and m138 assists to block expression of RAE-1ε, MULT1, and H60. (B) 
HCMV-encoded components (shown in red) also inhibit the expression of NKG2D ligands: UL142 inhibits MICA 
expression, UL16 binds MICB, ULBP1, and ULBP2 in the Golgi, and the miR-UL112 microRNA targets MICB 
mRNA for degradation leading to diminished cell surface expression of MICB. (Figure taken from Sun and Lanier, 
Viruses 1(3), 362 (2009) [222]). 
 
  Viral NK cell evasion is a field of research that has gotten a lot of attention in the 
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past due to its impact on pathogenesis and vaccine development and reviews summarizing the vast 
amount of research data surrounding this topic have been published over the years [241]. 
 
1.5.4 Evasion of the complement system 
Another integral part of the innate immunity is the complement system [242], a network of plasma 
proteins involved in direct lysis of infected cells and in amplifying the inflammatory response 
effectively bridging the innate and the adaptive immune response [243-247]. The complement 
system can be activated through different pathways (see Fig.9) either by binding antibody antigen 
complexes or by directly binding to the surface of pathogens or infected cells. In either case, this 
activation will ultimately lead to the formation of membrane attack complexes (MACs), which 
will integrate into the lipid cellular membranes and disrupt the cell by increasing the osmotic 
pressure [248]. Besides the formation of the MACs, activation of the complement will also lead to 
the expression of several anaphylatoxins (C3a, C4a and C5a), which are involved in the 
recruitment of antibodies, further complement proteins and leukocytes to the site of infection, and 
even direct interaction of complement proteins with viral virions has been reported and has a 
neutralizing effects [249-253].  
Multiple viral families have evolved means to evade the complement system, and HCMV-
infected cells have been shown to resist complement mediated cell lysis shortly after infection 
suggesting a viral mechanism to evade this host defense mechanism [254, 255]. One way the virus 
is able to achieve this, is by inhibiting complement activation through the classical pathway by 
avoiding complement binding to antibody–antigen complexes through the expression of viral Fc 
receptors on the surfaces of virally infected cells. As will be described later (see evasion of the 
humoral immune response), HCMV encodes for at least four functional viral Fc receptors which 
not only impair the humoral response, but also the activation of the complement system and so 
ultimately complement mediated cell lysis [256-258]. 
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Fig.9: Activation of the complement cascade via the classical (A), lectin (B) or alternative (C) pathway results 
in the initiation of the terminal complement pathway (D), leading to the formation of membrane attack 
complexes. (Taken from Favoreel et al., J Gen Virol 84(Pt 1), 1-15 (2003) [259]). 
 
Cells on the other hand will express ‘regulators of complement activation’ (RCA) like the 
membrane cofactor protein CD46, complement decay-accelerating factor CD55, and CD59 
(protectin), which will allow them to inhibit the complement system to a certain extent [260-262]. 
While CMV does not encode for a viral homologues of any of these RCAs like other viruses, it 
does incorporate cellular CD55 and CD59 into its virion [263] and it will also upregulate the 
expression of CD46 and CD55 on the surface of infected cells [264]. Both of these viral strategies 
have been shown to inhibit complement mediated cell lysis of HCMV infected fibroblasts [263-
265] increasing viral replication and survival. Members of the viral US6 family known to be 
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involves in CD8+ T cell evasion were examined as potential candidates for HCMV proteins 
responsible for the upregulation of CD59 and other RCA proteins, and all family members were 
shown to either increase the total expression or the number of cells that express at least one RCA. 
Furthermore, overexpression of US2 was shown to reduce cellular lysis by the complement system 
in a functional assay indicating a role of the protein in in vivo complement evasion [266]. 
 
 
1.5.5 Evasion of the adaptive T-cell response 
The second important arm of the immune response countering invading pathogens is the adaptive 
immunity. Here, T-cells, and for the defense against intracellular parasites like viruses, especially 
CD8+ cytotoxic T lymphocytes (CTLs), which patrol the body in search in infected cells, play a 
vital part in controlling the spread of previously encountered pathogens. Infected cells will be 
recognize by the CTLs through the peptides presented by the host cells on the plasma membrane 
by MHC-class I complexes. These peptides are derived from proteins degraded in the proteasomes, 
and virally infected cells will present peptides derived from virus proteins in addition to host 
peptides [267-269]. These foreign peptides will be recognized by the CTLs, which in turn will 
force the infected host cell into apoptosis to prevent spread of the infection and to avoid harm to 
the host. To counteract this host defense mechanism, CMV encodes for an entire family of proteins, 
termed the US6 family of proteins that will prevent viral recognition and secure survival of the 
virally infected cell. The four members of the US6 family are US2, US3, US6 and US11, and they 
interfere at different time points post infection with different steps of the MHC class I antigen 
presentation pathway [270]. Expression of US2 and US11 will lead to relocation of major 
histocompatibility complex class I heavy chains from the ER to the cytosol, where they are 
deglycosylated and subsequently degraded by the proteasome [271], whereas US6 acts as a TAP 
inhibitor, preventing the loading of MHC class I complexes with proteasomally derived peptides 
prevents ATP hydrolysis [272]. Finally, US3, the only US6 family member expressed with IE 
kinetics [273], retains MHC class I complexes in the ER [274]. Interestingly, RhCMV, the rhesus 
macaques counterpart of HCMV, contains locational and functional homologues to all four HCMV 
US6 family members [275], which enables in vivo research into the importance of these proteins 
in an animal infection model. When the US6 homologues of RhCMV (Rh182-Rh189) were deleted 
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from the viral genome, the mutant virus was still able to persistently infect naïve animals, but was 
incapable of infecting CMV positive macaques [276].  
 
Fig.10: Immunoevasins of the murine- and the human cytomegalovirus. A) Immunoevasins of murine 
cytomegalovirus (mCMV). m04 binds to MHC class I molecules in the endoplasmic reticulum (ER) and escorts them 
to the cell surface. The complex does not seem to be recognized by CD8+ T cells. It is unclear whether the complexed 
MHC molecules do not present peptide or whether the bound m04 prevents recognition. m04-mediated surface display 
of MHC class I molecules might silence natural killer (NK) cells. m06 binds through a lumenal domain to peptide-
loaded MHC class I molecules in the ER and reroutes the resulting complex to a late endosomal/lysosomal 
compartment for degradation. m152 triggers the retention and accumulation of peptide-loaded MHC class I molecules 
in the ER Golgi intermediate compartment (ERGIC). B) Immunoevasins of human cytomegalovirus (hCMV). US6 
blocks peptide translocation through the transporter for antigen processing (TAP) by interaction with the lumenal 
surfaces of both subunits of the TAP1–TAP2 heterodimer in the transient peptide-loading complex — which consists 
of TAP, the MHC class I complex and ER-resident chaperones. US3 is an immediate-early (IE) protein that causes 
retention of peptide-loaded MHC class I molecules in the ER. US3-bound complexes are degraded in the early (E) 
phase by US2- and/or US11-mediated mechanisms. US2 and US11 both induce rapid proteasomal degradation of 
MHC class I -chains by mediating retrograde translocation from the ER to the cytosol. Unlike US11, which remains 
in the ER membrane, US2 seems to be co-dislocated and to escort the MHC class I -chain to the cytosol. (Figure 
taken from Reddehase, Nature reviews. Immunology 2(11), 831-844 (2002) [277]). 
 
 
This underlines the importance of the virally encoded T-cell evasion genes, especially in the 
context of re-activation and re-infection, when the virus has to overcome a pre-existing T-cell 
response in order to establish a productive infection and persistence. This was additionally proven 
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when CMV positive rhesus macaques were CD8+ T-cell depleted, which now enabled the US6 
family deleted mutant to establish an infection [276]. Additionally, the viral Rh189 (US11) protein 
is responsible for a change in the T-cell epitope presentation. Whereas infection of macaques with 
SIV or SIV protein containing commonly used viral vectors (Ad5, MVA, etc.) leads to a 
presentation of canonical SIV epitopes, well characterized epitopes presented by all monkeys of a 
given MHC I allotype, RhCMV vectors will lead to the complete absence of canonical epitopes 
and the presentation of new, non-canonical SIV epitopes [278] Deletion of US11 from the RhCMV 
vaccine vector will restore the presentation of canonical epitopes, suggesting another active 
mechanism of the virus in derailing CTL response through inhibiting the presentation of highly 
active epitopes on the infected cell. One significant difference between RhCMV and HCMV is 
that RhCMV encodes for a fifth T-cell evasion gene that does not have a homologue in HCMV 
called Rh178 or VIHCE (Viral Inhibitor of Heavy Chain Expression) [279, 280]. This protein 
binds to the signal peptide of newly synthesized MHC class I heavy chains and inhibits the 
translation of the protein on ER bound ribosomes into the ER.  
 
1.5.6 Evasion of the humoral immune response 
Besides the T-cell response, B-cells and the antibodies they produce represent the second 
important arm of the adaptive immune response to fight invading pathogens and to develop an 
immunological memory to prevent reinfection with most formally encountered viruses. In the case 
of the human cytomegalovirus, protective immunity does not exist, and that even in the face of not 
only and incredible strong T-cell response to the virus [121] but also a strong and broad B-cell 
response against multiple glycoproteins and proteins complexes on the viral membrane [281-285]. 
An infected human will even produce neutralizing antibodies, mostly against the gB glycoprotein, 
but also against the pentameric complex needed for viral endocytosis into endothelial cells [286-
293], not resulting in complete sterilizing immunity, but in significantly reduced infectivity [56, 
294-298]. There is clinical evidence for a role of antibodies in limiting HCMV infection in vivo 
[299], which is why nowadays most proposed subunit vaccines have a T-cell (pp65 or IE1)- and a 
B-cell (gB or the pentameric complex) stimulating component, and this also explains why it is 
advantageous for the virus to encode for proteins counteracting the humoral immune response. 
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Like other viruses, HCMV does this by encoding for its own Fc-receptors [300, 301], which are 
thought to prevent antiviral immunoglobulin G (IgG) from neutralizing free virus and engaging in 
antibody-dependent cellular cytotoxicity (ADCC) against infected cells [302]. Initially, two such 
receptor have been described for HCMV, first the RL11 protein, which encodes for a 34kDa 
glycoprotein expressed with early kinetics.[256], and second the spliced UL119/UL118 protein 
which encodes for a glycoprotein of 68kDa [257]. Interestingly, although both well described 
virally encoded Fc-receptors show strong homology to human Fc-receptors, they resemble 
different host Fc-receptors. UL119-UL118 relates most closely to the third domain of Fcγ-receptor 
I, whereas RL11 is reminiscent of the second domain of Fcγ-receptor II/III [257], again 
emphasizing the importance to effectively evade the neutralizing antibody response, given that the 
virus independently integrated homologues to two different human Fcγ-receptor into its genome. 
Recently, further Fcγ-receptors have been discovered in the viral genome. RL13, a protein 
described to limit viral replication of primary isolates on human fibroblasts in vitro [303] has been 
shown to function as an Fcγ-receptor, as well as a third RL11 family member, RL12 [258]. 
 
1.6 In vivo models for HCMV 
 
Due to the strict species specificity of CMV and most herpesviruses, animal model have to be 
applied to study the virus in vivo [304]. Fortunately, CMVs are widespread and it is plausible that 
most species co-evolved with their own form of the virus, so establishing a wide array of different 
animal models is theoretically possible. In reality, only very few animal models have been pursued, 
the mouse model with its version of CMV the murine Cytomegalovirus (MCMV) being the most 
widely explored and utilized [305]. MCMV has been first isolated in 1954 by Margaret Smith from 
the salivary gland tissue of infected laboratory mice [306] and has since then been extensively 
examined in vitro and in vivo [307-311]. The virus also has been cloned as a bacterial artificial 
chromosome (BAC) [312], which enabled research groups to design and construct mutants for 
further characterization of the encoded viral proteins. Additionally, the mouse host has also been 
extensively characterized and might represent the mammal with the best described and analyzed 
molecular biology and biochemistry other than humans, and, moreover, mice are available as 
inbred mouse strains, increasing the reproducibility of achieved research data by decreasing the 
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background of variability in the host. Furthermore, the production of a range of genetically 
engineered mice enables the dissection of viral functions in vivo by selectively knocking out single 
pathways and by analyzing the effect these pathways have on the virus. The major problem of the 
mouse-model as a model system for HCMV is the distant relationship between the hosts and the 
viruses alike. While the two viral species share high homology in their coding content and in the 
pathogenicity they cause in their respective host, the differences are most apparent and important 
findings cannot be extrapolated without verification. Furthermore, although the two viruses show 
similar behavior regarding infection, replication and pathogenesis, MCMV will confer protective 
immunity against re-infection, at least under laboratory conditions using inbred mouse strains and 
laboratory MCMV strains, a result not achievable with HCMV. Also, the biggest threat to humans 
posed by HCMV is to unborn children through congenital infection, leading to severe neurological 
damage (see above), something that has never been observed in newborn mice, so the model cannot 
be applied to study this route of infection, which, unfortunately, is also true for another widely 
used animal model established for HCMV, rat CMV. RCMV is grouped into the same genus as 
MCMV (Muromegalovirus). Genome organization and infectious behavior mirror MCMV. One 
significant different between the two rodent CMV species is, that two of the isolated and sequenced 
RCMV strains differ so substantially that they are considered different species, which would mean 
that the rat has co-evolved with two different but equally virulent species of CMV [313, 314]. Still, 
for the investigation of congenital HCMV infection another in vivo model had to be developed, 
and it was finally found in the guinea pig and the guinea pig cytomegalovirus (GPCMV), a virus 
that does cross the placenta causing infection and disease in utero in unborn guinea pigs [315]. 
Although the commonly used strain of GPCMV is resistant to Ganciclovir, the drug of choice for 
treatment of CMV infections [316, 317], the model is widely usable for the in vivo testing of 
potential anti-herpesviral compounds, as well as for toxicity studies. 
 
1.7  Great Ape and Non-Human Primate (NHP) CMVs 
Besides the few rodent isolates mentioned above, cytomegaloviruses have been preferentially 
isolated from great apes and nonhuman primates (NHP) because of the close evolutionary 
connection to humans [318-328].  
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Fig.11: Phylogenetic tree of (A) gB and (B) the viral DNA polymerase for great ape and monkey CMVs. 
Accession numbers of the protein sequences used to make this figure are HCMV (X17403), CCMV (NC_003521), 
GgorCMV (FJ538490), PpygCMV (AY129396), RhCMV (AY186194), BaCMV (AC090446), SCMV (FJ483968), 
CyCMV (AY728171), MsphCMV (AY129399), CgueCMV (AY129397), AtriCMV (FJ483970) and SsciCMV 
(FJ483967). MCMV (GU305914) was used as an outgroup in both graphs. The phylogenetic trees were made using 
Geneious Pro 5.5.2. (Figure taken from Früh et al., In: Cytomegaloviruses: From Molecular Pathogenesis to 
Intervention, Caister Academic Press, 463-496 (2013) [329]). 
 
As can be seen in Fig.11, CMVs have been characterized from many different species of Great 
Apes as well as old- and new world NHP. Phylogenetically, the old world NHP CMVs are closer 
related to HCMV then the new world NHP CMVs which mirrors the relationship between the host 
species where the separation point between apes (Hominidea) and old world monkeys 
(Cercopithecidae, the superfamilies Hominidea and Cercopithecidae form the parvorder 
Catarrhini) on one side and new world monkeys (Platyrrhini) on the other was estimated around 
about 35 million years ago [330-334]. Interestingly, this would be substantially after the African 
and the South American continents divided, indicating that the two higher primates parvorders did 
not separated geographically with the continental divide, but that the new world NHP migrated to 
the American continent at a later timepoint [335, 336]. The divide within the parvorder Catarrhini 
between Old World monkeys and apes occurred more recently at about 23 million years ago [337] 
and the latest separation between the genera homo (humans) and pan (chimpanzees) occurred 
roughly 5 – 7.5 million years ago [338-341]. 
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Fig.12: Phylogenetic tree of some primates. The Old world monkeys split from the New world monkeys +/-35mya. 
The Human-Chimp-Gorilla-Orangutan lineage split from that of the rhesus macaque lineage after the last major 
genomic infection (+/-25mya). Then the Human-Chimp-Gorilla lineage split from the Orangutan lineage (+/-12mya), 
and then the Human-Chimp lineage split from the Gorilla lineage (+/-7mya), and finally Humans and Chimps diverged 
+/-6mya. (Taken from Blogs24 (http://blogs.24.com/insilico/2011/10/page/2/#_edn3), but adapted from Polavarapu 
et al., Genome Biol. 2006;7(6):R51.Nov;81(22):12210-7 [342]). 
 
The closest relatives to HCMV can be found in the closest relatives to man, the chimpanzees 
and gorillas as well as the Orang-Utans, but due to ethical and economical concerns and the fact 
that many of these species are endangered and protected, it is impossible to establish in vivo models 
in Great Apes. This is different for old world monkeys, which are widely utilized in biomedical 
research in primate centers all around the world. The most commonly kept species are rhesus 
macaques, cynomolgus macaques, mangabeys and baboons, all of which have been used in SIV 
models for HIV and AIDS and other related areas. Out of these monkey species, the rhesus 
macaque has the most extensively characterizes CMV, the rhesus cytomegalovirus RhCMV. In 
fact, two independent strain of RhCMV have been isolated and fully sequenced (68-1 [343] and 
180.92 [319]), and RhCMV 68-1 has been cloned as a BAC [344], so it can now be used to create 
mutants through homologous recombination. The coding potential of both isolated RhCMV strains 
differ, because both strains seem to have acquired deletions during serial passage on rhesus 
fibroblast [345], leading to the loss of multiple kilobases of coding DNA and to deletions similar 
to what has been described earlier for fibroblast adapted strains of HCMV like AD169 or Towne 
[346]. The published coding potential of RhCMV is estimated around 230 - 260 ORFs [319, 343, 
345], which exceeds the coding potential for all other published CMV genomes by at least 60 
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ORFs [346-351]. If all of the to date annotated RhCMV ORFs are indeed coding, then 60% of the 
encoded proteins have homologues to HCMV proteins, whereas 40% of all ORFs are old world 
monkey or even RhCMV specific [343]. To date only very few RhCMV genes not found in HCMV 
have been verifies and described (vCOX-2 [352], VIHCE [279, 280]). 
 
 
1.8 Utilizing CMV as a vaccine vector 
Given the remarkable feature of RhCMV to induce a strong B- and T- cell response without 
generating a sterilizing immunity opens up another interesting application for the virus, namely as 
a vector for the development of new vaccines. It is well established that T-cell epitopes introduced 
into CMV can generate strong in vivo T-cell responses [353] and given the non-sterilizing 
immunity, at least in HCMV and in NHP model systems, the same CMV vectors could be used 
over and over again to boost the initially primed immune responses to achieve an even greater 
number of cells of the adaptive immune response directed against a selected foreign antigen 
introduced into the CMV vector. The idea of using one virus as a vaccine vector to vaccinate 
against a second pathogen is not new and different viral families have been considered prospective 
candidates. Extensive research has been conducted using Adenovirus [354] or Parvoviruses (AAV, 
Adeno associated viruses) [355], and they proofed promising for some aspects of vaccine 
development, but they failed for the development of T-cell based vaccines against important 
human pathogens like HIV (Step study, Phambili study (HVTN 503) and HVTN 505 study) [356-
358]. It became apparent that CMV has some important attributes that makes it superior to all 
previously considered viral vectors for the development of T-cell based vaccines. First of all, CMV 
establishes a persistent infection. But it reactivates from this latency constantly, challenging the 
existing anti-CMV immune response over and over again, precluding the CTLs from reaching their 
central memory phenotype (TCM) and keeping them as effector memory T-cells (TEM) [353]. This 
means, that the T-cells against CMV and the inserted foreign antigen will be constantly activated 
and alarmed, and ready to fight the real infection immediately should they ever encounter it, 
whereas with other vaccine strategies, the CTLs would move on to central memory T-cells, from 
where they will have to be re-activated upon stimulation, and this delay of 1-2 week compared to 
the CMV vaccine strategy makes all the difference. In vivo experiments in rhesus macaques 
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showed no protective effect when using Ad5 based α-SIV vaccine vectors [359], but RhCMV 68-
1 based vaccine vectors enables 50% of the monkeys to control the viral infection and the 
associated viremia even after repeated SIV challenge [359], showing the first successful vaccine 
approach against SIV in a monkey model. Additionally, even though these monkeys initially were 
infected with SIV and then moved on to show elite controller phenotype in that they were able to 
control the infection with no significant viral load without any treatment, further experiments 
showed that they actually cleared the virus and adoptive transfer of leukocytes from these monkeys 
to SIV negative monkeys did not results in seroconversion [360]. 
 
Fig.13: (a,b) Combined FCICA and surface phenotype analysis of CD4+ (a) and CD8+ (b) peripheral blood T 
cells responding to wild-type (WT) RhCMV lysate, SIV Gag or Rev-Tat-Nef–overlapping 15-mer peptides. The 
graphs compare the CD28 versus CCR7 phenotype of RhCMV and SIV antigen-responsive CD4+ or CD8+ T cells 
(CD69+TNF+) in a representative initially RhCMV-positive rhesus macaque that was inoculated 595 d and 330 d 
earlier with RhCMV-Retanef and RhCMV-Gag, respectively (left and middle). They also compare the SIV Gag 
response of this rhesus macaque to another rhesus macaque that received a Gag protein prime and Ad5(Gag) boost 
(105 d after the boost; right). (Figure taken from Hansen et al., Nat Med 15(3), 293-299 (2009) [353]). 
 
Additionally, when SIV gag was introduced into several different viral delivery vectors 
and rhesus macaques were infected with all these different constructs, it was noticed that the T-
cell epitopes presented by RhCMV 68-1 were substantially different than in any other examined 
construct (Ad5, MVA, DNA, SIV) [278]. Our RhCMV vectors based on the laboratory adapted 
strain 68-1 that does not have a functional pentameric complex, presented substantially more and 
different, non-overlapping epitopes than were observed in all control samples (32 compared to 14) 
and 2/3 of these epitopes were actually MHC class II dependent [278], which had not been 
observed before. To top everything off, some of the epitopes were presented in all examined 
monkeys independent either by MHC class I or MHC class II and that independent of the MHC 
alleles encoded by the individual monkeys. These highly promiscuous peptides are extremely 
unusual and have not been described in connection with viral infections before. Because these 
newly discovered epitopes where so promiscuous and where found in all examined animals, they 
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were termed “supertopes” and they, in combination with the MHC class II dependent CD8+ T cells 
generated by the RhCMV 68-1 vaccine vector, could play a crucial role in the protection seen in 
SIV challenge experiments with SIV after RhCMV vector vaccination. A broader T-cell response 
against more epitopes essentially spanning the entire protein makes it substantially harder for the 
virus to evade the pressure of the immune system by mutation, even in the case of a highly variable 
and highly mutagenic virus like SIV (or HIV). The overall impact of the altered epitope repertoire 
being presented in regard to protection against challenge is still the matter of intensive research 
and preliminary data suggests, that restoration of the pentameric complex in 68-1 abrogated the 
generation of supertopes and MHC class II dependent CD8+ T cells [278], but deletion of single 
members of this complex did not lead to the restoration of the RhCMV 68-1 phenotype, although 
the tropism specificity induced by a fully functional pentameric complex is lost (unpublished data). 
This indicates that it is not the entire complex or the tropism that is responsible for the appearance 
of supertopes and MHC class II dependent CD8+ T cells, but a combination of single members of 
the complex.  
 As mentioned above, Rh189 (US11) also has an effect on the T cell epitopes that are being 
presented by the infected cell. In the presence on US11, the epitopes that are presented do not 
resemble the epitopes found in a natural SIV infection or after vaccination with any viral vector 
expression SIV gag other than RhCMV. Because these epitope are so common in SIV infection, 
they are termed canonical epitopes and the epitopes that are presented in the presence of US11 are 
termed non-canonical epitopes [278]. Interestingly, if US11 is deleted, the canonical epitopes will 
also be presented in the context of RhCMV as the delivery vector for gag [278], indicating that the 
exact design of the RhCMV vector has a deep and profound impact on the T cell response that will 
be generated against the viral vector as well as against the inserted foreign antigen. All these 
incredible findings enable us now to exactly customize the T-cell response we wish to achieve by 
constructing vectors containing or lacking certain genes involved in T-cell epitope generation and 
presentation. This immense flexibility has only been achieved with RhCMV vectors so far, and 
further steps are being undertaken right now to characterize the different T-cell responses 
generated to determine what vector configuration works best for the generation of a strong and 
broad immune response without sacrificing the viability and infectivity of the viral vector. With 
further animal studies planned, we hope that the protection achieved in our first published RhCMV 
vector study where 50% of the challenged rhesus macaques were protected from SIV challenge 
Intoduction                                          35 
[359] can be extended so that the number of protected animals, and further down the road humans, 
can be maximizes to protect as many individual as possible. 
 
 
Fig.14: RhCMV vector–elicited and conventional SIVgag-specific CD8+ T cell responses differ in epitope 
breadth and promiscuity. CD8+ T cell responses to SIVgag were epitope-mapped using flow cytometric ICS to 
detect recognition of 125 consecutive 15mer gag peptides (with an 11–amino acid overlap) in macaques vaccinated 
with strain 68-1 RhCMV/gag vectors [*BAC-derived RhCMV/gag; **non–BAC-derived RhCMV/gag(L); n = 14], 
electroporated DNA/gag + IL-12 vectors (n = 4), Ad5/gag vectors (n = 3), and MVA/gag vectors (n = 3) and in SIV+ 
macaques with controlled infection (n = 5). Peptides resulting in above-background CD8+ T cell responses are 
indicated by a colored box, with the total number of these positive responses and the minimal number of independent 
epitopes potentially contained within these reactive peptides in each macaque designated at right. P < 0.0001, epitope 
breadth of RhCMV/gag-vaccinated macaques compared to macaques pooled over the other groups, using two-tailed 
Wilcoxon rank sum tests. (Figure taken from Hansen et al., Science 340(6135), 1237874 (2013) [278].
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2. Main aims of this thesis 
In our previous studies, we were able to establish RhCMV as an in vivo model system for HCMV 
infection, and more importantly, we were able to establish RhCMV as a new viral delivery vector 
for T-cell vaccines against SIV and potentially against a wide range of different other deadly 
human pathogens [353, 359]. Our generated data was so promising, that the main focus now shifted 
towards the generation of an attenuated viral vaccine vector. This RhCMV mutant should still have 
the capability of inducing a strong T-cell response against the virus as well as against the inserted 
transgenes and should still re-activate occasionally to re-stimulate the virally induced T-cells to 
keep them in effector memory phenotype (TEM) instead of allowing them to progress to central 
memory T-cells (TCM). On the other hand, it should demonstrate reduced viral shedding to preclude 
transmission from animal to animal and most importantly, should not display any signs of 
pathogenesis even in the immunocompromised host, a point highly important for FDA approval 
of a potential HCMV counterpart of our RhCMV model virus for future human clinical trials. 
Attenuation of our viral delivery vectors should be achieved by generating deletion mutants 
lacking genes needed for efficient viral replication, effectively slowing down the viral replication 
and spread in vivo. As a result, the host’s immune system should be able to control the virus better, 
and should be capable to control the virus before it can cause any detectable medical condition. 
The reduced viral replication should also lead to reduced shedding of the virus in saliva and urine 
leading to significantly diminished horizontal transmission between animals. The first step in 
generating targeted viral deletions is actually a step back. Given the relative novelty of the RhCMV 
model system and the very limited use in the scientific community due to money restraints and 
lack of accessibility, the virus is not well characterized and further detailed characterization of the 
viral genome and the viral coding capacity is needed to generate a reliable genome map of RhCMV 
that can be used as a starting point for all further recombineering steps. To achieve this, the only 
existing RhCMV BAC of strain 68-1 has to be fully sequenced and the preliminary open reading 
frame (ORF) annotation has to be re-analyzed and either verified or dismissed for every single 
ORF. After generating the new viral genome map, target proteins can be chosen for deletion to 
create attenuated viral mutants. An import prerequisite for every potential RhCMV candidate ORF 
is, that it has to have an HCMV homologue, because RhCMV naturally only serves as a model 
system for HCMV and all the data generated in our model system must be translatable into HMCV 
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for future human clinical trials, which would exclude 40% of all annotated RhCMV ORFs [343]. 
Many different levels of attenuation can be achievable. Slight attenuation should lead to a vector 
that should be easily propagated in tissue culture to high viral titers, but this level of attenuation 
might not be sufficient to achieve enhance safety in vivo. This could be achieved by deleting a 
gene with higher importance during viral replication leading to a more attenuated virus, but the 
problem here might be the viral propagation in vitro, which might have to be achieved by 
complementing the virus in trans on a stable, complementing cell line. Lastly, the highest level of 
attenuation could be achieved by deleting a gene essential for viral replication. Such a mutant 
would have to be grown on a complementing cell line, creating a single step virus that generates 
infectious viral particles on complementing cells with high efficiency but is unable to generate 
infectious particles on non-complementing cells or in vivo. Although examples for single step 
viruses in CMV exist (i.e. gL deletion mutants in MCMV [361] and RhCMV [362]) it is not known 
whether these viruses are capable of creating a persistent infection in vivo, or if this level of 
attenuation will lead to an immediate clearance of the virus from the infected host. In a first step 
we will focus on the generation of mildly and moderately attenuated mutant viruses by deleting 
the major viral tegument proteins pp65a and b or pp71. These viral protein serve not only as 
structural proteins in the viral tegument, but also play an important role in the evasion of the 
intrinsic- and innate immune response immediately after viral infection of the host cell [363]. The 
resulting deletion mutants should show significant attenuation in vivo hopefully leading to better 
control of the viral vectors by the host immune response leading to improved safety.
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3.1 Abstract 
Cytomegaloviruses are highly host restricted, resulting in cospeciation with their hosts. As a 
natural pathogen of rhesus macaques (RM), rhesus cytomegalovirus (RhCMV) has therefore 
emerged as a highly relevant experimental model for pathogenesis and vaccine development due 
to its close evolutionary relationship to human CMV (HCMV). Most in vivo experiments 
performed with RhCMV employed strain 68-1 cloned as a bacterial artificial chromosome (BAC). 
However, the complete genome sequence of the 68-1 BAC has not been determined. Furthermore, 
the gene content of the RhCMV genome is unknown, and previous open reading frame (ORF) 
predictions relied solely on uninterrupted ORFs with an arbitrary cutoff of 300 bp. To obtain a 
more precise picture of the actual proteins encoded by the most commonly used molecular clone 
of RhCMV, we reevaluated the RhCMV 68-1 BAC genome by whole-genome shotgun sequencing 
and determined the protein content of the resulting RhCMV virions by proteomics. By comparing 
the RhCMV genome to those of several related Old World monkey (OWM) CMVs, we were able 
to filter out many unlikely ORFs and obtain a simplified map of the RhCMV genome. This 
comparative genomics analysis suggests a high degree of ORF conservation among OWM CMVs, 
thus decreasing the likelihood that ORFs found only in RhCMV comprise true genes. Moreover, 
virion proteomics independently validated the revised ORF predictions, since only proteins that 
were conserved across OWM CMVs could be detected. Taken together, these data suggest a much 
higher conservation of genome and virion structure between CMVs of humans, apes, and OWMs 
than previously assumed.  
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3.2 Introduction 
Human cytomegalovirus (HCMV), a member of the Herpesviridae subfamily Betaherpesvirinae, 
is a large DNA virus of about 235 kb [346] encoding approximately 165 different proteins [364]. 
It is widespread in the developing world, with infection rates of close to 100%, but is also very 
common in the developed world, where about 60% of the population is CMV positive [365]. CMV 
infection is generally asymptomatic in healthy, immunocompetent individuals but can cause severe 
diseases in immunodeficient patients. It is the major viral cause for congenital birth defects such 
as mental retardation and deafness in the United States [366]. HCMV can also cause disease in 
solid organ and bone marrow transplant recipients, where the virus can reactivate from either the 
transplanted organ or the CMV-positive recipient and lead to disease or graft rejection [367]. The 
Institute of Medicine (IOM) of the U.S. National Academy of Sciences declared the development 
of a CMV vaccine a high priority in 1999 [42]. However, attempts to develop a vaccine against 
HCMV have had limited success so far (for a recent review, see reference [368]. One of the 
challenges of vaccine development is that HCMV is strictly species specific and cannot infect 
immunocompetent animals that could serve as a model system. In fact, reports of CMVs infecting 
species other than their natural hosts are very rare and occur only under artificial circumstances 
such as laboratory infections or xenotransplantations [369-372]. There are no reports of proven 
natural zoonotic infections of humans by animal CMVs.  
Due to this species specificity, most current animal models employ CMVs that naturally 
infect the respective animal. Since the relatedness of CMVs generally mirrors the evolutionary 
relatedness of their hosts, many of the genes and gene families present in HCMV are absent in 
CMVs of small animals, thus limiting their usefulness in predicting the in vivo function of HCMV 
genes. The closest relatives to HCMV are CMVs of human primates. However, due to ethical and 
financial reasons, gorilla or chimpanzee models of CMV are not practical. Therefore, CMVs 
infecting nonhuman primate (NHP) species are the best alternative to those infecting small animals 
to study CMV pathogenesis and the establishment and maintenance of persistent infection [373]. 
In particular, rhesus CMV (RhCMV) has emerged as an attractive model for studying CMV 
infection, pathogenesis, and immunology [374, 375]. This model was further used for the 
development of CMV as a new vaccine vector platform against HIV [353, 359, 374]. In order to 
correlate results from in vivo studies using wild-type (WT) and recombinant RhCMVs with 
potential outcomes for HCMV, it is important to accurately predict the locations and potential 
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functions of open reading frames (ORFs) carried by RhCMV and their relationship to HCMV-
carried ORFs, as well as to have exact knowledge of the genome content of RhCMV used in each 
of the studies.  
Two different strains of RhCMV, 68-1 and 180.92, have been fully sequenced previously 
[319, 343], and partial sequences of various regions of the genome from low-passage-number 
isolates have been published [345]. However, many of the in vivo experiments performed to date, 
particularly those involving recombinant CMVs, employed RhCMV strain 68-1 cloned as a self-
excisable bacterial artificial chromosome (BAC) [344]. The previously determined RhCMV 68-1 
sequence was obtained by cosmid cloning from the original strain [343]. Since viable virus was 
not reconstructed from the individual cosmids, it is not known whether the respective genome 
sequence is infectious. During BAC cloning, a molecular clone of a selected virus strain is fixed 
as a genome and thus might differ in its genome content from the parental strain, which likely 
contains a mixture of molecular clones. For instance, the 68-1 BAC is known to contain a mutation 
in Rh61/Rh60, the RhCMV homologue of UL36, which is not present in the published RhCMV 
68-1 sequence [376]. Moreover, the extensive in vitro propagation required for BAC cloning might 
select for additional tissue culture adaptations compared to the original strain.  
For these reasons, we determined the full genome sequence of the RhCMV 68-1 BAC by 
whole-genome shotgun sequencing. Compared to the previously determined 68-1 sequence, 
several mutations in ORFs distributed across the entire genome were found and confirmed. To 
determine the potential impact of these mutations on the predicted function of RhCMV ORFs, we 
further reannotated the RhCMV genome by comparative genomics using recently completed 
CMVs of closely related Old World monkeys (OWM), thus creating a prototypical wild-type 
RhCMV sequence. We further experimentally verified the expression of a number of ORFs by 
proteomics. Our analysis revealed that RhCMV, as well as all other OWM CMVs, is much more 
closely related to ape and human CMVs than previously assumed, since almost all of the ORFs 
previously categorized as “RhCMV specific,” i.e., found exclusively in RhCMV, were rendered 
unlikely by this combined genomics, in silico, and proteomics approach. Most of the remaining 
ORFs are conserved in HCMV, and almost all RhCMV ORFs have closely related orthologues in 
OWM CMV genomes. The close relatedness to HCMV is also reflected in the fact that BAC-
derived RhCMV shows fibroblast adaptations that are remarkably similar to those of HCMV. In 
addition to the previously noted mutations in the RhCMV 68-1 orthologues of the endothelial cell 
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(EC) tropism-determining glycoprotein complex gH/gL/UL128/UL130/UL131A and the 
apoptosis inhibitor UL36, our analysis also suggests that all known RhCMV sequences and most 
OWM CMV sequences contain independent mutations in genes homologous to RL13, which was 
recently shown to limit HCMV growth in fibroblasts [303]. Despite these mutations, however, 
BAC-derived RhCMV is able to establish and maintain persistent infections upon experimental 
inoculation of CMV-naïve or CMV-positive rhesus macaques (RM) suggesting that persistent viral 
infection occurs despite multiple attenuating mutations.  
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3.3 Materials and Methods 
3.3.1 Cells, viruses, and reagents. Telomerized rhesus fibroblasts (TRFs) [377] were 
maintained in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum and 
were grown at 37°C in humidified air with 5% CO2. Generation of the RhCMV 68-1 BAC was 
previously described [344]. To derive the virus, TRFs were transformed via electroporation (250 
V, 950 μF) with BAC DNA and cytopathic effect (CPE) was observed after 7 to 10 days.  
 
3.3.2 454 sequencing and annotation of the BAC-cloned RhCMV 68-1 genome. RhCMV 68-
1 BAC DNA was prepared using the NucleoBond AX kit (Macherey-Nagel, Düren, Germany) 
following the manufacturer's instructions. 454 sequencing was carried out on a GS FLX instrument 
using titanium series chemistry by Eurofins MWG Operon (Huntsville, AL). Gap closure was 
performed by Sanger sequencing on an ABI 3730XL sequencer. The other genomes used in this 
study to annotate the RhCMV 68-1 BAC sequence were RhCMV 68-1 (accession number 
AY186194), RhCMV 180.92 (DQ120516), RhCMV CNPRC (EF990255), cynomolgus CMV 
(CyCMV) Ottawa (JN227533), SCMV GR2715 (FJ483968), simian CMV (SCMV) Colburn 
(FJ483969), SCMV Stealth virus 1 (U27883, U27627, U27469, U27770, U27471, and U27238), 
baboon CMV (BaCMV) OCOM4-37 (AC090446), chimpanzee CMV (CCMV) Heberling 
(AF480884), and HCMV Merlin (AY446894).  
 
3.3.3 RhCMV particle purification procedures. RhCMV 68-1 BAC-derived particles were 
purified as described before[18]. The virus was isolated from the culture medium of infected TRFs 
when the cells displayed maximal cytopathic effect. The cellular supernatants were first clarified 
by centrifugation at 7,500 × g for 15 min. The clarified medium was layered over a sorbitol cushion 
(20% d-sorbitol, 50 mM Tris [pH 7.4], 1 mM MgCl2), and virus was pelleted by centrifugation at 
64,000 × g for 1 h at 4°C in a Beckman SW28 rotor. The virus pellet was resuspended in TNE 
buffer (50 mM Tris [pH 7.4], 100 mM NaCl, and 10 mM EDTA). The virus particles were further 
purified by layering them over a discontinuous 5% to 50% Nycodenz (Sigma) gradient in TNE 
buffer and centrifuged at 111,000 × g for 2 h at 4°C in a Beckman SW 41 Ti rotor. The virion band 
in the gradient was isolated with a syringe through the side of the centrifuge tube, and the particles 
were pelleted in a Beckman TLA-45 rotor in a Beckman Optima TL 100 ultracentrifuge at 40,000 
× g for 1 h and washed twice with TNE buffer. The pellet was resuspended in TNE buffer, and 
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electron microscopy was performed to confirm the purity of the sample. In order to assess the 
protein content of the purified virions, a denatured protein preparation was separated on a 
NuPAGE morpholinepropanesulfonic acid (MOPS) gradient gel (Invitrogen, Carlsbad, CA) and 
visualized by Coomassie brilliant blue and silver staining.  
 
3.3.4 Tryptic digestion of RhCMV particles. RhCMV particles were denatured in 8 M urea–
100 mM NH4HCO3–5 mM dithiothreitol (DTT) at 56°C for 30 min. The cysteine residues were 
then alkylated by adding iodoacetamide to a final concentration of 10 mM and incubating in the 
dark at room temperature for 2 h. The sample was then diluted 4-fold with 25 mM NH4HCO3, and 
CaCl2 was added to 1 mM. Methylated, sequencing-grade porcine trypsin (Promega, Madison, 
WI) was added at a substrate-to-enzyme ratio of 20:1 (mass/mass) and incubated at 37°C for 15 h. 
The digested peptides were cleaned up with C18 cartridges, as previously described [378].  
 
3.3.5 Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. Peptides 
were loaded onto capillary columns (75 μm by 65 cm; Polymicro) packed with C18 beads (3-μm 
particles; Phenomenex) connected to a custom-made 4-column liquid chromatography system. 
The elution was performed in an exponential gradient from 0 to 100% solvent B (solvent A, 0.1% 
formaldehyde; solvent B, 90% acetonitrile–0.1% formaldehyde) over 100 min with a constant 
pressure of 10,000 lb/in2 and a flow rate of ∼400 nl/min. Alternatively, the separation was 
performed in a nanoAcquity instrument (Waters) using a longer capillary column (75 μm by 100 
cm; Polymicro) with a gradient of 0 to 45% solvent B over 10 h at a constant flow rate of 150 
nl/min. Eluted peptides were analyzed online in a linear ion trap Orbitrap mass spectrometer (LTQ 
Orbitrap XL; Thermo Scientific, San Jose, CA). Peptides were measured over a 400 to 2000 m/z 
range, and the 6 most intense ions were selected for collision-induced dissociation (isolation width 
of 3 Da and 35% normalized collision energy) in the linear ion trap. Each parent mass was 
fragmented once before being dynamically excluded for 60 s. 
 
3.3.6 Data analysis. LC-MS/MS spectra were converted into DTA files using default parameters 
and submitted for SEQUEST (v27.12) [379] searches against the RhCMV open reading frames 
(275 sequences) or stop-to-stop reads (4,304 sequences, ≥30 amino acid residues), the Macaca 
mulatta Ensembl database (21,905 sequences, downloaded from www.ensembl.org on 15 
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November 2010), and 186 common contaminant sequences (downloaded from 
www.ncbi.nlm.nih.gov/protein in August 2006). All sequences were searched in both the correct 
and reverse orientations (i.e., for a total of 44,732 or 52,790 searched sequences). Parameters 
employed for searches were as follows: (i) 50 ppm and 1 Da for peptide and fragment mass 
tolerance, respectively; (ii) tryptic digestion; (iii) maximum of two missed cleavage sites; and (iv) 
cysteine carbamidomethylation and methionine oxidation as static and variable modifications, 
respectively. Peptide-to-spectrum matches were then filtered with a mass spectrum-generating 
function (MS-GF) score of ≤1 × 10−8, and each protein was required to have at least one peptide 
with an MS-GF score of ≤1 × 10−10, which resulted in less than 1% of reverse sequences. Protein 
abundances were estimated with the exponentially modified protein abundance index (emPAI) as 
previously described [380].  
 
3.3.7 Nucleotide sequence accession number. The final BAC sequence determined in this work 
was submitted to GenBank under accession number JQ795930.  
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3.4 Results 
3.4.1 Determining the full-length sequence of the RhCMV 68-1 BAC. 
The rhesus cytomegalovirus strain 68-1 was cloned as a self-excisable bacterial artificial 
chromosome [344]. The BAC-derived virus showed essentially the same growth kinetics as the 
parental strain in vitro and retained pathogenicity in vivo [344]. Furthermore, BAC-derived viruses 
used as vaccine vectors against simian immunodeficiency virus (SIV) established and maintained 
persistent infection as indicated by shedding from infected animals as well as long-term effector 
memory T cell responses indicative of the continuous presence of viral antigens ([359],[353]). 
Previously, a full-length sequence of RhCMV 68-1 was assembled from individually sequenced 
cosmids. To determine whether the molecular clone preserved as a BAC was identical to this 
parental strain, DNA of the RhCMV BAC was obtained from Escherichia coli (EL250) ([381]) 
and subjected to shotgun sequencing on a GS FLX instrument using titanium series chemistry 
(Eurofins MWG Operon, Huntsville, AL). The resulting DNA contigs were assembled in silico, 
and gap closure was performed by Sanger sequencing technology on an ABI 3730XL sequencer. 
The final BAC sequence was aligned against the published RhCMV 68-1 sequence (accession 
number AY186194), and the differences in the DNA sequences between the viral genomes were 
resequenced for independent confirmation. By this analysis, a total of 39 DNA changes in the 68-
1 BAC compared to the published 68-1 sequence were confirmed, of which 18 were substitutions, 
9 were deletions, and 12 were insertions (Table 1). Out of the 39 mutations detected, 31 were 
located in regions predicted to encode a viral protein, whereas 8 mutations were in noncoding 
regions. To distinguish between true mutations present in the BAC but not in the parental 68-1 
sequence and sequence differences due to errors in the published 68-1 sequence, we also compared 
the BAC sequence to the second fully sequenced RhCMV genome of strain 180.92 
(DQ120516)[319]. If the BAC sequence was identical to that of 180.92 but different from that of 
68-1, the change was considered a sequencing error in the previous 68-1 sequence. In contrast, if 
the BAC sequence differed from both the 68-1 sequence and the 180.92 sequence, the new 
sequence was considered a mutation acquired during molecular cloning of the BAC. According to 
this analysis, only 13 true mutations are present in the BAC-derived genome compared to the 
parental genome, i.e., 10 point mutations, 1 insertion of a single base, 1 insertion of two bases, and 
1 deletion of a single base. These mutations cause amino acid changes in the following ORFs: 
Rh08 (RL11 family), Rh13.1 (RL13), Rh61/Rh60 (UL36), Rh67.1 (UL41A), Rh72 (UL45), 
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R152/Rh151 (UL119/UL118), Rh164 (UL141), Rh194 (US14), and Rh197 (US14) (Table 1; see 
Fig.S1A to I in the supplemental material). Overall, this result suggests that only a very limited 
number of changes occurred in the RhCMV genome despite extensive tissue culture and repeated 
plaque purification that occurred during BAC cloning.  
 
Change 
No. 
Nucleotide 
No. 
Change ORF AA 
Change 
Cause 
1 2487 G → A Rh01 G → E Sequencing Error 
2 3931 C → T Rh05 A → V Sequencing Error 
3 4642 G → A none none Sequencing Error 
4 4650 G → A none none Sequencing Error 
5 5369 C → T Rh07 silent Sequencing Error 
6 6126 G → A Rh08 silent Sequencing Error 
7 6327 A → - Rh08 Frameshift Mutation 
8 9869 - → C Rh10 Frameshift Sequencing Error 
9 9877 G → - Rh10 Frameshift Sequencing Error 
10 9958 - → A none none Sequencing Error 
11 10846 - → A none none Sequencing Error 
12 10951 T → - none none Sequencing Error 
13 12415 A → G Rh13.1 Stop → W Mutation 
14 12820 - → CT Rh13.1 Frameshift Mutation 
15 45935 C → - Rh57 Frameshift Sequencing Error 
16 48651 - → T Rh61/Rh60 Frameshift Mutation 
17 52900 C → A Rh67.1 W → C Mutation 
18 57844 C → T Rh72 E → K Mutation 
19 57848 C → T Rh72 C → Y Mutation 
20 78626 C → G Rh89 C → S Sequencing Error 
21 78687 G → T Rh89 Q → K Sequencing Error 
22 95620 C → - Rh100.1 Frameshift Sequencing Error 
23 98911 A → G none none Mutation 
24 153493 C → T Rh152/Rh151 W → Stop Mutation 
25 162589 – 162610 
- → 
AGACTAATTTGACCCGTCTCTC 
none none Sequencing Error 
26 169753 G → A Rh164 P → L Mutation 
27 184466 T → G none none Mutation 
28 202215 G → A Rh194 S → F Mutation 
29 204412 C → T Rh197 W → Stop Mutation 
30 206264 - → A Rh199 Frameshift Sequencing Error 
Results                                                   48 
 
31 219638 T → - Rh216 Frameshift Sequencing Error 
32 219641 A → - Rh216 Frameshift Sequencing Error 
33 219642 C → - Rh216 Frameshift Sequencing Error 
34 219645 C → - Rh216 Frameshift Sequencing Error 
35 219728 - → G Rh216 Frameshift Sequencing Error 
36 219729 - → C Rh216 Frameshift Sequencing Error 
37 219730 - → T Rh216 Frameshift Sequencing Error 
38 219732 - → A Rh216 Frameshift Sequencing Error 
39 219733 - → C Rh216 Frameshift Sequencing Error 
 
Table 1: Changes in the nucleotide sequence of the RhCMV 68-1 BAC compared to the parental virus 
 
3.4.2 BAC-carried ORFs containing mutations. 
Mutations in BAC ORFs could be divided into two categories: terminal mutations that changed 
the length of a given ORF and internal mutations that resulted in single amino acid changes within 
protein sequences (Table 2). As described previously[376], a point mutation in Rh61/Rh60 of the 
BAC introduces a premature stop codon resulting in a truncated, nonfunctional protein. Rh61/60 
encodes the RhCMV homologue of UL36, also called viral inhibitor of caspase-8-induced 
apoptosis (vICA). The full-length RhCMV protein was shown to be fully functional, whereas the 
shortened mutant is not, leaving the virus vulnerable to induced premature apoptosis in vitro.  
 
ORF (RhCMV) ORF    (HCMV) 
bp 
RhCMV 
68-1 
AA 
RhCMV 
68-1 
bp 
RhCMV 
68-1 BAC 
AA 
RhCMV 
68-1 BAC 
Rh08 RL11 family 516 171 507 168 
Rh13.1 RL13 300 99 969 322 
Rh61/Rh60 UL36 1416 471 765 254 
Rh67.1 UL41A 240 79 240 79 
Rh72 UL45 2550 849 2550 849 
Rh152/Rh151 UL119/UL118 1272 423 1212 403 
Rh164 UL141 1293 430 1293 430 
Rh194 US14 834 277 834 277 
Rh197 US14 726 241 702 233 
 
Table 2: Nucleotide changes affecting the lengths or sequences of predicted ORFs in BAC-derived RhCMV 68-1 
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Rh08 and Rh13.1, two members of the viral RL11 family, contain mutations in the RhCMV 
68-1 BAC. Since the RL11 family of proteins shows a very high degree of sequence variability 
even within a CMV species [382], the most closely related HCMV protein for Rh08 is difficult to 
define. The highest degree of homology is displayed by HCMV UL1, a predicted glycoprotein 
with unknown function. Figure S1A in the supplemental material shows a comparison of the Rh08 
proteins encoded by the RhCMV 68-1 BAC, the RhCMV 68-1 virus, and the RhCMV 180-92 
strain. The N-terminal portion of the protein is almost completely conserved between all 
sequences, whereas the C-terminal tail is entirely different in all published sequences. This finding 
suggests that the N terminus is functionally more important.  
Rh13.1 contains an A → G substitution in the BAC, which mutates the ORF's stop codon 
into a tryptophan codon, prolonging the entire ORF to 969 bp, more than three times the length of 
the ORF carried by the original strain 68-1. The BAC-encoded Rh13.1 now displays a significant 
homology to HCMV RL13 in both length and sequence, whereas both RhCMV 68-1 and RhCMV 
180.92 seem to carry truncated versions of this ORF. A closer inspection of the 68-1 and 180.92 
Rh13.1 sequences suggests that each virus contains a premature stop codon due to a single-base-
pair substitution, since the Rh13.1 ORF continues beyond the stop codon, encoding a highly 
conserved protein sequence (Fig.15). Similarly, SCMV strain GR2715 contains a full-length RL13 
homologue, whereas SCMV Colburn encodes a truncated version of the protein due to a premature 
stop codon. Similar to the case for RhCMV, the Colburn ORF continues beyond the stop codon, 
encoding an RL13-homologous protein fragment that is almost identical to the protein sequence 
encoded by strain GR2715. For HCMV, it was recently demonstrated that full-length RL13 protein 
inhibits viral replication in fibroblasts [303], resulting in the rapid selection of nonfunctional RL13 
variants in vitro. Therefore, it seems likely that the truncated RL13 ORFs found in several OWM 
CMVs represent such fibroblast adaptation mutants. Interestingly, despite the fact that the RL13 
homologue carried by the BAC seems to be full length, it is likely nonfunctional since it contains 
multiple mutations that frameshift part of the protein's C terminus. As a result, the predicted amino 
acid sequence of this protein part differs substantially from those of all other RL13 proteins 
encoded by OWM CMVs (Fig.15). It was previously shown that the BAC-derived virus shows the 
same growth characteristics in fibroblasts as the parental 68-1 strain [344]. The fact that all three 
currently sequenced RhCMV genomes contain independent mutations in this ORF that likely 
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render it nonfunctional suggests that, similar to the case for HCMV RL13, native Rh13.1 likely 
limits growth in fibroblasts.  
 
Fig.15: Alignment of Rh13.1 (RL13) from different species of Old World monkey cytomegaloviruses. (A) RL13 is 
mutated in most Old World NHP CMV isolates. The Rh13.1 (RL13) ORFs of the RhCMV 68-1 BAC, RhCMV 68-1, 
RhCMV 180.92, SCMV GR2715, and SCMV Colburn were aligned. Conserved amino acids are shown in yellow, 
whereas nonconserved amino acids are shown in red. Truncations due to premature stop codons are shown in green. 
(B) RL13 is highly conserved in Old World NHP CMVs. Stop codons were ignored for in silico translation, and an 
alignment of the resulting sequences is shown. A hypothetical consensus sequence for full-length Rh13.1 of RhCMV 
is also included. Both CLUSTAL format alignments were generated using MAFFT L-INS-i (v6.860b).  
 
Two members of the US12 family of proteins, Rh194 and Rh197, show mutations in the 
BAC compared to either 68-1 or 180.92 (see Fig.S1H and I in the supplemental material). Whereas 
the mutation in Rh194 is a single point mutation leading to a serine-to-phenylalanine substitution, 
Rh197 is truncated by 8 amino acids (aa) in the BAC due to point mutations resulting in a 
premature stop codon. Whether these mutations affect protein function is uncertain. The US12 
family is found only in primate CMVs [383] and encodes predicted seven-transmembrane-domain 
proteins that have some features in common with G-protein-coupled receptors [384]. Both Rh194 
and Rh197 are homologues of HCMV US14 which is additionally homologous to Rh195 and 
Rh196. Since US14 and other US12 family members locate to the cytoplasmic virion assembly 
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compartment (AC) in some cells [385], a possible role for these proteins in the process of virion 
maturation and egress is suspected.  
The ORFs Rh152/Rh151 encode the RhCMV homologue of the spliced viral Fcγ receptor 
UL119-UL118 (gp68) of HCMV [257]. In the BAC, a C → T substitution results in a premature 
stop codon, thus truncating the predicted Rh152/Rh151 protein by 20 aa. It is possible that this 
truncation affects the function of BAC-derived Rh152/Rh151, which is expected to be involved in 
counteracting the humoral immune response, similarly to gp68 of HCMV [300, 301].  
Three additional ORFs in the RhCMV 68-1 BAC show internal point mutations: Rh67.1, 
Rh72, and Rh164, the homologues of HCMV UL41A, UL45, and UL141, respectively (see 
Fig.S1D, E, and G in the supplemental material). UL41A is a protein of unknown function with a 
potential transmembrane domain [346]. UL45 of HCMV is homologous to the R1 subunit of the 
cellular ribonucleotide reductases and forms a complex with the cellular R2 subunit, effectively 
forming a mixed viral-cellular enzyme [386]. HCMV lacking UL45 showed a growth defect at 
low multiplicity of infection (MOI) in fibroblasts [387] but not at high MOI in endothelial cells 
[388], whereas the MCMV homologue of M45 is essential for viral replication in endothelial cells 
[389]. UL141 mediates NK cell immune evasion by downregulating CD155 and CD112, ligands 
of the NK cell receptors DNAM-1 (CD226) and TACTILE (CD96) [390, 391]. The UL141 
homologue Rh164 is absent in RhCMV 180.92 due to genomic rearrangements during fibroblast 
adaptation [319, 345]. Whether any of the point mutations found in the BAC-derived RhCMV 
genome affects protein function remains to be determined.  
 
3.4.3 Reevaluating the RhCMV genome. 
We further wanted to determine which ORFs were mutated in the BAC compared to a prototypical 
wild-type RhCMV sequence. To assemble the ORF map of such a RhCMV prototype, we initially 
recapitulated previous ORF identification methods using a 300-bp cutoff and the NCBI software 
ORF Finder [392] for full-length RhCMV genomes (strain 68-1 [343] and strain 180.92 [319]) and 
the ULb′ region of low-passage-number isolate RhCMV CNPRC (accession number EF990255) 
[345]. By this count, RhCMV 68-1 had 268 predicted ORFs, RhCMV 180.92 had 261 predicted 
ORFs, and the ULb′ region from the low-passage-number isolate of RhCMV had 19 ORFs (see 
Fig.S2 in the supplemental material). This analysis predicted 12 new genes, including Rh00 and 
Rh00.1 in RhCMV 180.92 and Rh142.4 and Rh220.1 in RhCMV 68-1. The new ORFs Rh00.2, 
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Rh94.1, Rh96.1, Rh228.1, and Rh231 are predicted for both RhCMV strains, whereas ORFs 
Rh163.1, Rh165.1, and Rh166.1 are conserved between RhCMV 68-1 and the ULb′ region of the 
low-passage-number isolate RhCMV CNPRC as described previously [345]. However, the total 
number of ORFs predicted by this method for either RhCMV strain was substantially higher than 
that for any other published CMV genome (HCMV [347], CCMV [346], mouse CMV [MCMV] 
[348], rat CMV [RCMV] [349], and guinea pig CMV [GPCMV] [350, 351]). Moreover, this 
annotation predicted that eight ORFs were unique to RhCMV 68-1 (Rh09, Rh39, Rh61, Rh93, 
Rh94, Rh142.4, Rh153, and Rh220.1) and that four ORFs were unique to RhCMV 180.92 (Rh13.1, 
Rh106.1, Rh142.3, and Rh178.2). This analysis raised the question whether RhCMV indeed had 
a higher number of ORFs than other primate CMVs and whether different strains of RhCMV 
differed substantially in their ORF content or whether these RhCMV-specific and strain-specific 
ORFs were, in fact, artifacts of the annotation method used and in reality do not encode proteins.  
 
 
Fig .16: Phylogenetic trees of the major capsid protein (UL48) and the viral DNA polymerase (UL54) of Old World 
primate cytomegaloviruses. MCMV K181 M48 (A) (CAP08095) and M54 (B) (CAP08103) were used for comparison 
in the graphs. The phylogenetic trees were generated using Geneious Pro 5.5.2.  
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Fig.17: Conservation of RhCMV ORFs compared to those of OWM, chimpanzee, and human CMVs. Comparison of 
different RhCMV and OWM CMV genomes reveals the hypothetical ORF composition of wild-type RhCMV. 
Conserved ORFs are shown in green. ORFs in yellow are members of the RL11 family in HCMV, a gene family that 
is conserved albeit highly polymorphic so that homologies between single family members cannot be clearly assigned. 
Genes in red are either absent from the indicated OWM CMVs or not conserved in human and great ape CMVs. Gray 
indicates missing sequence information. Shown in light green are two ORFs (BaCMV UL30 and UL144) that show 
strong sequence homology to their respective RhCMV and HCMV homologues but lack a start codon. ORFs 
highlighted in orange in the leftmost column were identified by proteomics in RhCMV virions.  
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To obtain a higher level of confidence in our ORF predictions, we took advantage of the 
recently determined full-length genome sequences for CMVs from OWM species that are 
evolutionarily closely related to rhesus macaques: cynomolgus CMV Ottawa (JN227533), simian 
CMV GR2715 (FJ483968), simian CMV Colburn (FJ483969), simian CMV Stealth virus 1 
(U27883, U27627, U27469, U27770, U27471, and U27238), and baboon CMV OCOM4-37 
(AC090446) (Fig.16). When the ORF predictions for the two RhCMV strains were compared to 
the ORF predictions for these other OWM CMVs (Fig.17), it immediately became apparent that 
almost all of the “RhCMV-specific” ORFs (i.e., ORFs only found in RhCMV) were not conserved 
in other OWM CMVs. Moreover, these RhCMV-specific ORFs were mostly or entirely carried 
within other ORFs on either the same or the opposite DNA strand of the RhCMV genome (Fig.17; 
see Fig.S2 in the supplemental material). Furthermore, most of these RhCMV-specific ORFs were 
rather small, with an average size of 417 bp. Therefore, we conclude that these ORFs most likely 
do not represent true genes, i.e., that they do not encode unique proteins. Removal of these small 
and overlapping ORFs from the ORF list results in a prediction of 167 ORFs for RhCMV strain 
68-1 and 160 ORFs for RhCMV 180.92. Taking this together with the BAC sequence and the 
RhCMV CNPRC sequence, it was now possible to generate a new ORF map for a prototypical 
wild-type RhCMV that contains 172 ORFs (Fig.18). Two different nomenclatures are in use for 
the various ORFs annotated in RhCMV [319, 343]. In Fig.18 we used the nomenclature introduced 
by Hansen et al. [343] for all ORFs. For ORFs first described by Rivailler et al. [319] or by us in 
this study, we chose names according to the original nomenclature by Hansen et al. to simplify the 
nomenclature. Additionally, a nomenclature is used that was recently introduced by Davison et al. 
[3] to underline the close relationship of most RhCMV proteins to their HCMV or OWM CMV 
homologues. Comparison of the prototypical RhCMV genome to those of chimpanzee CMV 
(Heberling, AF480884) and human CMV (Merlin, AY446894) reveals that 80% of the RhCMV 
ORFs have identifiable homologues in HCMV or CCMV and that 90% of the RhCMV ORFs show 
conservation at least at the protein family level (RL11 family) (Fig.17). In fact, almost every ORF 
carried between Rh31 (UL13) and Rh164 (UL141) of RhCMV is homologous to a corresponding 
gene in ape and human CMVs. Only two regions within the RhCMV genome diverged 
substantially from CMVs of humans and apes. The first region comprises the RL11 gene family, 
which shows an extremely high sequence variation even within a given CMV species such as 
HCMV [382]. The second unique genome region in RhCMV is homologous to the ULb′ region of 
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HCMV. This region contains a number of genes found only in OWM CMVs between the ORFs 
encoding homologues of UL141 and US1. In HCMV, this region also contains internal repeats that 
are lacking in RhCMV (e.g., IRS1) (Table 3). As previously described, laboratory strains of both 
HCMV and RhCMV display multiple deletions and mutations in this region due to fibroblast 
adaption [345]. Although diverging substantially between RhCMV and great ape CMVs, this area 
of the genome is highly conserved within the OWM CMVs with the exception of Rh165. The 
ORFs Rh165 and Rh166 are conserved among all RhCMV strains and also among the closely 
related CyCMV strain Ottawa, whereas SCMV and BaCMV carry only one copy of this gene, 
which shows stronger homology to Rh166 than to Rh165. As shown in Fig.19, Rh166 and Rh165 
are closely related and most likely represent the result of a recent gene duplication event. The 
Rh165 ORF is thus the only bona fide RhCMV-specific ORF when our filtering criteria are 
applied. Rh166 shows weak homology to UL133 and UL138 of HCMV [393]. The UL133-UL138 
locus in HCMV has been implicated in latency [113], and it has been hypothesized that the region 
Rh166-Rh171 performs a similar function in RhCMV [393]. However, the functions of these genes 
as well as those of most OWM CMV-specific genes in the ULb′ region remain to be determined. 
The only gene product in this region that has been characterized is Rh178 (VIHCE), which was 
shown to inhibit expression of the major histocompatibility complex class I (MHC-I) heavy chain 
[279, 280]. This region also carries several ORFs encoding predicted chemokines [345, 394]. 
HCMV ORF Function Reference 
RL5A no known function  
RL6 no known function  
RL8A no known function  
RL9A no known function  
RL10 no known function  
RL11 type 1 membrane protein; binds IgG Fc; involved in immune regulation 
Lilley et al., [256]; Atalay et al., 
[257] 
RL12 RL11 family, no known function  
UL1 RL11 family, no known function  
UL2 no known function  
UL4 RL11 family, no known function  
UL5 RL11 family, no known function  
UL7 RL11 family, no known function  
UL8 RL11 family, no known function  
UL9 RL11 family, no known function  
UL10 RL11 family, no known function  
UL15A no known function  
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UL16 
NK-cell evasion through intracellular retention of NKG2D ligands MICB, 
ULBP1, and ULBP2 
Dunn et al., [236]; Welte et al., [395] 
UL18 
MHC-I homologue, NK cell inhibition through binding  to the inhibitory NK 
cell receptor LIR-1 
Cosman et al., [396]; Reyburn et al., 
[397]; Prod’homme et al., [233] 
UL22A binds CC chemokine RANTES; involved in immune regulation (predicted)  
UL30A no known function  
UL74A no known function  
UL147A no known function  
UL142 
NK-cell evasion through intracellular retention of NKG2D ligands MICA 
and ULBP3 
Chalupny et al., [238]; Bennett et al., 
[398] 
UL140 no known function  
UL139 
highly polymorphic type I membrane glycoprotein; shared sequence 
homology with human CD24, a signal transducer modulating B-cell 
activation responses 
Qi et al., [399]; Bradley et al., [400] 
UL138 needed to establish latency in vitro in CD34  hematopoietic progenitor cells Goodrum et al., [113] 
UL136 support of pUL138 expression Grainger et al., [114] 
UL135 support of pUL138 expression Grainger et al., [114] 
UL133 support of pUL138 expression Grainger et al., [114] 
UL148A no known function  
UL148B no known function  
UL148C no known function  
UL148D no known function  
UL150 no known function  
UL150A no known function  
IRS1 
transcriptional activator; blocks phosphorylation of eIF2alpha and host 
shutoff of protein synthesis; binds dsRNA; involved in gene regulation; 
involved in translational regulation 
Hakki et al., [401] 
US7 no known function  
US9 
cytoplasmic glycoprotein dispensable for growth in tissue culture, no 
undisputed function 
Huber et al., [402]; Mandic et al., 
[403] 
US15 
type 3 membrane protein; 7 transmembrane domains; possibly involved in 
virion morphogenesis (predicted) 
 
US16 
type 3 membrane protein; 7 transmembrane domains; possibly involved in 
virion morphogenesis (predicted) 
 
US27 
7 transmembrane domains; putative chemokine receptor; possibly involved 
in intracellular signaling (predicted) 
 
US33A no known function  
US34 Expressed, no known function Scott et al., [404] 
US34A no known function  
 
Table 3: HCMV ORFs not found in rhesus or OWM CMVs 
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Fig.18: Annotated genome map of a hypothetical low-passage-number RhCMV isolate. The genome of this 
hypothetical RhCMV strain was generated as a consensus sequence between the fully sequenced strains 68-1 and 
180.92 and the ULb′ region of low-passage-number isolate RhCMV CNPRC. It contains all ORFs found in a low-
passage-number RhCMV isolate in their correct order. The nomenclature is based on the original nomenclature 
introduced by Hansen et al. ([359]), whereas the nomenclature in parentheses was newly introduced by Davison et al. 
([3]) and was slightly modified by us. The genomic map was generated using Geneious Pro 5.5.2.  
 
 
Besides the RL11 and ULb′ regions, only a small number of predicted genes are unique to the 
OWM CMV subfamily. One characterized gene is Rh10 (vCOX-2), a viral homologue to the gene 
for the host cyclooxygenase-2 enzyme (COX-2), which is a member of the eicosanoid synthetic 
pathway. Unlike HCMV ([405], [406],[407]), RhCMV does not induce cellular COX-2 
expression, suggesting that the virus encodes its own copy of the protein to compensate for this 
lack. vCox-2 was shown to facilitate growth in endothelial cells ([352]). Other ORFs not found in 
great ape and human CMVs are Rh04, Rh188, Rh228, and Rh228.1, which have not been 
characterized to date.  
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Fig.19: Phylogenetic tree of the OWM CMV Rh165/Rh166 gene family. UL138 of HCMV strain Merlin was used as 
an outgroup because it showed some homology to the Rh165/Rh166 gene family. The phylogenetic tree was generated 
in Geneious Pro 5.5.2. 
  
HCMV-specific ORFs that are absent in RhCMV are summarized in Table 3, using the 
HCMV strain Merlin as the prototype HCMV strain [347, 364]. While most gene families are 
conserved between ape CMVs and monkey CMVs, individual family members might differ. 
Examples are the RL11, UL146/147, and US12 families of proteins. The latter comprises 10 
members in HCMV from US12 to US21, of which the ORFs UL15 and UL16 have no homologue 
in RhCMV. No function is known for the two proteins encoded by these ORFs.  
Interestingly, all OWM CMVs lack several known HCMV antagonists of NK cell function, 
including UL16, which retains the NKG2D ligands MICB, ULBP1, and ULBP2 [236, 395], 
UL141, which retains the NKG2D ligands MICA and ULBP3 [238, 398, 408], and UL18, which 
encodes an MHC-I homologue that binds to the inhibitory NK cell receptor LIR-1 [233, 396, 397]. 
Since evasion of NK cell immunity is conserved in MCMV [409], it is likely that OWM CMV-
specific genes will encode NK cell evasins.  
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In addition to the HCMV-specific ORFs absent from WT RhCMV, the RhCMV 68-1 BAC 
lacks the endothelial cells tropism genes Rh157.5 (UL128) and Rh157.4 (UL130) [345], the above-
mentioned UL36, and the viral chemokine genes Rh158.2 (vCXCL4), Rh158.3 (vCXCL3), and 
Rh161.1 (vCXCL2) (Fig.20).  
 
 
Fig.20: Annotated genome map of the RhCMV 68-1 BAC. The genome map shows the genomic organization of the 
RhCMV 68-1 BAC. Viral ORFs are shown in orange, and BAC genes are shown in green. Approximate locations of 
mutations described in Table 1 are shown as red arrows, and RhCMV ORFs mutated compared to the RhCMV 68-1 
parental virus sequence are shown in pink. The ORF annotation is based on the filtered ORF analysis discussed in the 
text. The sequence is available in GenBank (accession number JQ795930). The genome map was generated using 
Geneious Pro 5.5.2.  
 
3.4.4 Validating ORF predictions by proteomics. 
To verify our ORF predictions in an unbiased manner, we determined the proteome of RhCMV 
virions. While this approach is limited to verifying ORFs that are incorporated into virions, 
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previous analysis of HCMV (59 proteins) ([18]) and MCMV (58 proteins) ([410]) virions revealed 
that more than a third of all predicted ORFs are contained in virus particles.  
 
Fig.21: Isolation and purification of RhCMV virions. (a) RhCMV virions were purified from the supernatant of 
telomerized rhesus fibroblasts infected with BAC-derived RhCMV 68-1 (MOI of 0.01) until complete cytopathic 
effect was reached (10 days). Virus particles were separated and concentrated using a Nycodenz gradient as described 
in Materials and Methods. The single band isolated from the gradient was enriched for herpesvirus-like particles of 
170 nm to 200 nm with an icosahedral capsid of 80 nm to 90 nm in diameter as revealed by electron microscopy. (b) 
Gradient-purified virus particles were highly enriched and contained only minor contaminations of cellular debris. No 
dense bodies or NIEPs could be identified. (c) Purified virions were lysed, and 10 μg of proteins were 
electrophoretically separated using NuPAGE MOPS gradient gels and visualized by Coomassie blue or silver staining.  
 
 
Results                                                   61 
 
 
Results                                                   62 
 
 
 
Fig.22: Protein composition of BAC-derived RhCMV 68-1 virions. (A) Shown are all proteins identified in at least 
one of six MS/MS runs (two biological repeats and four technical repeats; see Fig.S2 in the supplemental material). 
Red bars indicate the ranked average abundance relative to total virion proteins of all virus proteins identified in three 
repeat runs of the same sample (repeats B01, B02, and B03 of biological repeat B). The standard deviation (STDEV) 
is shown for the mean abundance of the three technical repeats. Proteins identified in other experiments are included 
but were not quantified (NQ). If applicable, the HCMV nomenclature for the identified proteins is shown in addition 
to the RhCMV nomenclature. (B) The proteins shown in panel A were grouped according to function and/or 
localization within the virion.  
 
The RhCMV BAC-derived virions were isolated from the supernatant of infected 
telomerized rhesus fibroblasts as described earlier for HCMV ([18]). Virions formed a single band 
on the Nycodenz gradient (Fig.21a), and the most abundant proteins contained in this fraction 
migrated at very similar molecular weights as and displayed abundances comparable to those of 
previously reported HCMV virion proteins upon NuPAGE (Fig.21c) ([18]). Additionally, we 
performed electron microscopy (EM) to visualize the particles and to verify the purity of the 
sample (Fig.21a and b). RhCMV virions displayed a diameter ranging from 170 nm to 200 nm, 
with an icosahedral capsid of about 80 nm to 90 nm in diameter. While some cell debris 
contamination was visible (Fig.21b), all viral particles were highly similar in appearance, 
indicating that the virion preparation was rather homogeneous. 
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The samples were then analyzed by one-dimensional (1D) LC-MS/MS and searched 
against stop-to-stop translated sequences of the RhCMV 68-1 BAC genome for ORFs encoding 
proteins of ≥30 aa. The virion preparation was analyzed by MS/MS upon elution from a 0 to 100% 
acetonitrile gradient over 100 min. This analysis was repeated three times, and the protein content 
in each experiment was quantified. The average percentage of these results is shown in Fig.22 (red 
bars). Additional proteins that were identified in independent virion preparations or upon MS/MS 
from samples eluted over a longer time period (10 h) from a 0 to 40% nanoAcquity gradient are 
also shown, but these proteins were not included in the quantification. In total, peptides of 70 
different viral proteins could be identified in at least one of the MS/MS analyses (Fig.22A; see 
Tables S1 and S2 in the supplemental material). All of these proteins were predicted by the filtered 
ORFs (Fig.20), with the exception of Rh164.1, which was not included in our prediction due to its 
small size. However, similar to the case for other predicted ORFs, Rh164.1 is highly conserved in 
OWM CMVs (O11). In contrast, “RhCMV-specific” ORFs predicted by ORFinder (see Fig.S2 in 
the supplemental material) were notably absent from the virion proteome. The proteomics analysis 
thus further supported our conclusion that most, if not all, RhCMV ORFs are shared among OWM 
CMVs. Of the 70 proteins identified in RhCMV virions, 61 are homologous to HCMV, and these 
homologues corresponded to 99 mol% of virion proteins. Thus, RhCMV virions consist largely of 
proteins conserved in HCMV. The most abundant protein was pp65b (Rh112, UL83b). With 7.24 
mol%, pp65b was almost twice as abundant as the second pp65 homologue, pp65a (Rh111, 
UL83a), with 3.76 mol%. Interestingly, this correlates with the finding that Rh112 induces stronger 
humoral and cellular immune responses in vivo than Rh111 [343, 411]. Overall, 22.03 mol% of 
the proteins can be categorized as capsid proteins, 45.09 mol% as tegument proteins, 22.38 mol% 
as envelope or glycoproteins, and 5.58 mol% as proteins of the transcription-replication 
machinery, and 4.92 mol% are uncharacterized proteins with unknown function and localization 
(Fig.22B). These ratios are remarkably similar to ratios determined by Varnum et al. [18] for 
HCMV AD169, where the virion was comprised of 30% capsid proteins, 50% tegument proteins, 
13% envelope proteins, and 7% undefined proteins. The only major difference between HCMV 
and RhCMV is that capsid proteins were comprised of larger amounts of UL48A and UL80 (12.6% 
and 7.7%, respectively) in HCMV, whereas among the RhCMV capsid proteins they comprised 
only 2.34 mol% and 0.10 mol%. 
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3.5 Discussion 
By combining genomic sequencing, comparative genomics, and virion proteomics, we generated 
a simplified ORF map of rhesus CMV in general and of a molecular clone derived from strain 68-
1 in particular. This approach filtered out many ORFs previously annotated as RhCMV specific, 
resulting in a much larger percentage of RhCMV ORFs being homologous to HCMV ORFs than 
previous ORF annotations had indicated. Our results thus further support the notion that infection 
of rhesus macaques by RhCMV is the closest animal model for infection of humans with HCMV. 
Molecular cloning of viral strains as a BAC singles out a viral genome as the starting point 
for the generation of all subsequent recombinant viruses. Thus, any initial genomic variability that 
was present in the original isolate will be lost upon BAC cloning. Moreover, the in vitro 
manipulation and selection occurring during BAC cloning might further result in divergence from 
the BAC-derived genome of the parental sequence. However, the sequence relationship between 
parental CMV isolates and their BAC offspring has, so far, been studied in only one example: the 
HCMV isolate Merlin. In that instance, the BAC clone of Merlin contained 12 differences 
compared to the parental isolate [303]. For RhCMV, we concluded that the BAC-derived sequence 
contained 13 nucleotide differences compared to strain 68-1. Thus, it seems that the genetic 
variability present within a given CMV strain or isolate is rather limited and that BAC-derived 
molecular clones contain a very limited set of mutations. In contrast, recent deep-sequencing 
results for CMV genomes ex vivo revealed the presence of an unexpectedly complex mixture of 
viral genomes within a given host [412]. However, once an isolate is established in vitro, the 
genomic variability seems to be quite limited, consistent with a low error rate during genome 
replication.  
Interestingly, the adaptations that do occur as a consequence of adaptation to in vitro 
culture of CMV isolates in fibroblasts are remarkably similar in HCMV and RhCMV. Five of the 
12 mutations occurring in the Merlin BAC clustered in UL36 [303]. Similarly, the UL36 
homologue Rh61/Rh60 is mutated in the RhCMV BAC compared to the parental 68-1 strain 
([376]). The independent mutation of this gene upon BAC cloning in two different CMV species 
indicates that expression of UL36 might represent a growth disadvantage in vitro despite its 
antiapoptotic function. In addition, the Merlin BAC contained mutations in RL13, and repairing 
this gene decreased growth kinetics in fibroblasts [303]. The RhCMV BAC contained frameshift 
mutations in the RL13 homologue Rh13.1. Since this gene is truncated in the parental 68-1 strain, 
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it seems that several independent Rh13.1 mutants were present in the original isolate. A detailed 
analysis of HCMV adaptations to tissue culture revealed that RL13 is rapidly mutated ([413]) even 
when starting with a molecular clone [303]. Thus, RL13 seems to be rapidly selected against in 
both HCMV and RhCMV. Finally, the gene UL128 is mutated even prior to BAC cloning both in 
RhCMV and in many HCMV isolates, including Merlin, as discussed elsewhere [414]. Thus, 
compared to their original wild-type strains, BAC clones of both HCMV and RhCMV share 
mutations in three loci: RL13, UL36, and UL128. In previous work, two of these genes, UL36 and 
UL128, were repaired in RhCMV [415], and it was demonstrated that the repaired virus grew 
better in epithelial cells. In contrast, repair of RL13 would be expected to decrease the ability of 
RhCMV to grow in tissue culture as reported for HCMV.  
The impact of these tissue culture adaptations on viral pathogenesis in vivo is not known 
for HCMV, but a recent side-by-side comparison of BAC-derived RhCMV and a low-passage-
number isolate of RhCMV revealed clear signs of attenuation, such as lower plasma titers and 
shedding [416]. However, these attenuations do not prevent BAC-derived RhCMV vectors from 
establishing persistent infections, even in CMV-positive hosts, as evident from persistent immune 
stimulation and long-term, low-level shedding of RhCMV expressing heterologous antigens [353, 
359]. Moreover, RhCMV 68-1 and BAC-derived vectors retain their pathogenicity in fetal 
macaques [417]; P. A. Barry, unpublished data). Therefore, it seems that while tissue culture 
adaptations render BAC-derived viruses less fit, they still seem to retain the ability to establish and 
maintain persistent infection.  
With a total of 173 ORFs, the number of ORFs in the simplified ORF map of RhCMV is 
now in the same range as that reported for other primate CMVs. As shown previously for CCMV 
and HCMV [346], the comparison of closely related CMV genomes greatly facilitates genome 
annotations. By taking into account recently completed full genome sequences of CMVs from Old 
World monkey (OWM) species such as African green monkey (Cercopithecus aethiops), baboon 
(Papio anubis), and cynomolgus macaque (Macaca fascicularis) [321, 418], we constructed a 
hypothetical WT genome. This was facilitated by the fact that the genomes of OWM CMVs are 
highly conserved across different species, with only very minor differences. Most previously 
annotated RhCMV-specific genes are now absent from our prediction. We believe that these ORFs 
are unlikely to encode unique proteins, since most of them are shorter than average and are carried 
within other ORFs on either the same or the opposite DNA strand. Moreover, all ORFs identified 
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by proteomics analysis are conserved among OWM CMVs despite the fact that the peptides were 
compared to an unbiased database consisting of stop-to-stop translated sequences of the RhCMV 
68-1 BAC genome for ORFs encoding ≥30 aa. While it is conceivable that virion proteomics shows 
a bias toward highly conserved ORFs compared to proteomics of the infected cell, our analysis 
detected more than one-third of the predicted ORFs, including many ORFs not conserved in ape 
or human CMV or with low homology. Thus, while the proteomics analysis does not formally rule 
out that RhCMV-specific ORFs exist, the results suggest that such ORFs must be rather rare.  
Taken together, this analysis suggested a high degree of conservation between OWM 
CMVs and HCMV, not only with respect to genome structure but also for the virion composition, 
since the relative abundances of many proteins and the abundance rankings of the proteins were 
very similar in RhCMV 68-1 and HCMV AD169. Moreover, some of the differences detected 
might be due to experimental differences in virion preparations and data analysis. For instance, the 
large amounts of UL80.5 detected in HCMV virions might indicate the presence of noninfectious 
particles (NIEPs) in the HCMV virion preparations, since NIEPs were not separated by the 
gradient used. Moreover, the method we used to determine the relative abundance of proteins in 
our sample was different from the technique used in the previous study. Whereas Varnum et al. 
[18] averaged the intensities of the Fourier transform ion cyclotron resonance (FTICR) MS spectra 
of the most abundant peptides for each protein to determine the relative quantities of the viral 
proteins, we transformed our raw peptide data into molarities and ranked the proteins as moles 
percent of the entire protein amount, taking into account only viral proteins.  
In summary, the combined analysis of BAC sequence, comparative genome analysis, and 
virion proteomics performed here revealed a much closer evolutionary relationship between rhesus 
and human CMVs than previously assumed. These results thus further validate the importance of 
RhCMV as a model system for HCMV, because the close genomic relationship facilitates 
deciphering the role of individual genes and gene families found only in primate CMVs for 
infection, spread, and pathogenesis as well as for shaping and evading the host's immune response. 
Together with the close relationship of the host species, this similarity aids the development of 
therapeutic and preventative approaches for HCMV as well as the development and evaluation of 
novel CMV-based vaccine vector systems.  
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4.1 Abstract 
The most abundantly produced virion protein in human cytomegalovirus (HCMV) is the 
immunodominant phosphoprotein 65 (pp65), which is frequently included in CMV vaccines. 
Although it is nonessential for in vitro CMV growth, pp65 displays immunomodulatory functions 
that support a potential role in primary and/or persistent infection. To determine the contribution 
of pp65 to CMV infection and immunity, we generated a rhesus CMV lacking both pp65 orthologs 
(RhCMVΔpp65ab). While deletion of pp65ab slightly reduced growth in vitro and increased 
defective particle formation, the protein composition of secreted virions was largely unchanged. 
Interestingly, pp65 was not required for primary and persistent infection in animals. Immune 
responses induced by RhCMVΔpp65ab did not prevent reinfection with rhesus CMV; however, 
reinfection with RhCMVΔUS2-11, which lacks viral-encoded MHC-I antigen presentation 
inhibitors, was prevented. Unexpectedly, induction of pp65b-specific T cells alone did not protect 
against RhCMVΔUS2-11 challenge, suggesting that T cells targeting multiple CMV antigens are 
required for protection. However, pp65-specific immunity was crucial for controlling viral 
dissemination during primary infection, as indicated by the marked increase of RhCMVΔpp65ab 
genome copies in CMV-naive, but not CMV-immune, animals. Our data provide rationale for 
inclusion of pp65 into CMV vaccines but also demonstrate that pp65-induced T cell responses 
alone do not recapitulate the protective effect of natural infection. 
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4.2 Introduction 
Human cytomegalovirus (HCMV) persistently infects most of humanity [419]. While the vast 
majority of these infections are asymptomatic and not associated with any pathologic consequence, 
HCMV can cause serious disease in the setting of immune deficiency or immaturity, including 
late-stage AIDS, iatrogenic immune suppression (particularly, organ and stem cell 
transplantation), and fetal infection (where infection can cause hearing loss and mental retardation) 
[420, 421]. In maternal-to-fetal transmission and, to a certain extent, with transplantation, the most 
serious disease appears to arise in the setting of primary HCMV infection [421-423]. Therefore, 
vaccination has been proposed as potential intervention to ameliorate these poor outcomes [41]. 
Although it was initially thought that an effective HCMV vaccine might prevent acquisition of 
HCMV altogether, accumulating data indicate that even the potent natural immunity elicited by 
persistent HCMV infection of healthy subjects is, at best, only partially protective against 
superinfection [424]. Thus, conceptually, the most realistic goal of an HCMV vaccine would be to 
establish a similar level of immunity as present in typical HCMV+ individuals, in HCMV– females 
prior to pregnancy, or all HCMV– subjects prior to transplantation with HCMV+ cells or tissue, so 
as to prevent the potentially severe consequences of primary infection in these subjects. Indeed, 
due to the importance of HCMV in causing congenital disease and complications in transplant 
recipients, vaccine development efforts have been given high priority by the Institute of Medicine 
of the National Academy of Sciences [42].  
While initial approaches to CMV vaccines focused on the development of an attenuated 
strain of HCMV (Towne) [425, 426], more recently, the focus has shifted toward the development 
of subunit vaccines [427], either single antigen vaccines [56] or cocktails of antibody-inducing 
and T cell–inducing subunits [428]. A frequently used T cell–inducing subunit in the development 
of CMV vaccines is the phosphoprotein 65 (pp65), which is consistently a major target for the T 
cell response in infected individuals [121, 429-431]. HCMV pp65 is part of the viral tegument and 
the most abundant virion protein [18]. Multiple functions in modulation of innate and intrinsic 
immunity [151, 152, 432] as well as adaptive immune responses [230, 433, 434] have been 
assigned to HCMV pp65. Moreover, pp65 has been shown to modulate the activity of 
serine/threonine kinases [435-437], Polo-like kinase 1 [438], and the viral UL97 serine/threonine 
kinase [439]. Nevertheless, pp65 is dispensable for viral replication in HCMV-infected fibroblasts 
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[440], but pp65-deleted HCMV showed decreased virus production in monocyte-derived 
macrophages [441].  
The role of pp65 for the establishment and maintenance of persistent infection by HCMV 
is unknown, due to the strict species specificity of HCMV that does not infect immunocompetent 
experimental animals. Thus, animal CMVs are generally used as models to study CMV and CMV 
vaccines [374, 442, 443]. Since host restriction resulted in coevolution of CMVs with their 
respective hosts, infection of rhesus macaques (RMs) with rhesus CMV (RhCMV) represents an 
animal model that closely resembles infection of humans with HCMV [375]. We therefore used 
this model to study the role of RhCMV pp65 in infection and immunity. RhCMV encodes 2 ORFs, 
Rh111 and Rh112, with comparable homology to HCMV pp65 (pp65a ~34%, pp65b ~40%) and 
40% identity to each other [343, 411]. The 2 proteins combined comprise approximately 11% of 
the entire viral proteome in RhCMV virions [444], which is similar to HCMV, in which the single 
pp65 protein makes up 15% of the virion proteins [18]. To examine the function of pp65 in vitro 
and in vivo, we deleted both pp65 homologs from the genome of RhCMV. We characterized the 
impact of pp65 deletion on viral growth in vitro and on the composition of the virion proteome. 
We then determined the role of pp65 for the ability of RhCMV to establish primary or secondary 
persistent infection in RhCMV+ or RhCMV– animals, respectively. By challenging with 
recombinant RhCMV lacking the immunoevasins US2, 3, 6, and 11, a virus incapable of 
superinfecting, we further evaluated whether pp65-specific T cells are required for the protective 
effect of preexisting CMV infection or sufficient to recapitulate T cell–mediated protection 
induced by natural infection. Our observations demonstrate a unique physiologic role for pp65 in 
CMV biology and, moreover, have implications for the use of pp65 as a subunit vaccine.  
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4.3 Methods 
4.3.1 Cells and reagents. TRFs [377] were maintained in DMEM with 10% fetal bovine serum, 
100 U/ml penicillin, and 100 μg/ml streptomycin and were grown at 37°C in humidified air with 
5% CO2.  
 
4.3.2 Viruses and construction of recombinant mutants. BAC-derived RhCMV 68-1 [344] 
was reconstituted by electroporating BAC DNA into TRFs (250 V, 950 μF), and cytopathic effect 
was observed after 7 to 10 days. Recombinant RhCMV mutants were created by homologous 
recombination [445, 446] in E. coli strain EL250, which contains heat-inducible λ-recombination 
(rec) genes and an arabinose-inducible FLP recombinase [381]. Bacterial cultures were grown in 
LB at 30°C until an OD of 0.35 at 600 nm was reached, and the rec genes were induced through 
heat induction by shaking the culture at 42°C in a water bath for 15 minutes. The bacteria were 
subsequently chilled on ice for 10 minutes and made electrocompetent by washing them 4 times 
with cold, deionized water. Electrocompetent EL250 were always made and used fresh to increase 
the recombination efficiency.  
To construct the pp65a and pp65b (RhCMV-Δpp65ab) double-deletion virus, 
recombination primers containing 50 bp homology to regions flanking the pp65 ORFs (forward 
mutagenesis primer 5′-
GAAATAAGTGTGCGGTCTCGGGGGATTGGGGTTTTTATATAGGTATGGGT-3′ and 
reverse mutagenesis primer 5′-
ATGAGCCAAGTTGCGCAGCTCAGTCGGCGGTGTCGCCAAAGTCAGACAAC-3′) were 
used to amplify a kanamycin (Kan) resistance cassette from plasmid pCP015 [447]. The pCP015 
forward primer binding site (5′gtaaaacgacggccagt) and reverse primer binding site 
(5′gaaacagctatgaccatg) were added to the 3′ end of the mutagenesis primers.  
Competent EL250 bacteria containing WT RhCMV BAC were then electroporated with the PCR 
product for recombination using a MicroPulser (Bio-Rad) and selected for Kan and 
chloramphenicol (Cm) resistance at 30°C on LB agar. To induce the FLP recombinase excising 
the Kanr cassette, clones were grown in LB with Cm until they reached an OD of 0.5 at 600 nm 
and incubated with 1 mg/ml arabinose for 1 hour. The bacteria were streaked out on an LB plate 
with Cm selection using an inoculation loop and incubated overnight at 30°C. After colonies were 
visible, clones were replica plated on LB agar with Kan and Cm and LB agar with Cm only, and 
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colonies were selected that had lost Kanr and characterized by restriction digest, Southern blot, 
and partial sequencing. Virus was reconstituted by electroporation of TRFs with 5 to 10 μg of BAC 
DNA.  
To construct the second pp65ab double-deletion mutant containing the SIV ref/tat/nef 
(retanef) fusion protein, which was driven by the EF1α promoter and inserted in place of the 
pp65ab proteins, recombination primers containing the same 50 bp homology to regions flanking 
the pp65 ORFs as before were used to amplify a Kan resistance cassette from plasmid 
pCP015rtndx [353]. The pCP015rtndx forward primer binding site (5′gtaaaacgacggccagt) and 
reverse primer binding site (5′gtatgttgtgtggaattgtgag) were added to the 3′ end of the mutagenesis 
primers. All subsequent steps to generate the final mutant virus were the same as described above. 
The lack of expected genes in the recombinant viruses and lack of WT contamination was 
confirmed by Western blot analysis of purified viral stocks (Fig.24D) and RT-PCR of cDNA from 
virally infected cells (Fig.23A). The antibodies used in this study to confirm the presence or 
absence of RhCMV viral proteins were generated at the VGTI Monoclonal Antibody Core (mouse 
α-RhCMV pp65a clone 3H3.1.2, mouse α-RhCMV pp65b clone 19C12.2, and mouse α-RhCMV 
clone 6H7.3).  
 
4.3.3 RhCMV particle purification procedures. RhCMVΔpp65ab virions were purified over 
a discontinuous Nycodenz gradient, as described before for HCMV AD169 [18] and RhCMV 68-
1 BAC-derived WT [444]. The virus was isolated from the culture medium of infected TRFs when 
the cells displayed maximal cytopathic effect. The cellular supernatants were first clarified by 
centrifugation at 7,500 g for 15 minutes. The clarified medium was layered over a sorbitol cushion 
(20% D-sorbitol, 50 mM Tris [pH 7.4], 1 mM MgCl2), and virus was pelleted by centrifugation at 
64,000 g for 1 hour at 4°C in a Beckman SW28 rotor. The virus pellet was resuspended in TNE 
buffer (50 mM Tris [pH 7.4], 100 mM NaCl, and 10 mM EDTA). The virus particles were further 
purified by layering them over a discontinuous 5% to 50% Nycodenz gradient (Sigma-Aldrich) in 
TNE buffer and centrifuging at 111,000 g for 2 hours at 4°C in a Beckman SW41 Ti rotor. The 
virion bands in the gradient were isolated with a syringe through the side of the centrifuge tube, 
and the particles were pelleted in a Beckman TLA-45 rotor in a Beckman Optima TL 100 
Ultracentrifuge at 40,000 g for 1 hour and washed twice with TNE buffer. The pellet was 
resuspended in TNE buffer, and electron microscopy was performed to confirm the purity of the 
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sample. In order to assess the protein content of the purified RhCMVΔpp65ab virions, especially 
in comparison to a parental RhCMV WT sample, a denatured protein preparation was separated 
on a NuPAGE morpholine propanesulfonic acid (MOPS) gradient gel (Invitrogen) and visualized 
by Coomassie brilliant blue staining (Fig.24C).  
 
4.3.4 Quantitative proteomic analysis. The quantitative proteomic analysis was performed as 
previously described in detail [444]. Briefly, RhCMV particles were denatured in 8 M urea, 100 
mM NH4HCO3, and 5 mM DTT, and the cysteine residues were alkylated with 10 mM 
iodoacetamide. Then, the samples were 4-fold diluted with 25 mM NH4HCO3 and 1 mM CaCl2 
and digested overnight with a 1:20 (mass/mass) trypsin-to-protein ratio. The digested peptides 
were desalted with C18 cartridges and dried in a vacuum centrifuge before being separated in 
capillary columns (75 μm × 65 cm capillary [Polymicro] packed with 3-μm C18 particles 
[Phenomenex]) connected to a custom-made 4-column liquid chromatography LC system [448] or 
a longer capillary column (75 μm × 100 cm) connected to a nanoAcquity system (Waters). Eluting 
peptides were analyzed directly in a linear ion-trap orbitrap mass spectrometer (LTQ Orbitrap XL, 
Thermo Scientific).  
Collected MS/MS spectra were searched against forward and reverse sequences of the 
RhCMV ORFs (275 sequences), Macaca mulatta Ensembl database (21,905 sequences, 
downloaded from http://www.ensembl.org on November 15, 2010), and 186 common 
contaminants (downloaded from http://www.ncbi.nlm.nih.gov/protein on August, 2006). 
Identified peptides were first filtered with a mass spectrum–generating function (MS-GF) [449] 
probability of ≤ 1 × 10–8 and, to ensure a low false discovery rate, each protein was required to 
have at least one peptide with MS-GF ≤ 1 × 10–10. Protein abundances were estimated by 
exponentially modified protein abundance index as previously described [380]. Data are available 
at Pacific Northwest National Laboratory ( http://omics.pnl.gov) and in the PeptideAtlas online 
database ( http://www.peptideatlas.org; dataset identifier: PASS00367).  
 
4.3.5 RMs. A total of 9 male and 4 female purpose-bred juvenile RMs (M. mulatta) of Indian 
genetic background were used in this study. All RMs were specific-pathogen free (SPF), as defined 
by being free of cercopithecine herpesvirus 1, D-type simian retrovirus, simian T lymphotrophic 
virus type 1, SIV, rhesus rhadinovirus, Mycobacterium tuberculosis, and RhCMV infection at the 
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start of the study. The Δpp65ab-deleted RhCMV vector was tested in vitro by administering the 
deletant virus s.c. at a dose of 1 × 107 PFUs to 2 SPF (defined above) RMs. To test whether the 
immune responses generated by the primary infection with Δpp65ab were sufficient to prevent 
superinfection, the same 2 RMs were inoculated with the same 1 × 107 PFUs dose with 
ΔVIHCEΔUS2-11gag, followed by superinfection with RhCMVgag and later with 
Δpp65ab(retanef).  
To determine whether vaccine-induced pp65-specifc T cells could prevent CMV infection, 
3 SPF RMs were vaccinated intramuscularly with 1.0 mg pND/pp65b DNA followed by an 
intramuscular boost using 5 × 108 PFUs pp65b-MVA at week 6 and 12 after DNA vaccination. 
For a control in these experiments, 3 additional SPF RMs were vaccinated following the same 
vaccine strategy using pND (empty) and MVA (empty), respectively [450, 451]. The plasmids 
pND and pND/pp65b were provided by Peter A. Barry, UCD, Davis, California, USA [450]; the 
empty MVA as well as the pp65b-expressing recombinant MVA were provided by Don J. 
Diamond, City of Hope, Duarte, California, USA. As a first step, the gene encoding RhCMV 68-
1 pp65-2 was amplified from previously described plasmid expression vectors and engineered into 
the pZWIIA MVA transfer vector using established protocols [451]. rMVA expressing RhCMV 
pp65-2 (Rhpp65-MVA) was generated on BHK-21 cells via homologous recombination. The 
protein expression levels for RhCMV pp65-2 in infected BHK-21 cells were confirmed by Western 
blot using polyclonal antibodies to RhCMV pp65-2 by chemiluminescence detection (ECL, 
Amersham Pharmacia Biotech). The plasmid DNA of pND and pND/pp65-2 was isolated using 
the EndoFree Plasmid Mega Kit (Qiagen) to avoid any endotoxin contamination of the DNA. 
Vaccinated animals were challenged s.c. 18 weeks after the initial DNA vaccination with 107 PFUs 
RhCMV ΔUS2-11gag.  
BAL fluid, peripheral blood, and urine samples were collected at specified time points (see 
Fig.25-27) throughout the entire experiment. Isolated CD4+ and CD8+ T cells from BAL fluid and 
peripheral blood were stimulated with antigen-specific peptides to examine the immune response 
induced by the initial vaccination and the subsequent viral challenge.  
 
4.3.6 Nested real-time PCR. To determine the viral copy numbers of RhCMV 68-1 GAG and 
RhCMVΔpp65ab retanef, 3 naive and 2 CMV+ RMs were infected s.c. with 107 PFUs of each virus 
in the opposite arm on the same day. Blood samples were taken once a week to monitor CD4+ and 
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CD8+ T cell responses and to determine the presence of cell-free virus in PBMCs. At the indicated 
time points after infection, the macaques were necropsied and tissues were harvested. DNA was 
isolated from the samples by ONPRC’s Molecular Virology Support Core (MVSC). Tissue 
samples (<100 mg) were prepared using FastPrep (MP Biomedicals) in 1 ml TriReagent 
(Molecular Research Center Inc.). 100 μl bromochloropropane (MRC Inc.) was added to each 
homogenized tissue sample to enhance phase separation. 0.5 ml DNA back-extraction buffer (4 M 
guanidine thiocyanate, 50 mM sodium citrate, and 1 M Tris) was added to the organic phase and 
interphase materials, which was then mixed by vortexing. The samples were centrifuged at 14,000 
g for 15 minutes, and the aqueous phase was transferred to a clean microfuge tube containing 240 
μg glycogen and 0.4 ml isopropanol and centrifuged for 15 minutes at 14,000 g. The DNA 
precipitate was washed twice with 70% ethanol and resuspended in 100 to 500 μl ddH2O. Nested 
real-time PCR was performed with primer and probe sets for the inserted SIV proteins GAG (first 
round: for-GAAACCATGCCGAAGACCTCTC and rev-CTCGTTGATGATGTCACGGATG; 
second round: for-CAACTACGTCCACCTGCCACTGTC, rev-
TCCAACGCAGTTCAGCATCTGG, and probe-
CCGAGAACCCTGAACGCTTGGGTCAAGC-FAM) and SIVretanef (first round: for-
CGGAAGCAGAACATGGACGAC and rev-CCCCTTCTCCTTGATGAAGTGC; second round: 
for-CGACGAGGAGGACGACGACTTA, rev-CCAACTTGTACGACATCGTCCG, and probe-
TCTCAGTGCGGCCGAAGGTCCC-FAM). For each DNA sample, 10 individual replicates (5 
μg each) were amplified by first-round PCR synthesis (12 cycles of 95°C for 30 seconds and 60°C 
for 1 minute) using Platinum Taq in 50 μl reactions. Then, 5 μl of each replicate was analyzed by 
nested quantitative PCR (45 cycles of 95°C for 15 seconds and 60°C for 1 minute) using Fast 
Advanced Master Mix (ABI Life Technologies) in an ABI StepOnePlus Real-Time PCR machine. 
The results for all 10 replicates were analyzed by Poisson distribution and expressed as copies per 
cell equivalents [452].  
 
4.3.7 Viral detection in urine by coculture. We centrifuged filter-sterilized (0.4 mm) urine at 
16,000 g for 1 hour at 4°C to concentrate virus for coculture on rhesus fibroblasts. Cell lysates 
were prepared after we observed extensive cytopathic effects or after 42 days of coculture if 
cytopathic effects were minimal or not observed. The prepared cell lysates were assessed for the 
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presence of RhCMV on the basis of expression of RhCMV- or SIV-specific antigens by Western 
immunoblotting.  
 
4.3.8 Immunologic assays. RhCMV- and SIV-specific CD4+ and CD8+ T cell responses were 
measured in mononuclear cell preparations from blood and BAL fluid by flow cytometric 
intracellular cytokine analysis, as previously described [353]. Briefly, sequential 15-mer peptides 
(overlapping by 11 amino acids) comprising the SIVMAC239Gag, or Rev/Nef/Tat and RhCMV 
68.1pp65ab, or IE1/2 were used in the presence of costimulatory CD28 and CD49d monoclonal 
antibodies (BD Biosciences). Cells were incubated with antigen and costimulatory molecules 
alone for 1 hour, followed by addition of Brefeldin A (Sigma-Aldrich) for an additional 8 hours. 
Costimulation without antigen served as a background control. Cells were then stained with 
fluorochrome-conjugated monoclonal antibodies, flow cytometric data were collected on a LSR II 
(BD Biosciences), and data were analyzed using the FlowJo software program (version 8.8.7; Tree 
Star). Responses frequencies (CD69+/TNF+ and/or CD69+/IFN+) were first determined in the 
overall CD4+ and CD8+ population and then memory corrected (with memory T cell subset 
populations delineated on the basis of CD28 and CD95 expression).  
 
4.3.9 Measuring RhCMV-specific antibody responses by ELISA. Antibody levels to RhCMV 
were measured in circulating plasma of RMs by standard ELISA using plates coated with lysates 
of fibroblasts infected with either WT-RhCMV or RhCMV-Δpp65 at 10 μg total protein per well. 
Nonspecific binding sites were blocked with 2% milk powder resuspended in PBS. Serial 2-fold 
dilutions of plasma were incubated for 1.5 hours prior to washing 3 times with ELISA wash buffer 
(PBS with 0.1% Tween-20; 200 μl per well). Primary antibody binding was detected and quantified 
with HRP-conjugated anti-rhesus IgG/IgA/IgM secondary antibody and addition of o-
phenylenediamine chromogen substrate. A log-log transformation was performed on the linear 
portion of the curve and end point titers were calculated using 0.1 OD units as the cutoff point. 
Each plate contained a positive control sample to normalize ELISA titers between assays and a 
negative control sample to ensure assay specificity and to subtract background. Graphical data was 
generated using Prism GraphPad software. 
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4.3.10 Measuring RhCMV-specific antibody responses by SDS-PAGE and Western blotting. 
Rhesus fibroblasts infected with WT-RhCMV or RhCMV-Δpp65 were solubilized in 2× 
Laemmeli’s sample buffer, and 200 μg total protein per lane were loaded onto NuPAGE 4%–12% 
Bis-Tris gradient gels (Invitrogen, Life Technologies) and run in MOPS buffer. Proteins were 
transferred to Immobilon-P blotting membrane, and nonspecific binding sites were blocked in 2% 
milk powder in Tris-buffered saline with 0.02% Tween-20 for 60 minutes. Primary rhesus monkey 
polyclonal antisera was added at 1:700 dilution in blocking buffer for 60 minutes, and membranes 
were washed 3 times for 10 minutes each in Tris-buffered saline plus 0.2% Tween (TBST). 
Secondary goat anti-rhesus-HRP conjugate was added at 1:5,000 in blocking buffer for 30 minutes, 
and membranes were washed 3 times for 10 minutes each in TBST. Membranes were developed 
using ECL Advance Lumigen-TNA (GE Healthcare) for 1 minute and exposed to Biomax Light 
Film (Kodak) at various exposure times. 
 
4.3.11 Ethics statement. All RMs were handled in accordance with good animal practice, as 
defined by relevant national and/or local animal welfare bodies. The use of nonhuman primates 
was approved by the ONPRC Institutional Animal Care and Use Committee (IACUC no. 0691). 
The ONPRC is fully accredited by the Assessment and Accreditation of Laboratory Animal Care 
International. For blood and BAL collection, monkeys were anesthetized with ketamine by 
intramuscular injection. Monkeys were humanely euthanized by the veterinary staff at ONPRC in 
accordance with end point policies. Euthanasia was conducted under anesthesia with ketamine, 
followed by overdose with sodium pentobarbital. This method is consistent with the 
recommendation of the American Veterinary Medical Association. 
 
4.3.12 Statistics. All P values in this study were determined using a 1-tailed unpaired Student’s t 
test. The cutoff for statistical significance was defined as P < 0.05 unless otherwise specified. All 
error bars shown in all presented figures represent mean ± SD.  
 
4.3.13 Study approval. All animals in the presented study were used with approval of the 
ONPRC Animal Care and Use Committee, under the standards of the US NIH Guide for the Care 
and Use of Laboratory Animals. 
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4.4 Results 
4.4.1 RhCMVΔpp65ab shows delayed growth kinetics at low MOI. To study the function of 
pp65 in RMs, we deleted the pp65a- and pp65b-encoding genes Rh111 and Rh112 in the RhCMV 
strain 68-1–derived BAC [344] to generate Δpp65ab. Upon reconstitution of recombinant virus in 
telomerized rhesus fibroblasts (TRFs), we verified that genes Rh111 and Rh112 were absent, 
whereas the neighboring genes Rh110 (UL82 [pp71] homolog) and Rh114 (UL84 homolog) were 
still expressed (Fig.23A).  
 
Fig.23: Characterization of RhCMVΔpp65ab in vitro. (A) RT-PCR results for cDNA of infected TRFs showing 
the expression of pp65a (Rh111) and pp65b (Rh112) and their neighboring ORFs Rh110 (pp71) and Rh114. IE1 and 
GAPDH were included as controls. (B) Single-step (MOI of 3) and (C) multistep (MOI of 0.01) growth curves of 
RhCMV WT and RhCMVΔpp65ab on TRFs. *P < 0.05, Student’s t test; **P < 0.01, Student’s t test.  
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To determine whether pp65 deletion affected in vitro growth properties of RhCMV, we 
compared the growth kinetics of Δpp65ab with those of BAC-derived RhCMV 68-1 (herein 
referred to as WT control). TRFs were infected with Δpp65ab or WT either at a high MOI of 3 to 
generate a single-step growth curve or at a low MOI of 0.01 to measure multistep growth. 
Supernatants collected at high MOI contained similar titers of the 2 viruses, with a peak titer 
reached on and after 4 days postinfection (dpi) (Fig.23B). However, when multiple rounds of 
infection were measured, Δpp65ab displayed a modest, but significant, delay in viral growth, 
ultimately reaching the same peak titer as WT (Fig.23C).  
 
4.4.2 Characterization of Δpp65ab virions. Since previous reports suggested that pp65 in 
HCMV affected viral assembly and thus the incorporation of other viral proteins [441], we studied 
the structure and protein composition of Δpp65ab virions. Using mass spectrometry, we 
demonstrated recently a remarkable similarity between the predominant viral proteins found in 
both RhCMV and HCMV, with respect to protein ratios and protein abundance [444]. To similarly 
determine the proteome of Δpp65ab virions, we concentrated viral particles from the supernatant 
of infected TRFs followed by purification over a discontinuous Nycodenz gradient (see Methods). 
Compared with WT, we observed an increased appearance of particles that sedimented with higher 
density in virion preparation of Δpp65ab (Fig.24A). Electron microscopy of this high-density band 
revealed abnormal structures consistent with capsidless (defective) viral particles. However, the 
lower density virion band contained an essentially pure preparation of particles with the same 
general structure as WT RhCMV, including an icosahedral capsid containing the viral DNA as the 
core of the virion surrounded by a tegument layer and enveloped by a lipid membrane (Fig.24B). 
NuPAGE and Western blot analysis of gradient-purified WT and Δpp65ab mutant virions 
demonstrated the absence of pp65a and pp65b in the deletion mutant (Fig.24, C and D). 
Comparison of the dimensions of the WT versus Δpp65ab virions revealed an overall reduced 
diameter of Δpp65ab virions (173.4 nm) compared with that of WT virions (222.5 nm) (Fig.24E). 
This reduction in particle size was primarily due to a significant reduction of the viral tegument 
layer (38.4 nm [Δpp65ab] compared with 61.2 nm [WT]), consistent with the fact that pp65a and 
pp65b constitute a major portion of the viral tegument in WT (approximately 24.4%; ref.[444]). 
In addition, the capsid appeared to be diminished in size, although to a lesser degree (89.7 nm 
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[Δpp65ab] compared with 100.2 nm [WT]). Thus, both phenotypically normal, but smaller, virions 
and defective particles were recovered from the supernatant of cells infected with Δpp65ab.  
 
Fig.24: Intact and defective viral particles are secreted from fibroblasts infected with Δpp65ab. (A) Image of a 
Nycodenz gradient loaded with RhCMVΔpp65ab, and electron microscope images of virions (top image) and 
defective particles (bottom image) contained in the visible bands of the gradient. (B) Electron microscope image of 
purified RhCMVΔpp65ab virions showing the purity of the sample. (C) Purified RhCMV WT and Δpp65ab virions 
were lysed, and 10 μg protein was electrophoretically separated using NuPAGE MOPS gradient gels and visualized 
by Coomassie blue staining. (D) Western blots of 5 μg gradient-purified RhCMV 68-1 WT and viral mutant Δpp65ab 
stained for RhCMV pp65a, pp65b, or a RhCMV-specific antibody. (E) Various electron microscopy images of 
purified WT and Δpp65ab virions were taken, and the diameters of virions, capsids, and the tegument were determined 
in multiple images and magnifications (WT, n = 39; Δpp65ab, n = 45). The mean diameters with their respective SDs 
are shown, and Student’s t tests were performed to determine the P values. Scale bars: 100 nm.  
 
To further characterize the proteome of the virions contained in the upper band by mass 
spectrometry, the recovered material was digested with trypsin and analyzed by 1D LC-MS/MS. 
The resulting mass spectra were initially searched against stop-to-stop translated sequences of the 
RhCMV 68-1 BAC genome for ORFs ≥30 amino acids. Since all proteins identified by this method 
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corresponded to proteins contained in our recently published reannotation of the RhCMV 68-1 
BAC genome [444], we also used a protein library based on the revised annotation for further 
analysis of protein abundance. The virion preparation was analyzed by LC-MS/MS upon elution 
from 0% to 100% acetonitrile gradient over 100 minutes, and 5 technical repeats were performed. 
68.5 mol% of all identified proteins and 69.9 mol% of all identified peptides corresponded to viral 
proteins, whereas 31.5 mol% of the proteins and 30.1% of the peptides were derived from the host 
(Supplemental Figure 3B; supplemental material available online with this article; doi: 
10.1172/JCI67420DS1). This result is similar to that previously obtained for WT (64.8 mol% viral 
proteins, 63.4% viral peptides and 35.2 mol% host proteins, 36.6% host peptides), suggesting a 
similar level of sample purity. As expected, peptides corresponding to pp65a or pp65b were not 
detected in the Δpp65ab virion preparation (Table 4). However, a total of 50 different viral proteins 
could be identified for Δpp65ab, which is comparable to that for WT virions, for which 53 different 
viral proteins were identified. Every capsid protein found in WT virions was found in the deletion 
mutant, and besides the deleted pp65 proteins, this also holds true for the tegument proteins (Table 
4). Similarly, all major glycoproteins were present in Δpp65ab in equal abundance compared to 
WT. In fact, most proteins that differed in their abundance between Δpp65ab virions compared 
with WT were low-abundance proteins, suggesting that these proteins might not be consistently 
part of the virions or that they were missed in our analysis due to low abundance. If an abundance 
threshold of 0.25 mol% is applied, 8 proteins differ between Δpp65ab and WT: Rh17 (RL11 
family), Rh131 (UL96), Rh211 (US26), and Rh214 (US28) are decreased in the Δpp65ab mutant 
compared with the WT, whereas Rh05 (RL11 family), Rh13.1 (RL13), Rh173 (RL11 family), and 
Rh218 (US28) were increased in the Δpp65ab mutant compared with the WT (Fig.25). Of those, 
Rh211 is the only protein with a substantial presence with 0.85 mol% in WT virions that is 
completely absent in mutant virions. Rh211 is the homolog of HCMV US26, whose function is 
unknown. Thus, our proteomics analysis revealed that only 8 proteins with a higher abundance 
than 0.25 mol% showed marked changes of more than 2-fold between the WT and the pp65ab 
deletion mutant, with most of these being low-abundance proteins. 
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 Fig.25: Δpp65ab establishes primary and secondary infections and protects against superinfection with ΔUS2-
11. (i) Two RhCMV seronegative male RMs (filled circles, Rh22037; open circles, Rh23016) were infected s.c. with 
107 PFUs of Δpp65ab at day 1. CD4+ (blue) and CD8+ (red) T cell responses were monitored in peripheral blood 
(PBMCs) by intracellular cytokine staining at the indicated days using overlapping peptides of pp65ab and IE1/2. (ii) 
On day 659, the 2 animals were inoculated s.c. with 107 PFUs of ΔUS2-11gag (green dotted line), and the T cell 
response to SIVgag was measured in addition. Note the absence of a T cell response to SIVgag or pp65 and a lack of 
boosting of responses to IE1. (iii) On day 876, the 2 RMs were inoculated with 107 PFUs of WTgag (black dotted 
line), and the T cell response was monitored by intracellular cytokine staining. Note the appearance of de novo 
responses to SIVgag and pp65 and a boosting of the T cell response to IE1. (iv) On day 1,107, the 2 RMs were 
inoculated with 107 PFUs of Δpp65ab-rtn (blue dotted line). Using overlapping 15-mer peptides, a de novo response 
to SIVretanef was detectable, indicating superinfection. Also note a boosting of the IE1 response but not of pp65- or 
SIVgag-specific responses. The corresponding T cell responses obtained from BAL fluid are shown in Supplemental 
Figure 4. 
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Table 4: Comparison of viral proteins contained in WT and Δpp65ab virions. 
Results                                                   85 
 
 
In general, there was surprisingly little impact of pp65ab deletion on the presence of other 
proteins in the virions. There was no substantial difference among nonstructural proteins 
(transcription/replication machinery or uncharacterized category), whereas the quantities of most 
structural proteins (capsid, envelope, glycoproteins) were, in fact, slightly elevated in Δpp65ab 
compared with those in WT (Table 5). Moreover, we did not observe a decrease in specific, non-
pp65 tegument proteins, but rather, we saw a decrease in the abundance of all non-pp65 tegument 
proteins in Δpp65ab virions. This is in contrast to a previous report for HCMV, describing selective 
lack of specific tegument proteins in pp65-deleted virions [441]. Thus, it seems that RhCMV 
virions assembled normally but with an overall reduced tegument. Indeed, when virion protein 
abundance is adjusted for the absence of pp65ab by normalizing to a total of 89% (11% of the WT 
virion is made up by pp65a and pp65b combined), protein quantities are very similar to those of 
WT (Tables 4 and 5). Despite the lack of major tegument proteins that normally represent 11% of 
the viral particle mass, there was little change in virion composition.  
Table 5: Relative abundance of the 5 functionally different groups of viral proteins in RhCMV WT and 
Δpp65ab. 
 
In contrast to the limited impact of pp65ab deletion on virion proteins, a number of host 
proteins were substantially different between WT and Δpp65ab (Supplemental Figure 3). 279 host 
proteins were identified in WT, whereas 240 host proteins were identified in Δpp65ab. Only 172 
host proteins were identified in both viral samples, with the remaining proteins being unique to 
each sample. The role of host cell proteins in CMV virions is unknown, but it seems likely that 
these proteins reflect the source or host cell membrane used for envelopment. The differential 
presence of host cell proteins could thus indicate that envelopment of pp65ab-deleted viruses 
differs somewhat from that of WT virus. This would be consistent with the increased production 
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of defective particles described above. The differential incorporation of host cell proteins likely 
reflects changes in viral assembly pathways but is less likely of consequence for virion function. 
 
4.4.3 Infection of RMs with Δpp65ab. To determine whether pp65ab-deleted viruses would be 
infectious, we inoculated 2 seronegative male RMs with 107 PFUs of Δpp65ab and monitored the 
CMV-specific T cell response using overlapping peptides to the RhCMV proteins IE1/2 and, as 
control, to pp65ab for about 22 months. We also monitored viral shedding by coculture of urine 
samples with rhesus fibroblasts. In previous experiments, we showed that infection of RhCMV-
negative RMs results in the appearance of peak T cell responses within the first 2 weeks of 
infection, followed by a contraction and stabilization of the T cell response at a level that remains 
more or less constant for the duration of the life of the animal [353, 453]. The maintenance of such 
a long-lived effector memory T cell response reflects the establishment of persistent infection. 
Similarly, both animals infected with Δpp65ab responded vigorously to IE1/2, with a peak CD4+ 
and CD8+ T cell response in PBMCs and bronchoalveolar lavage (BAL) fluid at 2 weeks, followed 
by a slow decline and stabilization of the response that lasted for the entire time (Fig.25, i, and 
Supplemental Figure 4A). Importantly, T cell responses to pp65ab were not observed, which is 
consistent with the IE1/2 responses being induced by the pp65ab-deleted virus. The stable T cell 
response to IE1/2 suggested that the pp65-deleted virus established persistent infection. 
Persistence was further confirmed by coculture of urine samples with TRFs, in which IE1 was 
detected in urine cocultures of Δpp65ab-infected animals but pp65 was not detected, confirming 
that there was no contamination with WT virus (Fig.26). Thus, these data suggest that RhCMV is 
able to establish and maintain a persistent infection despite the absence of pp65ab.  
Although pp65 is one of the major targets of the CMV-specific T cell response in both 
humans and monkeys [121, 411, 429-431], the contribution of pp65-specific T cells to control of 
CMV replication is not known. Indeed, the experimental determination of the efficacy of RhCMV-
specific T cell responses is complicated by the fact that RhCMV readily superinfects RhCMV+ 
RMs, overcoming preexisting T cell responses due to the presence of viral proteins that inhibit 
MHC-I antigen presentation [276]. However, RhCMV lacking the genes encoding for homologs 
of the HCMV US2, 3, 6, and 11 immunoevasins is unable to superinfect CMV+ RMs but is capable 
of establishing persistent infection in CMV-naive animals or upon depletion of CD8+ T cells from 
CMV-immune animals [276]. Thus, the ability to protect against superinfection with ΔUS2-11 
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RhCMV is a convenient surrogate marker for the quality of T cell responses, i.e., a T cell response 
that is as efficient as that induced by natural infection. To test whether the T cell responses induced 
by Δpp65ab to antigens other than pp65 would be sufficient to prevent superinfection with 
immunoevasins-deleted virus, we inoculated the 2 Δpp65ab-infected RMs with ΔVIHCEΔUS2-
11gag, a previously described recombinant virus that expresses the SIVgag as immunological 
marker. In addition to US2-11, this virus lacks the RhCMV-specific viral inhibitor of heavy chain 
expression (VIHCE), which is not required for superinfection [276]. As observed for RMs 
naturally infected with RhCMV, ΔVIHCEΔUS2-11 was unable to superinfect Δpp65ab-infected 
animals, as evident from the absence of an immune response to SIVgag as well as a lack of a 
boosting response to IE or a de novo response to pp65 (Fig.25, ii, and Supplemental Figure 4B). 
In fact, T cell responses to IE1/2 remained stable for the entire duration of this experiment (200 
days). Thus, the T cell responses generated by Δpp65ab were as efficacious as T cell responses 
induced by WT in protecting against immunoevasins-deleted virus challenge, indicating that a 
pp65-specific T cell response is not required for an effective anti-RhCMV immune response and 
that T cells specific for other codominant or subdominant antigens are sufficient for protection. 
 
Fig.26: RhCMVΔpp65ab is persistently secreted from infected animals. (A) The time line depicts the time points 
of inoculation with different RhCMV constructs and the days when cocultures were started from urine. Time points 
marked with asterisks indicate additional days in which cocultures were positive for Δpp65ab, but the data are not 
shown. PID, postinoculation day. (B) Immunoblot for the indicated antigens in lysates from representative viral 
cocultures with urine collected on the indicated dpi. The presence of RhCMV-IE1, RhCMV-pp65b, SIVgag, and 
SIVretanef in cell lysates was detected by immunoblot using antibodies specific for the respective antigens (IE, pp65) 
or for epitope tags fused to SIVgag or SIVretanef. Note that, initially, secreted RhCMV expressed IE, but not pp65, 
whereas superinfection with WTgag and Δpp65retanef is indicated by the appearance of pp65-containing virus 
expressing the respective antigens. As positive control (Con), coculture lysates from a RM inoculated with WTgag 
and WTretanef is included.  
  
Results                                                   88 
 
To determine whether animals infected with Δpp65ab are resistant to superinfection by WT 
RhCMV, we inoculated both RMs with WT-gag, a previously described virus that carries SIVgag 
inserted into the ORF Rh211 between hypothetical ORFs 213 and 214 [353]. Upon inoculation of 
107 PFUS WT-gag, both animals displayed clear signs of superinfection, as evident by the 
development of de novo responses to SIVgag and pp65ab and by boosting of the preexisting T cell 
response to IE1/2 (Fig.25, iii, and Supplemental Figure 4C). Moreover, cocultures of urine samples 
from these animals contained SIVgag-expressing virus (Fig.26). These data thus demonstrate that 
the immune responses induced by Δpp65ab, like those elicited by WT RhCMV, are unable to 
protect against superinfection with WT RhCMV.  
Given the role of HCMV pp65 as modulator of several immune response pathways 
(including protecting against IE-specific T cells [23] and NK cells [22]), it was possible that pp65 
itself contributed to the ability of WT to overcome preexisting immune responses. In fact, our 
previous finding that evasion of T cell responses plays a central role in overcoming preexisting 
immune responses does not rule out that evasion of other immune response components, e.g., B 
cells and NK cells, might also contribute to superinfection [276]. To examine whether RhCMV 
lacking pp65ab would be able to superinfect CMV-positive animals, we inserted an expression 
cassette for SIVretanef (a fusion protein of rev, int, tat, and nef; refs. [353, 454]) into the RhCMV 
genome by replacing the pp65-encoding genes Rh111 and Rh112. After confirming pp65 deletion, 
in vitro growth properties, and expression of SIVretanef (data not shown), we inoculated the 2 
RMs previously infected with Δpp65ab and WT-gag with Δpp65ab-retanef and monitored the 
immune response to SIVretanef. As shown in Fig.25, iv (Supplemental Figure 4D), both animals 
showed clear signs of superinfection, as evident from the development of a de novo T cell response 
to SIVretanef and a boosting of the preexisting IE1/2 response. Note that the T cell responses to 
pp65ab and SIVgag were not boosted, confirming the lack of pp65ab and SIVgag. We thus 
conclude that pp65ab is dispensable for the establishment of both primary and secondary persistent 
infections.  
 
4.4.4 Vaccine-induced pp65-specific T cells do not recapitulate the protective effect of T 
cells induced by natural infection. In the RM model, it was previously demonstrated that 
vaccination with subunit vaccines consisting of pp65b (with or without IE1) as T cell–inducing 
components and gB as neutralizing antibody-inducing component reduced RhCMV viremia and 
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shedding [450, 451, 455]. However, our data also suggest that T cell responses to antigens other 
than pp65 play an important role in the protective effect of RhCMV infection against ΔUS2-11 
challenge. We were therefore wondering whether induction of a T cell response to pp65 alone 
would be sufficient to recapitulate the protective effect of preexisting infections against challenge 
with RhCMV lacking the US2-11 immunoevasins [276]. Therefore, we used a previously 
described heterologous prime-boost regimen to induce pp65b-specific T cell responses [450, 451]. 
Three animals were vaccinated with DNA encoding pp65b, followed by 2 boosts with pp65b-
expressing modified vaccinia Ankara (MVA). For control, we vaccinated 3 animals with antigen-
free plasmid and MVA. As shown in Fig.27A (Supplemental Figure 5), all 3 pp65b-vaccinated 
animals developed a robust CD4+ and CD8+ T cell response to pp65b after this prime-boost 
vaccination regimen that, in the 6 weeks following the final boost, was similar in magnitude and 
phenotype to pp65-specific T cell responses that develop in the context of RhCMV infection 
(Fig.25, iii and iv, and Supplemental Figure 4). As expected, pp65b-specific T cells were not 
observed in the control MVA-vaccinated group. Six weeks after the final MVA/pp65 versus 
control MVA boost, all animals were challenged with RhCMV lacking US2-11 and expressing 
SIVgag (ΔUS2-11gag). Similar to ΔVIHCEΔUS2-11gag, this virus is unable to overcome 
preexisting T cell immunity, despite the presence of the RhCMV-specific MHC-I inhibitor VIHCE 
[276]. All 3 control-vaccinated animals developed the expected T cell response to pp65 as well as 
SIVgag consistent with infection. However, the pp65-vaccinated animals also developed T cell 
responses to SIVgag with similar kinetics and magnitude compared with those in the control group. 
We further observed a boost of the T cell response to pp65b consistent with infection by ΔUS2-
11gag. These data indicate that pp65-specific T cells alone are unable to provide the level of 
protection against CMV afforded by natural infection or experimental infection with whole virus.  
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Fig.27: T cells induced by heterologous prime-boost vaccination with pp65b do not protect against 
superinfection with ΔUS2-11. (A) Three CMV-negative RMs were vaccinated with 1 mg pND/pp65b and boosted 
with 5 × 108 PFUs MVApp65b at 6 and 12 weeks after the initial vaccination (black). As controls, 3 CMV-negative 
RMs were vaccinated with the parental pND plasmid not expressing any antigen and boosted with WT MVA at 6 and 
12 weeks after the initial vaccination (green). At 18 weeks after the initial DNA vaccination, both groups of animals 
were challenged with 107 PFUs ΔUS2-11gag. The top row shows the specific T cell responses to pp65, whereas the 
bottom row shows specific T cell responses to SIVgag. T cells were isolated from peripheral blood (PBMCs). The 
corresponding T cell responses obtained from BAL fluid are shown in Supplemental Figure 5. The production of anti-
RhCMV antibodies in pp65-vaccinated animals (Rm23557, Rm27814, Rm27838) was compared to that in control-
vaccinated animals (Rm23672, Rm25052, Rm27821) prior to and upon challenge with RhCMV-ΔUS2-11. At the 
indicated time points, RhCMV-specific end point antibody (IgG, IgA, IgM) titers were measured in plasma from each 
animal by ELISA using lysates from fibroblasts infected with either (B) RhCMV-Δpp65 or (C) WT-RhCMV as the 
capture antigen. (D) Viral proteins recognized by the antibodies were detected by Western blotting. Lysates of cells 
infected with WT-RhCMV or RhCMV-Δpp65 were separated by SDS-PAGE and immunoblotted with antisera from 
the pp65-vaccinated animal (Rm27838) or a control-vaccinated animal (Rm23672). Asterisks denote the pp65 
proteins. The results from these 2 animals are representative of the responses observed in the other animals of each 
group.  
 
Conceivably, pp65 vaccination could affect the viral loads of ΔUS2-11gag, as has been 
reported for pp65/gB-vaccinated animals challenged with RhCMV [455]. Since primary infection 
with RhCMV 68-1 (the parental strain of ΔUS2-11gag) does not result in robust viremia (see 
below), direct measurements of viral loads were unlikely to be informative. Instead, we used the 
development of anti-CMV antibodies as a surrogate for CMV antigen load, because it was shown 
previously in the murine model that reduced viral spread correlates with reduced antibody 
responses but does not affect T cell responses [456]. However, when lysates of Δpp65-infected 
cells were used as antigen, a very modest antibody response was observed in all animals challenged 
with ΔUS2-11gag, and there was no difference in the kinetics or magnitude specificity of this 
response between pp65-vaccinated and control-vaccinated animals (Fig.27B), and we did not 
observe a difference in the specific antigens recognized by immunoblot (Fig.27D). Remarkably, 
when pp65-containing CMV lysate was used as antigen for our ELISA or immunoblot, we 
observed an extraordinary increase in the titers of pp65-specific antibodies induced by DNA/MVA 
vaccination. As shown in Fig.27B, pp65-specific antibodies were above background levels upon 
boosting with MVApp65. Moreover, subsequent challenge with ΔUS2-11gag increased these 
pp65-specific antibodies by several orders of magnitude. pp65 antigen was recognized in sera from 
pp65-vaccinated animals by immunoblot, and this response was strongly increased upon challenge. 
In contrast, control-vaccinated animals did not recognize the corresponding 65-kDa band even 
after ΔUS2-11 challenge (Fig.27D). These data indicate that pp65 vaccination did not affect ΔUS2-
11 viral load to a level that would affect the induction of CMV-specific antibodies, although a 
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modest reduction, as reported previously, cannot be ruled out. In addition, these observations 
suggest that antibody responses to pp65, and potentially to other antigens as well, are substantially 
boosted upon infection with ΔUS2-11 virus.  
 
 Table 6: Copy numbers of RhCMV WT-gag and Δpp65ab-retanef genomes in CMV+ RMs.  
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Table 7: Genome copies of RhCMV 68-1 WT-gag in CMV+ RMs.  
 
 
Table 8: Copy numbers of RhCMV WT-gag and Δpp65ab-retanef genomes in CMV-naive RMs. 
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4.4.5 pp65 limits dissemination of RhCMV in vivo. Taken together, these data suggest that 
neither pp65 itself nor the T cell response to pp65 have a major impact on the overall course of 
either primary or secondary RhCMV infection. However, it remained possible that the extent of 
RhCMV replication is affected by the presence or absence of pp65. If lack of pp65 delays RhCMV 
replication kinetics in vivo, as it does in vitro, infections with pp65-deleted RhCMV would be 
expected to proceed more slowly and/or manifest reduced spread or peak viral production relative 
to WT virus. On the other hand, if pp65-induced immune responses have superior efficacy, 
infections with pp65-deleted RhCMV would manifest greater viral replication and spread than WT 
RhCMV. To address these possibilities, we performed experiments in which genetically marked 
WT and Δpp65ab RhCMV constructs (using SIVgag and SIVretanef as the identifying markers, 
respectively) were simultaneously, but separately (right arm vs. left arm), inoculated into either 
RhCMV seropositive (n = 2) or RhCMV seronegative RMs (n = 3). These RMs were sacrificed 
and taken to necropsy at 14, 21, or 28 days after inoculation; DNA was isolated from the sites of 
inoculation and distant tissues; and the extent and magnitude of viral spread was determined by an 
ultrasensitive, nested quantitative PCR analysis using primers that specifically amplify fragments 
of the SIVgag versus SIVretanef inserts [359]. In the setting of superinfection, little tissue-
associated viral DNA was detected for either the WT or Δpp65ab constructs, with the former only 
identified in one of the inoculation sites in the RM analyzed at day 14 and the latter identified at 
very low level in inoculation sites and scattered distant tissues in both the RMs analyzed at day 14 
and day 28 after inoculation (Table 6). Although, in these 2 RMs, the extent of spread by the 
Δpp65ab RhCMV was greater than that of the coadministered WT RhCMV, the level of tissue-
associated virus observed in the Δpp65ab RhCMV superinfection was still within the range of that 
found in WT RhCMV superinfection in other RMs (Table 7), and thus, deletion of pp65 does not 
seem to significantly affect viral dissemination during superinfection. In striking contrast, the 
extent of Δpp65ab RhCMV replication in RhCMV-naive RMs was 3 to 4 logs higher than the 
simultaneously administered WT RhCMV (Table 8). Indeed, the degree of Δpp65ab RhCMV 
replication during primary infection was astonishing, reaching almost 108 DNA copies in the LN 
draining the injection site at day 14 after inoculation. Analyses of viral loads in blood indicate that 
the difference in WT versus Δpp65ab RhCMV replication by can be observed by day 7 after 
inoculation (Table 8). The levels of Δpp65ab RhCMV in blood and tissue declined dramatically at 
later time points, indicating that this virus is eventually brought under immune control. Taken 
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together, these data unequivocally indicate that expression of pp65 strongly limits primary viral 
dissemination over several orders of magnitude and suggest that, while RhCMV-specific T cells 
can control RhCMV in the absence of pp65, a rapid immune response to pp65 is necessary to limit 
viral spread during the early days of primary infection. 
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4.5 Discussion 
The goal of this study was to assess the role of one of the major structural components of the CMV 
virion in infection and immunity. Similar to HCMV, a large percentage (approximately 11%) of 
the protein mass of RhCMV virions consists of the 2 pp65 homologs [444]. Nevertheless, in both 
HCMV and RhCMV, pp65 is not essential for growth in vitro although increased production of 
defective particles occurs during infection with RhCMVΔpp65ab. This could be reflective of 
assembly defects due to the lack of pp65ab. For HCMV, it has been reported that pp65 is required 
for the incorporation of other virion proteins, most notably UL25, UL69, and UL97 [441]. 
However, we did not observe a major skewing in the protein composition of the viral tegument as 
would have been expected if pp65 selectively controls the incorporation of other viral proteins. 
Instead, the tegument composition seemed normal but without pp65 present. Conceivably, this 
could be due to a difference in virion assembly between HCMV and RhCMV. However, the overall 
virion proteome of RhCMV is highly similar to that of HCMV [444], and UL25, UL69, UL97 are 
highly conserved in RhCMV. Therefore, it seems more likely that effects of pp65 on incorporation 
of other tegument proteins are nonselective. The fact that virions are assembled, carrying the same 
ratios of viral proteins as WT, while lacking pp65, suggests that although pp65 might facilitate 
virus assembly, once the virus is assembled, the lack of pp65 does not affect the overall viral 
structure, except for a reduction on overall virion size due to a reduced tegument protein layer.  
In addition to viral assembly, pp65 has an immediate function upon release of the tegument 
into cells during membrane fusion. Similar to other tegument proteins (e.g., pp71 and UL35), pp65 
is thought to contribute to setting the stage for optimal viral replication by counteracting intrinsic 
and innate antiviral host response mechanisms [68]. HCMV lacking pp65 showed increased 
induction of IFN-stimulated genes (ISGs) [151, 152]. We reported previously that RhCMV 
particles inhibited ISG expression [148] and pp65 was a possible candidate for this inhibition. 
However, Δpp65ab did not induce ISGs, suggesting that inhibitory mechanisms mediated by other 
RhCMV proteins perform this function (data not shown). It has also been reported that HCMV 
pp65 binds to and induces the major immediate early promoter (MIEP) in conjunction with the 
cellular protein IFI16 [432]. We have not investigated in detail the impact of pp65 on IE expression 
in RhCMV. However, in this study, we did observe a delay in virus production in multistep growth 
curves (Fig.23C), consistent with this effect. Thus, RhCMV pp65 proteins appear to facilitate 
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optimal expression of viral genes in the early stages of cellular infection but are not required for 
productive infection.  
The role of HCMV pp65 for the establishment and maintenance of infection in vivo is 
unknown due to the strict species specificity of HCMV. The rationale for studying RhCMV pp65 
in the RM model was therefore the close evolutionary relationships of both the host to human and 
of the virus to HCMV. Given the multiple functions assigned to HCMV pp65, it was completely 
unexpected that deletion of both homologs in RhCMV did not only not affect the ability of RhCMV 
to establish and maintain a long-term infection in the rhesus host but, in fact, strongly increased 
the ability of RhCMV to replicate and disseminate during primary infection. In contrast, lack of 
the pp65 homologous genes M83/M84 and GP83 in murine CMV (MCMV) and guinea pig CMV, 
respectively, reduced peak viremia during primary infection [457-459]. In contrast to primary 
infection, differences in the replication and dissemination of Δpp65ab versus WT RhCMV were 
minimal, if not absent, in the setting of superinfection of CMV+ RMs, suggesting that once 
established, adaptive immune responses to antigens other than pp65 can effectively control the 
infection. These data suggest that pp65 likely acts as an “immunological brake” during the initial 
stages of primary infection to limit viral replication and dissemination. We therefore hypothesize 
that the main function of pp65 is not that of immune evasion, but immune induction, i.e., eliciting 
a rapid immune response that controls viremia. The most likely candidate mechanism for this effect 
is the pp65-specific effector T cell response, which, due to the abundance and immunogenicity of 
pp65 proteins, might appear earlier in primary infection than the response to other CMV proteins. 
Alternatively or additionally, pp65 might induce innate immune responses that limit viral 
replication in primary infection. This immune induction function of pp65 is reminiscent of the NK 
cell–stimulating protein m157 of MCMV, whose deletion or mutation increases viral replication 
and titers in mice carrying the NK cell receptor Ly49H for which m157 is a ligand [460, 461].  
The parental strain used to generate Δpp65ab, RhCMV 68-1, shows reduced secretion from 
infected animals, most likely due to the lack of genes in the ULb′-homology region required for 
tissue tropism [345]. Since RhCMV 68-1 does not generate robust plasma viremia in infected 
animals, the appearance of RhCMV-Δpp65ab in plasma samples became particularly striking. 
Thus, it is conceivable that the increased dissemination of Δpp65ab might be less pronounced in 
viruses carrying an intact ULb′ region. However, in preliminary observations, we did not observe 
increased dissemination of RhCMV 68-1.2, a virus that is repaired for tissue tropism [415]. Thus, 
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it is likely that pp65 deletion will have a similar effect on a repaired or low-passage viral 
background, although this still needs to be verified experimentally.  
T cells from HCMV-infected individuals recognize a broad spectrum of viral ORFs that 
are highly variable between individuals [121]. Although no ORFs are recognized by all 
seropositive people, pp65 is one of the most consistently recognized CMV proteins by both CD4+ 
and CD8+ T cells [121], a level of immunogenicity that has led vaccine developers to include pp65 
in HCMV vaccines [427, 462-466]. However, relatively little is known about the protective effect 
of pp65-specific T cells in humans, since vaccine trials generally involve a cocktail of proteins and 
efficacy cannot be directly correlated to pp65 alone [428]. The most direct evidence for a protective 
effect of pp65-specific T cells comes from adoptive T cell transfer experiments that used pp65-
derived peptides to expand HCMV-specific T cells [467-472]. In these studies, transfer of pp65-
specific T cells accelerated the restoration of antiviral immunity posttransplantation, without graft 
versus host side effects associated with nonspecific T cell transfer. Our finding that pp65-specific 
immunity seems to curtail viral dissemination in the early stages of infection would support the 
inclusion of pp65 in subunit vaccines, provided it is indeed the pp65-specific T cells that are 
responsible for this effect.  
On the other hand, our data also indicate that pp65-specific T cell responses are not 
sufficient to recapitulate the level of protective immunity generated by actual viral infection. To 
examine the protective effect of pp65-specific T cells or T cells specific to other CMV antigens 
we developed a novel challenge strategy. Our approach relies on our previous observation that 
viral genes encoding the RhCMV homologs of HCMV immunoevasins US2, 3, 6, and 11 are 
essential for RhCMV to superinfect RhCMV-positive animals [276, 278]. The ability to establish 
secondary persistent infections is also a common occurrence in HCMV, resulting in frequent 
coinfection with different strains of HCMV [424]. Since depletion of CD8+ T cells restores the 
ability of US2-11–deleted RhCMV to infect seropositive animals, infection with ΔUS2-11 viruses 
can be used to monitor the quality of a vaccine-induced T cell response. Moreover, the clear 
protection observed by natural infection allows these studies to take place in a very small group of 
animals, since the outcome of superinfection is binary. The results shown in Fig.25 are typical: 
both animals inoculated with Δpp65ab were clearly protected against superinfection with US2-11–
deleted RhCMV but not with WT. (In fact, we observed superinfection in more than 200 animals 
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inoculated with recombinant RhCMV.) Evidently, the T cell responses to antigens other than pp65 
are protective in this challenge model.  
Using the US2-11 challenge approach we were able to examine whether pp65-specific T 
cells elicited by heterologous prime-boost vaccination were sufficient to recapitulate the protective 
effect of T cells elicited by preexisting infection. We used a DNA-prime/MVA-boost protocol 
employed previously to vaccinate animals with a combination of pp65, IE1, and gB [455]. In this 
previous work, it was shown that this vaccination regimen, while unable to protect against 
superinfection with RhCMV, reduced local and systemic viremia as well as viral shedding. 
Moreover, reduction in shedding correlated with the magnitude of pp65-specific T cell responses 
[455]. In our hands, the heterologous prime-boost vaccination induced a robust CD4+ and CD8+ T 
cell response to pp65b that in the blood was similar in magnitude to pp65-specific T cell responses 
elicited by RhCMV infection. Although prime-boost vaccination would not be expected to 
maintain the effector-memory–biased T cells responses elicited by RhCMV infection over the long 
term [278, 353, 359], at the time of challenge (6 weeks after the final MVA boost), the responses 
generated by the prime-boost vaccine still manifested a predominant effector memory phenotype. 
Despite this, these vaccine-generated pp65-specific T cell responses were insufficient to protect 
against infection by ΔUS2-11gag virus, as shown by the induction of Gag-specific T cell responses 
and CMV-specific antibody responses. This suggests that T cells induced by pp65 alone do not 
reproduce the protective effect of T cells induced by ongoing persistent infections. Since the T cell 
response to pp65 was substantial in all 3 animals, it seems unlikely that a different vaccination 
strategy would have induced a better protection. Rather, it seems more likely that additional 
antigens might be required to recapitulate the protective effect of natural infection. Thus, our 
results caution against the use of pp65 as the only T cell stimulatory subunit in a CMV vaccine.  
The ΔUS2-11 challenge used in this study provides an excellent tool to evaluate the T cell 
component of subunit vaccines. Conceivably, a similar approach could be used in human clinical 
trials to specifically evaluate the T cell immunity generated by a given vaccine. Recently, challenge 
with the Towne strain was used to evaluate the efficacy of subunit vaccines by monitoring an 
anamnestic HCMV-specific immune response [465]. Conceivably, a US2-11–deleted Towne 
strain would not generate an anamnestic response, similar to our observation that IE1-specific 
responses were not boosted when RhCMVΔUS2-11 failed to superinfect (Fig.25). In this case, a 
second challenge with WT-Towne could be used to monitor protection and T cell boosting as 
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described previously [465]. In contrast, a boosting of the pp65-specific T cell and antibody 
responses, as observed in pp65-vaccinated animals (Fig.27), would be a clear indication of 
infection by US2-11–deleted Towne and lack of protection by the T cell component of a given 
vaccine. Furthermore, our observation that vaccine-induced antibody responses against pp65 were 
strongly boosted by inoculation with ΔUS2-11 virus suggests that a safe, US2-11–deleted HCMV 
could be used to boost antibody levels induced by a given vaccine. Since high levels of antibodies 
are a desired feature of many vaccine regimens, inclusion of CMV as a new tool to enhance 
antibodies should be considered.  
In summary, our work revealed a novel and surprising function of pp65, suggesting that 
this viral protein acts as an immune inducer that generates an immune response that stringently 
restricts viral replication during primary infection but that has little impact on long-term 
maintenance, immunogenicity, or viral shedding. A likely explanation for this finding is that the 
highly abundant and immunogenic protein pp65 induces a rapid T cell response that limits viral 
dissemination. Since an intact immune system is required for this “immunological brake” 
mechanism to function, the lack of pp65-mediated control likely contributes to the high level of 
dissemination observed in immunocompromised individuals, such as transplant recipients, or in 
fetuses with immature immune systems. In RMs, RhCMV can cause severe sequelae, including 
spontaneous abortions, when injected into the developing fetus [473, 474]. Since the immune-
dominance of pp65 is conserved in HCMV, it is likely that this “antivirulence” function is 
conserved as well. HCMV and RhCMV thus seem to use the adaptive immune response to limit 
their dissemination during primary infection. It is not immediately obvious why CMV would 
choose such a self-imposed restriction. However, since the establishment and maintenance of 
persistent infection, as well as persistent shedding from the infected host, is not affected by the 
presence or absence of pp65, it seems that the ultimate “goal” of CMV, to establish a benign 
infection that easily spreads through the human population, is unaffected by pp65. The pp65-
mediated immunological control of CMV dissemination might thus serve to soften the impact of 
primary infection on the host to ensure a healthy host that is able to maintain and transmit the virus 
for a long time.  
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5. Discussion and Future Perspectives 
In the study presented here, we tried to shed light on a fascinating new vaccine platform which 
showed promising results in protecting rhesus macaques against challenge with highly virulent 
SIVmac239 [359, 360]. RhCMV has been shown to induce unique T-cell responses substantially 
different from any other vaccine vector examined previously [278]. Due to the nature of the virus 
as a persistent pathogen, CMV will remain with the infected host for life and reactivate 
continuously from latency [475]. This chronic infection induces a massive T-cell response to 
proteins encoded by the CMV vector backbone as well as any introduced foreign antigens. T-cell 
frequencies can comprise as much as 10% or more of circulating memory T-cells in the host [121].  
These T-cells control the lytic viral infection and limit viral reactivation from latency. Upon 
depletion of T-cells from test animals or if the host becomes immunosuppressed, either due to 
disease or medication, the virus can reactivate and cause disseminated infections, observations that 
underline the importance of a persistent T-cell response to control cytomegalovirus. Due to 
repeated reactivation and the resulting constant challenge, the T-cells cannot progress to central 
memory (TCM) phenotype as they would after infection with non-persistent viruses (e.g. 
adenoviruses), but display effector memory (TEM) phenotype [353]. As such they remain 
polyfunctional and capable of CTL activity immediately upon encounter of their target antigen. 
Since effector memory T-cells do not proliferate in response to pathogen challenge they provide 
an immediate defense at the entry or reactivation sites of potential infections. Whereas CMV 
evolved mechanism to evade clearance by the host’s immune response [124], SIV and other 
pathogens do not have this capability, and by inserting SIV antigens into the RhCMV backbone  
the highly pathogenic SIV strain mac239 was eventually cleared by the CMV-induced immune 
response [360]. The significance of this finding cannot be stressed enough since for the first time 
these results suggest that a HIV vaccine might be possible which would save the life of millions 
of people. CMV is normally a benign infection causing only mild pathology in the naïve host [28]. 
Seropositivity in a population increases with age and is dependent on the location and the living 
conditions of an individual. Close to 100% of individuals will become seropositive during 
childhood in most developing countries whereas seronegative individuals can still be found in the 
highest age brackets in developed nations [22-24]. Given the almost universal distribution of the 
virus, utilizing this virus as a new vaccine delivery vector does not introduce a never before 
encountered pathogen into the human population. Thus, vaccinating with a live, un-attenuated 
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vaccine vector would not be different than exposing an individual to wildtype CMV. However, 
while this might be acceptable in individuals that are already infected by CMV, non-attenuated 
vectors would likely not be acceptable in CMV-negative vaccine recipients due to the risk of 
causing pathology upon immunosuppression or upon fetal infection. Therefore, current work in 
RhCMV focuses on modeling possible attenuation strategies by selecting potential candidate genes 
for deletion in the viral genome for future development of attenuated HCMV vaccine vectors. 
 
5.1 Characterization of the protein coding content of RhCMV 
To design a functional in vivo monkey model for HCMV, it is important to determine the exact 
coding potential of our RhCMV vaccine vector in comparison to HCMV. Multiple studies have 
tried to estimate the number of potential ORFs encoded by this virus, but some predictions 
increased the total number of putative viral proteins well above experimentally determined results 
achieved for other CMV family members like HCMV and MCMV [347, 348]. Therefore, it seemed 
likely that a significant number of predicted ORFs were false and non-coding. These predictions 
were based on very simple computer algorithms that only searched for potential proteins spanning 
more than 100 amino acids and encoding for a start and a stop codon, without further examining 
the validity of these proposed ORFs. For HCMV, one possible method to elucidate the true coding 
potential is to compare multiple different fully sequenced genomes and determine the ORFs 
conserved among all of them, since it is very unlikely that different full length isolates encode for 
vastly different proteins. The first step is to eliminate all strain-specific predictions. However, this 
approach cannot be used for RhCMV since only two RhCMV strains have been fully sequenced, 
and both appear to have undergone major tissue culture adaptations and deletion of ORFs [345]. 
Therefore, we started with the assumption that NHP CMV members are closely related so that 
sequence comparisons of isolates from different NHP species would reveal the likely coding 
content of a prototypical RhCMV isolate. This assumption is based on the fact that HCMV and 
CCMV show remarkable coding similarity [346] and that several NHP species are so closely 
related that they can produce fertile offspring [476-478]. 
 Alignment of several genomes of NHP CMVs of Asian and African origin showed high 
sequence similarity of the genomic DNA sequence, particularly in the central genome region 
encoding most of the structural proteins and proteins responsible for DNA replication. However, 
even the less-conserved terminal genome regions were remarkably conserved, not only among 
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NHP CMVs but also between human and NHP viruses, with 90% of all HCMV ORFs having 
homologues in NHP CMVs, at least on the protein family level. This conservation is substantially 
higher than predicted previously [343] supporting a close genetic relationship between non-human 
and human primate cytomegaloviruses. In contrast, MCMV, the most widely used animal model 
system for HCMV, shows very little homology to the human virus outside the core region with 
many genes having functional but not sequence or locational homologues. Our finding that 
RhCMV has true homologues to almost all HCMV ORFs thus highlights the potential of the virus 
as a valuable tool to determine in vivo functions of important HCMV proteins. A further difference 
between primate and murine CMV is the fact that MCMV provides its host with protective 
immunity after sublethal challenge of naïve mice [305], so the boosting of initially generated T-
cell responses with another MCMV based vaccine vector is impossible, although superinfections 
have been demonstrated in wild mice [479].  
Interestingly, there are small differences between CMVs derived from different primate 
species with evolutionary distances between the host species reflecting evolutionary distances 
between the corresponding CMVs (see Fig.11). In addition to differences in sequences of 
homologous proteins, there are also differences in the number of viral proteins encoded by 
individual genomes. For instance, NWM CMVs as well as great ape and human CMVs encode 
only one copy of the major tegument protein pp65, whereas all OWM CMV genomes, both Asian 
or African monkeys CMVs, encode two copies of the ORF [444]. These two copies are not fully 
equal, since we were able to show that the pp65b protein is twice as abundant in the viral virion as 
the pp65a protein [444].  
A further difference can be found in the number of viral CXCL chemokines encoded by 
the different viruses. HCMV encodes for two of these proteins (UL146 and UL147), whereas 
CCMV encodes for three (UL146, UL146A and UL147) [346]. OWM of Asian origin have six 
chemokine family members (UL146B, UL146C, UL146D, UL146F, UL146H and UL147) while 
OWM of African origin have eight of these proteins (UL146B, UL146C, UL146D, UL146E, 
UL146F, UL146G, UL146H and UL147) [444]. Finally, NWM, like HCMVs, only encode two 
viral CXCL chemokines [3].  
Besides differences in coding capability, homologous viral proteins from different CMV 
species can also exhibit altered functions. In HCMV, pp71 is an almost essential viral protein 
[211]. The virus does not replicate at low MOIs in the absence of this protein, since pp71 is 
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responsible for, among other things, the degradation of DAXX [480]. By doing so the viral protein 
enables viral gene expression and viral genome replication by hijacking the cellular DNA 
replication machinery. In an HCMV pp71 deletion mutant, DAXX is not degraded, leading to a 
severe attenuation of the virus at low MOI [194, 211]. RhCMV also encodes for a pp71 protein 
with significant identity to the HCMV protein. Like its HCMV homologue, it also degrades DAXX 
and other ND-10 body components (data not shown), but the virus only exhibits a moderate 
attenuation at low MOI in non-complementing cells (Fig.29-30). The probable explanation for this 
difference is that, other than in HCMV, a RhCMV pp71 deletion mutant still delocalizes and 
degrades DAXX efficiently (data not shown), indicating that RhCMV might encode a second 
DAXX-targeting protein that, in the absence of pp71, can partially compensate for this defect. 
Another example can be found in the viral NK cell evasion. For HCMV the viral proteins 
UL16 and UL142 as well as the viral miRNA miR-UL112 have been shown to interfere with the 
activating NKG2D ligands (MICA, MICB and the UL16-binding protein (ULBP) 1-6) by 
sequestering them in the ER or downregulating their expression [481]. Interestingly, neither of 
these proteins, nor the described miRNA is conserved in RhCMV [444]. In fact, only HCMV and 
CCMV have been described to encode for these proteins whereas OWM CMVs as well as NWM 
CMVs do not contain homologues of these proteins. This implies that these viruses must use other 
mechanisms to evade NK cells, since work in MCMV suggests that NK cell evasion is important 
for the viral replication in vivo [224, 482-485]. Work performed in our lab led to the idetification 
of Rh159 as the viral protein responsible for downregulating NKG2D ligands from the cell surface 
of infected cells by sequestering them in the ER (Sturgill et al, manuscript in preparation). This 
protein is conserved in all OWM and NWM CMVs and also has a homologue in HCMV and 
CCMV termed UL148 [444]. This conservation does not extend to rodent CMVs, indicating that 
this protein has been part of the primate CMV genome for at least before the separation of NWM 
(Platyrrhini) and OWM (Catarrhini) about 35 million years ago [330-334]. As mentioned above, 
UL16 and UL142 are specific to the human- and great ape CMVs which indicates that these genes 
entered the viral genome after the separation of OWM and apes about 23 million years ago [337] 
and before the separation of the genera homo (humans) and pan (chimpanzees) roughly 5 – 7.5 
million years ago [338-341]. This finding leads us to speculate, that the common ancestor of all 
primate CMVs contained a UL148 homologue as its main mean of NKG2D evasion whereas over 
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the course of millions of years of co-evolution with its host, the common ancestor of human and 
chimpanzee CMV acquired UL16 and UL142 after the species separated from the OWM.  
 To further determine which potential ORFs actually encode for proteins we decided to 
determine the protein content of purified RhCMV virions using mass spectrometry comparable to 
what has been published by Varnum et al. for HCMV AD169 [18]. Admittedly, this only enabled 
us to detect structural proteins of the viral virion and we were not able to detect nonstructural 
proteins involved in immune evasion since they are not integrated into the viral virion, but we 
nevertheless obtained insight into a substantial part of the viral proteome and, more importantly, 
we were able to determine the validity of our ORF prediction. If we had found multiple proteins 
in the virion that were not predicted by our prior bioinformatics analysis, this would have indicated 
that our analysis did not lead to a better and more reliable annotation of the viral genome as 
compared to the stop-to-stop analysis used previously. However, only a single protein (Rh164.1) 
identified in the virion was not predicted during our initial analysis (Fig.22) due to our arbitrary 
cutoff of 300bp. In addition, Rh164.1 does not have a homologue in HCMV, so it was excluded in 
our preliminary annotation. All other proteins identified in the virion were predicted by our 
analysis. Nevertheless, it is still possible that some of the genes we predicted will not give rise to 
proteins so that further work will be needed to generate the final finished genome map of the virus. 
Yet, the overall match between predicted and confirmed protein sequences indicates that our 
approach showed reliable results and that the predicted genes are likely to be coding. It is possible 
that we might have missed several viral ORFs, especially very small ORFs that were recently 
found in HCMV by ribosomal profiling [486]. However, since our predicted total of 175 ORFs is 
consistent with the number of ORFs predicted for all other CMVs we have a high degree of 
confidence in our new annotation. 
 
5.2 Use of attenuated RhCMV vectors in vaccine development 
To further improve our previously established RhCMV vaccine vectors for potential use in humans 
against HIV, tuberculosis (Tb) or any other potential pathogen, we had to confirm that the vaccine 
backbone itself was safe. To ensure this, we encountered the problem to design a vector construct 
that would generate a high and specific T cell response against the targeted organism without 
exhibiting any pathogenicity by itself in immunocompetent adult macaques. In the long run this 
vector should even have the potential to be used safely in immunocompromised individuals and 
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neonates, since these two target groups are most affected by the virus. Furthermore, it is of the 
utmost importance that our final vaccine vector cannot be transmitted either horizontally or 
vertically between individuals, but remains solely in the vaccinated individual. 
 As a first target for attenuation, we chose the two RhCMV homologues of the HCMV pp65 
protein (pp65a and pp65b). The HCMV pp65 protein is involved in the evasion of the innate [151, 
152, 432] as well as the adaptive immune response [230, 433, 434], but deletion of the protein 
from the virus does not affect virus growth in fibroblasts [440], so viral stocks of the deletion 
mutant can be grown on non-complementing cells, saving us the effort to generate a 
complementing cell line. Furthermore, as we have shown earlier, pp65 a and b are two of the most 
abundant members of the viral tegument [444], so deleting these ORFs and inserting a foreign 
antigen in its place under the endogenous viral promoter should lead to comparably high levels of 
targeted antigen expression while at the same time attenuating the virus in vivo. Generating the 
RhCMV deletion mutants proved to be unproblematic and the reconstituted virus showed similar 
in vitro growth characteristic as its previously described HCMV and MCMV counterparts [440, 
457]. The growth defect in vitro, even at low MOIs was minor, and only a short delay in peak viral 
titer was noticed whereas the viral peak titers were unchanged. 
 To evaluate the impact of the absence of both pp65 proteins on the viral virion, we gradient 
purified mutant virus and performed mass spectrometry on in 8M urea denatured virions. It has 
been noted for HCMV pp65 deletion mutants, that the absence of this major tegument protein 
affects the levels of other virion protein and that pp65 might play a significant role in the loading 
of proteins into the viral virion [441]. Contrary to this data and to data published in another study 
performed and published after the publication of our work [487], the total absence of both pp65 a 
and b had only a minor impact on the protein levels of other virion components. When we adjusted 
the relative protein abundances of all proteins found in the RhCMV virion to the absence of pp65 
a and b by adjusting the total relative amount of proteins to 89% (11% representing the absence 
pp65 proteins) to render the two datasets of the WT and the deletion mutant more comparable, we 
obsered that none of the more abundant proteins showed a significant increase or decrease in 
relative abundance between our two independent experiments. Significant changes can be found 
in proteins that show very low abundance, but it is unclear if theses changes reflect real differences 
in protein composition, or technical difficulties picking up trace amount of low abundance proteins 
using mass spectrometry. Additionally, when we examined the viral virions of RhCMV WT and 
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our pp65 deletion mutant by electron microscopy, no obvious structural differences were observed, 
A more detailed measure of the different virion dimensions (diameter of the virion, the capsid and 
the tegument layer) revealed that the overall size of the mutant virions was significantly reduced, 
and that this reduction is mostly due to a significantly smaller tegument layer, This data indicates 
that the virus does not compensate for the absence of the major tegument components pp65 a and 
b by inserting more of the other dominant tegument proteins into the virion, but that the absence 
of pp65 a and b simple leads to an overall decrease of tegument. The relative decrease of the 
tegument layer by ≈25% is in the same range as the percentage of tegument normally taken up by 
pp65a and b. Thus, the deletion of these proteins does not affect other tegument or virion protein 
significantly, but leads to a reduced tegument layers.  
 To determine the overall strength of the T-cell response generated by our potential vaccine 
vector in vivo in comparison to the RhCMV WT, we challenged the vaccinated animals with a 
previously described RhCMV 68-1 ΔUS2-ΔUS11 deletion mutant [276]. This mutant exhibits an 
interesting phenotype in that it infects naïve animals normally and establishes persistent infections 
in vivo in these animals, but is incapable of infecting seropositive animals, since these animals 
posses a pre-existing anti-RhCMV T-cell response. The proteins encoded within the US2-US11 
region are known T-cell immune evasion genes [124], and the virus cannot overcome the 
preexisting adaptive host T-cell response in the absence of these proteins [276]. We expected our 
pp65 deleted vaccine vector to induce a T-cell response with similar amplitude and efficacy as the 
T-cell response induce by the 68-1 WT, but since pp65 is a major target for CD8+ T-cells, its 
absence might weaken or misdirect the host immune response to the vector. Initial results in naïve 
rhesus macaques showed that the amplitude of the anti-CMV CD4+ and CD8+ T-cell responses in 
BAL as well as PBMCs were comparable to the overall levels achieved in WT infections. A 
RhCMV mutant lacking the US-US11 region was not able to overcome the T-cell response induced 
by the pp65 deletion mutant, indicating that the T-cells directed to proteins other than pp65 are 
capable of controlling RhCMV in re-infection or, potentially, re-activation. Vaccination with our 
deletion mutant did not protect against challenge with a 68-1 WT vaccine vector. This finding is 
not surprising, as vaccination with a WT vaccine vector does not protect against re-challenge with 
the same virus either [353]. Re-infections are common in the human as well as animal populations, 
and protective immunity does not exist in humans and primates after infection with their respective 
CMVs. Lastly, RhCMV 68-1 Δpp65ab was able to superinfect CMV positive animals. This 
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attribute is essential for every potential CMV vaccine vector, since superinfection is needed for its 
use as a vaccine vector, not only for the purpose of boosting established immune responses, but 
also to inoculate naturally HCMV positive individuals with CMV based vaccine vectors. Pre-
existing immunity can be an issue in vaccine trials as has been encountered in the use of HAdV-5 
based vaccine vectors, human vectors based on the human adenovirus type 5, a type widely 
common in the human population [488-490]. 
 Since pp65 is such a prominent target for the T cell response, the protein by itself has been 
proposed a potential subunit vaccine [491]. Several in vivo animal and human trials with pp65 as 
the sole constituent, or with pp65 as the T cell component or part of the T cell component in an 
anti-CMV subunit vaccine have been tested [455, 463, 465, 492, 493]. The results were in many 
cases promising, and future trials with different compositions are under way or have been 
proposed. Given that our RhCMV deletion mutant still protected against re-infection with a ΔUS2-
ΔUS11 deletion mutant, we wanted to examine whether pp65 responses by themselves could 
achieve similar results. Interestingly, although we were able to generate strong pp65b specific 
immune responses with our DNA prime MVA boost strategy, the T cell responses were not good 
enough to protect against our subsequent RhCMV ΔUS2-ΔUS11 challenge, indicating that not 
only the amplitude, but also a certain breadth in T-cell targets is needed to generate an effective 
anti-CMV T-cell response. This very interesting finding suggest, that subunit vaccine based on 
pp65 as their sole T-cell target, or even vaccines with two or three of the most prominent T-cell 
targets might not generate a T-cell response with the same breadth and hence the same efficacy as 
the WT infection does. Thus, it might be better to use a live attenuated or single cycle CMV vaccine 
vector, since these vectors, if constructed properly, should generate a broader and superior immune 
response. 
 Since viremia is the single-most determining factor in the pathogenesis in CMV-related 
diseases [494], we wanted to compare the virus load in tissues in infected animals. For this purpose, 
the same CMV naïve rhesus macaques were infected with a WT vaccine vector and Δpp65 deletion 
mutant expressing different SIV markers, and the animals were sacrificed at predetermined 
intervals after vaccination. Because of their different foreign antigens, the two vaccine vectors 
could be detected by nested PCR in the same samples and viral loads could be determined. RhCMV 
68-1 is a laboratory strain of RhCMV, and as such, has adapted to culture in rhesus fibroblasts. 
Similar to what has been observed in HCMV AD169 or HCMV Towne [495], genomic regions in 
Discussion                                                   110 
 
the co-called ULb’ region of HCMV have been lost in RhCMV 68-1 due to in vitro passaging. As 
a result, the virus lost its pentameric complex needed to infect cells through endocytosis and 
successively its ability to infect cells other than fibroblasts effectively [415]. Consequently, the 
virus is barely detectably in the saliva and urine of naïve rhesus macaques infected with the BAC 
derived virus early after infection compared to low passage clinical isolates [416], and we see very 
low copy numbers of vaccine vectors based on 68-1 in animal tissues, even the injection site, 2-3 
weeks post infection. Deleting pp65a and b from the 68-1 WT revealed a very different picture. 
The virus was easily detectable in almost all tissues of infected animals, whereas the WT was 
mostly restricted to the injection site and the nearest draining lymph node. Moreover, the viral 
loads of the pp65 deletion mutant were in some cases 6-7 logs higher than measured for the 68-1 
WT in the very same animals. Our data indicate that in vivo pp65 acts as a silencer or damper of 
its own viral replication in the context of a primary infection, probably limiting the virus to a viral 
load that will ensure the survival and well being of the host, so that the virus can establish a 
persistent infection and spread to other individuals who are in contact with the infected individual. 
This is the first time we encountered that a deletion mutant in on a somewhat benign parental virus 
led to a highly significant increase of viral replication and dissemination in vivo. Therefore, 
deleting pp65 from a potential vaccine vector is not an option.  
 
5.3 Developing a pp71 deletion virus into a 2nd generation CMV vaccine vector. 
Given that the pp65 deletion mutant did not achieve the expected results, we had to explore other 
options to create a safer vaccine vector platform with high immunogenicity. The second potential 
candidate was pp71, another structural virion protein found in the tegument [18, 444]. Like pp65, 
this protein was also shown to have immediate intrinsic immune evasion functions by degrading 
multiple proteins within ND10 bodies including DAXX and ATRX [192, 480], enabling the viral 
replication utilizing the host DNA replication machinery [208]. It also appears to be involved in 
viral reactivation, as the protein remains in the cytosol during latency, not affecting the endogenous 
DAXX levels, whereas re-entry into the nucleus seems to shift the virus from latency into lytic 
replication [68]. Preliminary data from our institute indicates that HCMV lacking pp71 can infect 
humanized mice normally and establishes latency but cannot reactivate from this state (Crawford 
et al., unpublished data). 
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Fig.28: Subcellular localization of tegument-delivered pp71 determines whether HCMV initiates lytic 
replication or establishes quiescent, latent-like infections. (A) Lytic replication initiates when tegument-delivered 
pp71 is allowed access to the nucleus. Capsids docked at nuclear pores release their DNA into the nucleus, and viral 
genomes associate with cellular histones (H). The Daxx protein, which rapidly dissociates from, and reassociates with, 
PML-NBs, accumulates around viral genomes, recruits an HDAC, and silences viral IE gene expression. Other PML-
NB components are also recruited and participate in the silencing of viral genomes. pp71 binds to Daxx in these newly 
formed PML-NBs, induces Daxx degradation, derepresses viral IE gene expression, and thus initiates the lytic 
replication cycle. (B) In cells where quiescent or latent infections are established, tegument-delivered pp71 remains 
in the cytoplasm. Daxx (and presumably other PML-NB proteins) silences viral gene expression in these cells (taken 
from Kalejta, Microbiol Mol Biol Rev. 2008 Jun;72(2):249-65.).  
 
 One fundamental problem with generating a pp71 deletion mutant is that this virus was 
shown to have a severe replication defect in HCMV at low MOIs. As a matter of fact, the virus 
barely replicated at all at an MOI of 0.01 in primary human fibroblasts, whereas viral replication 
an a high MOI of 3 did not seem to be affected as much (Fig.29) [211]. When we repeated these 
experiments ourselves with the same virus provided to us by the authors of the study, we achieved 
similar results (Fig.30). Interestingly, when we constructed a pp71 deletion mutant based on the 
RhCMV laboratory train 68-1, we were able to reconstitute the virus in non-complementing tRFs. 
To generate high titers of the virus, we established a complementing cell line conditionally 
expressing RhCMV pp71 controlled by a Tet-On operon [496]. Although expression of the protein 
should be inhibited in the absence of doxycycline, the regulation of the operon turned out to be 
leaky, and even uninduced cells expressed small amounts of the viral proteins, even enough to 
complement a full deletion mutant. Using this cell line, high titer stocks of the pp71 deletion mutant 
could be generated. Because the attenuation of the pp71 deletion is alleviated at high MOIs, stocks 
generated on complementing cell lines can subsequently be used to create new stocks of the 
deletion mutant on non-complementing cells by infected these cells at a high MOI. The hereby 
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generated virus is negative for pp71 in the genome as well as in its virion, since virus grown on 
complemented cells still contains pp71 expressed by the host cells in trans in its virion, giving it a 
replication advantage and WT appearance during its first round of replication. 
 
Fig.29. Growth kinetics of wt and mutant viruses. Human fibroblasts were infected (3 or 0.01 pfu per cell) with wt 
(closed circles), AD Sub UL82+UL82 (open circles), or AD Sub UL82-UL82 (closed triangles) virus. Cultures were 
harvested at the indicated times after infection, and infectious virus was quantified by plaque assay on WF28-71-HA 
cells (taken from Bresnahan and Shenk, Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14506-11.). 
 
Single and multistep growths curves performed at different MOIs on tRFs revealed that the 
RhCMV Δpp71 deletion mutant only showed a minor delay in viral titers at high MOI, independent 
of the virus being grown on complementing or non-complementing cells, whereas both version of 
the mutant showed significant attenuation at lower initial MOIs (Fig.31). It was surprising that the 
virus showed grew at low MOIs, even in the absence of pp71, given that a similar HCMV deletion 
mutant did not grow under these conditions [211].  
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Fig.30: Multi-step growth curve of HCMV AD169 ΔUL82 (pp71). Primary human foreskin fibroblasts (1°HFFs, 
solid squares) or telomerized human fibroblasts stably expressing HCMV UL82 (pp71) (tHFs + UL82, open squares) 
were infected with HCMV AD169 WT or HCMV AD169 ΔUL82 (pp71) at an MOI of 0.01. Supernatant was 
harvested in 3 day intervals, and the viral titers were determined by limited dilution assay. 
 
Further examination of the RhCMV pp71 protein revealed, that the protein is sufficient to 
delocalize DAXX and ATRX from the nucleus of transfected cells in a fashion similar to the 
HCMV pp71 protein. Interestingly, when we examined tRFs infected with our RhCMV Δpp71 
deletion mutant, DAXX as well as ATRX were still delocalized and DAXX was still degraded, 
indicating that RhCMV must encode for a second viral protein with a similar function as pp71 
(Marshall et al., unpublished data). This protein is, at least functionally, not conserved between 
RhCMV and HCMV, explaining why an HCMV Δpp71 deletion mutant can no longer degrade 
DAXX to transactivate viral gene expression and viral genome replication and why a deletion 
mutant in the human virus is more growth deficient in the absence of pp71 compared to 
homologues RhCMV constructs. While  this indicates that pp7-deleted RhCMV vectors are likely 
less attenuated in vivo compared to the corresponding HCMV mutant, any in vivo attenuation 
observed for RhCMV will most likely be conserved in HCMV since the HCMV version will be 
even more attenuated than the comparable RhCMV version.  
Although our deletion mutant only showed a moderate growth reduction in vitro at low 
MOIs compared to the HCMV Δpp71 construct, the level of in vivo attenuation achieved with this 
mutant was remarkable. After infection of naïve RMs with the construct, urine was collected from 
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the animals on a regular basis to detect secreted virus by co-culturing the urine on tRFs stabily 
expressing RhCMV pp71. RhCMV 68-1 based WT vaccine vectors can be detected by 
immunoblot from urine co-cultures by day 28, whereas we were not able to detect our RhCMV 
pp71 deletion at any time point up to day 231 in co-cultures on complementing cells (Fig.32). This 
indicates that the virus is not shed by the infected animals, which could indicate that the pp71 
deletion mutant, if used as the backbone for a future vaccine vector, probably cannot be transmitted 
horizontally between humans, since transmission generally occurs through secretion in bodily 
fluids. Given the more severe attenuation of the human deletion virus in vitro, it is very likely that 
we will see a similar effect for an HCMV Δpp71 deletion vector backbone, fulfilling one essential 
requirement for future use in the human population. 
 
Fig.31: Growths kinetics of complemented and uncomplemented RhCMV 68-1 Δpp71 deletion mutants 
compared to 68-1 WT. Telomerized rhesus fibroblasts (tRFs) were infected with RhCMV 68-1, RhCMV 68-1 Dpp71 
grown on complementing tRFs stably expressing pp71, or RhCMV 68-1 Dpp71 grown on non-complementing tRFs 
at an MOI of 3 (A), 0.1 (B), 0.01 (C) and 0.001 (D). Cell free supernatant was collected on the indicated time points 
and the viral titers were determined with limited dilution assays and graphed over time. 
 
Interestingly, while the deletion mutant was not shed by the infected naïve animals, 
indicating in vivo spread-deficiency compared to the WT, the immune response induced by the 
vector exhibited the same kinetics, amplitude and duration as the immune responses induced by 
Discussion                                                   115 
 
RhCMV 68-1 WT vectors (Fig.33). CD4+ and CD8+ T-cell responses against the immunodominant 
CMV proteins IE and pp65 (Fig.33A) or against complete CMV lysates (Fig.33B) are detectable 
in PBMC as well as BAL 7-14dpi and peek around 21dpi. Thereafter, the amplitude of the response 
declines and plateaus at a steady level around 56dpi where it remains ad infinitum. Similar to data 
generated with our pp65ab deletion vector, infection with a pp71 deletion vector induces an 
adaptive immune response strong enough to protect against re-infection with a ΔUS2-ΔUS11 
deleted RhCMV mutant. This shows a breadth in CD8+ T cells responses broader than achieved 
with pp65 alone (Fig.27) and potentially equally protective as responses generated by the WT 
vectors. 
 
 
Fig.32: RhCMV 68-1 Δpp71 is not shed by infected animals. (Upper panel) Naïve RMs were infected with RhCMV 
68-1 Δpp71 and urine was collected in 14 days intervals after infection. The urine samples were co-cultured on pp71 
expressing telomerized rhesus fibroblasts. 28 days after inoculation, the cells were lysed and Western blots were 
performed to detect the RhCMV IE protein. (Lower panel) CMV positive RMs were superinfected with RhCMV 68-
1 Δpp71 SIV RTN. Like described above, Urine was collected in 14 day intervals and co-cultures were performed on 
complementing cells. After 28 days of co-culture, cells were lysed and Western blots were performed to detect the V5 
tagged RTN transgene. 
 
The quality of the immune response is impressive especially considering the spread-
deficiency observed in vivo, but it indicates that this vector could work as a T-cell inducing vaccine 
vector. Moreover, also considering the required safety of the vaccine backbone, especially in CMV 
vulnerable populations like women of childbearing age and immunocompromised individuals, the 
combination of high immunogenicity paired with high attenuation and probably low pathogenicity 
would make this vectors design perfect for future human applications. 
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Fig.33: RhCMV 68-1 ΔRh110 (pp71) infects naïve RMs normally and protects against RhCMV 68-1 ΔRh182 
(US2)-Δ189 (US11) GAG + ΔRh178 superinfection. A) Two naïve RMs were infected with infected with RhCMV 
68-1 ΔRh110 on day 0. PBMCs (upper panel) and BAL (lower panel) were harvested in 7 day intervals and RhCMV 
IE and pp65 specific CD4+ (left panel, blue lines) and CD8+ (right panel, red lines) T-cell responses were determined 
by co-culturing isolated T-cells with APCs presenting specific peptides for IE and pp65. Results of prior experiments 
infecting naïve RMs with RhCMV 68-1 WT are shown for comparison (black lines). B) To determine broader RhCMV 
specific T cells responses, peptides from whole RhCMV lyses were loaded onto APCs and presented to T-cells isolated 
from PBMCs (upper panel) or BAL (lower panel). On day 231 post infection, the RMs were superinfected with 
RhCMV 68-1 ΔRh182 (US2)-Δ189 (US11) GAG + ΔRh178. As can be seen in all panels, no boost in CD4+ or CD8+ 
T cell responses was detected after superinfection, indicating, that the virus did not successfully superinfect. 
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 To determine just how powerful the level of attention of the pp71 deletion in vivo really is, 
we constructed a mutant virus lacking pp71 replaced with SIV GAG. On top of it, we subsequently 
deleted pp65 a and b from the viral genome creating a GAG expressing triple deletion mutant. The 
absence of pp65ab alone from the RhCMV backbone leads to a massive increase of viral 
replication in naïve animals with 3-6 logs increased viral loads of the mutants compared to the 68-
1 WT vectors in almost all tissues in the same animals (Table 8). This massive replication and the 
connected higher probability of increased CMV induced pathology led us to exclude pp65 as a 
potential candidate for attenuation of the WT vector. When we now co-infected naïve juvenile 
RMs with RhCMV Δpp65ab RTN and RhCMV Δdpp71 GAG + Δpp65ab deletion mutants and 
compared viral loads in tissues at 14 dpi, it became apparent, that while the pp65 deletion showed 
increased viral loads in the test animals, this phenotype was overcome by the additional deletion 
of pp71 (Table 9), reducing the viral loads to viral titers seen in similar experiments performed 
with pp71 deletion mutants (data not shown). Furthermore, deletion of pp71 also reduced the 
dissemination of the vaccine vector. Whereas the pp65ab deletion virus spreads to all major organs 
in the infected animals, the pp71 deletion restricts the viral spread mostly to the injection site and 
the nearest draining lymph nodes. All these factors further underline the potential of our pp71 
deletion to serve as an attenuation factor to create a safer CMV vaccine vector that retains the full 
CMV potential to induce a strong and lasting adaptive immune response against the vector as well 
as against any inserted foreign protein. In addition to the data presented here, we were also able to 
show that a pp71 deleted vector is still fully capable to re-infect CMV positive animals and that 
the virus induces T cells with TEM phenotype.  
As mentioned above, the TEM phenotype of the CD8
+ T cells is likely the reason for the 
superior efficacy of our CMV-based T cell vaccine vectors compared to any other previously 
studied vaccine platforms, since these T cells do not have to proliferate like TCM after re-
encountering their target antigen, giving them a faster response time and a kinetic advantage 
against the initial encounter of invading pathogens. Additionally, we were able to demonstrate, 
that pp71 deleted vectors cause substantially reduced pathogenesis when directly injected into RM 
fetuses compared to WT vectors and especially clinical isolates with fewer incidents of 
spontaneous abortions and less severe or even total absence of virus induced pathology and viral 
titers in tissues. As shown in Fig.32 the vectors are not shed by infected animals, and by observing 
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a nursing mother vaccinated with multiple different pp71-based vaccine vectors, we were able to 
demonstrate that our vectors were not transmitted to the baby, and the young animals remained 
seronegative for all vaccine vectors for the entire time it was monitored (Marshall et al., 
unpublished data). Additionally, when we tried to adoptively transfer the RhCMV Δpp71 deletion 
mutant through isolated PBMCs from a vaccinated macaque to naïve animals, we failed, and the 
recipient animals never showed immune responses against SIV (Hansen et al, unpublished data). 
Using PBMCs from animals vaccinated with vaccine vectors based on the RhCMV 68-1 WT, 
horizontal transmission through adoptive transfer is easily achievable. 
 
Table 9: Genome copy numbers of RhCMV Δpp65ab RTN and RhCMV Δdpp71 GAG + Δpp65ab CMV-naive 
RMs. 
Taken all these data into consideration, this indicates that although pp71 deletion mutant 
are only moderately growth-deficient in vitro they are attenuated in vivo in regards to shedding 
Δpp65ab Δpp65ab/Δpp71 Δpp65ab Δpp65ab/Δpp71
Skin Injection Site (Left) 54 ND ND 2,080
Skin Injection Site (Right) 31,767 ND 173 ND
Axillary LN (Left) 1,338 34,044 ND 68,146
Axillary LN (Right) 6,289 ND 15,032 ND
 Iliosacral LN 44,447 ND ND 12
Tonsil ND 5 ND ND
Tracheobroncial LN 69,901 ND ND ND
Submandibular Salivary Gland (Left) 3 600 23 ND
Submandibular Salivary Gland (Right) 3,867 ND ND ND
Thyroid 3 ND 3 ND
Lung 7,843 ND 5 ND
Spleen 88,148 ND 528 ND
Kidney 4,475 ND ND ND
Esophagus ND ND 7 ND
Ileum 5 ND 1,725 ND
Colon 2,230 ND 72 ND
Liver 38,320 ND 946 ND
Ileocaecal ND ND 3 ND
Inguinal LN (Left) 417 452 ND ND
Inguinal LN (Right) 2,699 ND ND ND
 Inferior Mesenteric LN 491 ND ND ND
Medial Mesenteric LN 3 ND ND ND
Superior Mesenteric LN 1,147 ND 3 4,465
Urinary Bladder 32 ND 1,871 ND
Brain 17 ND ND ND
Spinal Cord (Thoracic) ND ND 4 ND
Spinal Cord (Cervical) 9 ND ND ND
Bone Marrow 7 ND ND ND
PBMC 100 ND ND ND
Tissue Type
Rh21112 Rh21979
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and horizontal transmission, they still induce T-cell responses that seem to be as frequent and 
effective as responses observed in animals infected with vaccine vectors based on the RhCMV 68-
1 WT virus. In fact, preliminary challenge studies resulted in similar levels of protection as 
observed previously [359] indicating that our pp71 deletion vectors achieve similar if not higher 
levels of protection and clearance in monkeys challenged with the virulent SIVmac239 strain. 
 
5.4 The bright future (or where to go from here). 
Our preliminary results shown here for vaccine vectors based on pp71 deletion mutants are very 
encouraging and warrant further studies and closer examination. But to push our vaccine platform 
from the bench and the animal model system into the real world and the human patient, it is also 
essential, in parallel to conducting further animal trials and studies, to generate a human version 
of our vaccine platform to facilitate future clinical trials. Several issues have to be overcome to 
achieve this goal. First and foremost, as was shown in previous publications and by us, a HCMV 
pp71 deletion mutant is severely attenuated and does not show spreading through tissue cultures 
at low MOIs [211], so generating stocks of vaccine vectors in HCMV is more challenging that it 
has been for the RhCMV Δpp71 mutant, since this virus still retains a medium level of spreading 
at low MOIs. Additionally, since the HCMV vaccine mutants are meant to be generated for future 
human trials, all steps of virus reconstitution from the BAC and generation of viral stocks have to 
comply with FDA guidelines and will have to be approved by this institution, further complicating 
an already challenging task. To this end, only MRC-5 fibroblast as host cells to grow our vaccine 
stocks for further in vivo trials in humans are FDA approved, whereas FDA approved pp71 
complementing cell lines currently do not exist. Thankfully due to the innovative efforts of 
multiple scientists in our group, we have succeeded in generating high titer stocks of HCMV pp71 
deletion mutants without the use of complementing cells, simple by inhibiting DAXX translation 
with specific siRNAs, a function performed by pp71 in the WT (van den Worm et al., unpublished 
data). These stocks can now be produced in our own facility under GRP conditions to generate 
research virus seed stocks. Final clinical trial material will be generated by contract manufacturing 
organizations specialized on generating GMP products. 
 In addition to solving the production issues with our vaccine platform, we also have to 
demonstrate immunogenicity of antigens introduced into our HCMV vectors, since data generated 
with RhCMV in rhesus macaques cannot be simply extrapolated. This is very problematic, since 
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all CMVs are considered to species specific, and no animal model other than humanized mice can 
be employed to test HCMV infections in vivo. This model system is used in our institute by 
engrafting human CD34+ stem cells into Nod/SCID/IL2Rγ k.o. mice. As mentioned above, 
HCMV WTs as well as pp71 deletion mutants based on the low passage HCMV strain TR (repaired 
for its US2-US11 deletion) are able to infect humanized mice and establish viral latency. More 
importantly, whereas all tested HCMV low passage WTs are capable of reactivating from latency, 
pp71 deletion mutants are not, indicating in vivo attenuation. However, this model is not suitable 
to study immunogenicity of HCMV-based vectors. To study immunogenicity an 
immunocompetent animal model is required that can be infected with HCMV. Jurak and Brune 
[497] were able to show that MCMV does not replicate in human cells, because the virus cannot 
counteract the virus-induced apoptosis like it would in mouse cells through its antiapoptotic 
proteins. Interestingly, when the antiapoptotic UL37x1 protein from HCMV is introduced into 
MCMV, the generated mutant is able to inhibit apoptosis and to replicate in human cells. 
Importantly, HCMV vectors based on clinical isolates containing full-length genomes, apart from 
deletions and mutations indroduced to attenuate the virus in vivo (like pp71), can infect rhesus 
macaques (Caposio et al., unpublished data). These data indicate that the species specificity is not 
absolute, and the virus can cross the species barrier, at least in the context of a forced s.c. injection. 
These infections do, in all likelihood, not occur naturally by co-hosting two different species 
together in close quarters. Prior reports show the isolation of African green monkey derived simian 
CMV (SCMV) from humans in two independent cases [370, 498, 499], without any examination 
regarding the source of the virus, but these cases were generally regarded to be anecdotal at best. 
We are now able to study the immunogenicity, and potentially efficacy against pathogen challenge, 
of our HCMV vaccine vectors in vivo in rhesus macaques, and we are able to determine the 
immunogenicity of attenuated mutants to select those most likely to succeed in humans prior to 
clinical trial, making our final construct more like lo prevail in this rigorous process. 
 As a second essential step to construct a new, marketable vaccine platform, it is more than 
desirable to have a technology that is applicable to more than one, although very important, 
pathogen. Most of our studies so far have been focused on SIV, and by extension HIV, but we 
have also explored other important human pathogens. RhCMV vector expressing Mycobacterium 
tuberculosis antigens have been generated and tested in vivo in several trials, and preliminary data 
indicates that the protection achieved by our vectors in the rhesus macaque model is superior to 
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the protection generated by the licensed BCG vaccine (Xu, Hansen and Picker, unpublished data). 
This is even more interesting given that in SIV, large regions of the viral genome were integrated 
into the different RhCMV vaccine vectors to generate broad T-cell responses against most of the 
major viral proteins, whereas in Tb, only a small fraction of the pathogen genome can be inserted 
given the immense size of the bacterial genome (4 million bp, 4000 genes, compared with 10000 
bp and 19 proteins in SIV). Still, by selecting the right combination of T-cell targets, protections 
can be achieved, even in the rhesus macaque model where infection with 25 CFU of Tb is lethal 
within months. Similarly, preliminary studies using vaccine vectors generated in RhCMV 
encoding for immunodominant protein of the liver stage (sporozoite) of the protozoan parasite 
Plasmodium, the infectious cause of malaria, showed a significant effect in vivo against challenge 
with P. knowlesi sporozoites (Scholz et al., unpublished data). However, given the immense size 
of the parasite’s genome (14 chromosomes, varying in size from 500 kb to 3500 kb, combined 
accumulating to 23Mb encoding for about 5300 genes), the major challenge is to find the right 
combination of potential T-cell targets to generate sterile immunity and further studies are needed 
to optimize antigen and vector backbone combinations. In addition to the aforementioned 
pathogens, a wide array of other human pathogenic viruses, bacteria and parasites as well as 
cancers are studied right now to broaden the applicability of our vaccine platform, and we are 
confident that our work will help to save and improve the lives of millions of people all around the 
globe in the future.  
 Finally, the last point of improvement we have to achieve to increase the applicability of 
our vaccine platform is its efficacy. In our SIV challenge studies, we were able to generate T-cell 
responses against SIV that enabled 50% of the vaccinated animals to not only control, but 
eventually clear the virus altogether [359, 360]. This is an impressive result and it is superior to all 
prior studies using other vaccine platforms, but it also means that 50% of the animals were not 
protected and that the vaccine was ineffective in these animals. We are still investigating the 
immunological differences between the animals that were protected and the animals in which the 
vaccine proved to be ineffective. Given the high virulence of SIV, it is important to stress, however, 
that 50% protection in animals does not necessarily predict 50% protection in humans. In addition 
to studying genetic or stochastic paramerters for this outcome, we are also evaluating the role of 
various vector backbones on this outcome because it became apparent over the course of our 
investigation that the vector design of our CMV vaccine construct has a tremendous effect on the 
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generated T-cell response and probably subsequently on the vaccine efficacy. As we were able to 
show, RhCMV vaccine vectors induce broad T-cell responses against foreign antigens with total 
numbers of specific, independent epitopes well above what has been achieve in natural SIV 
infections or with any other vaccine platform [278]. The T-cell epitope coverage of foreign 
antigens in the context of RhCMV is so high, that in the case of SIV-GAG epitopes spanning large 
parts of the viral protein are presented to T-cells [278]. This breadth alone makes it hard, even for 
a highly mutagenic pathogen like a retrovirus, to evade the T-cell response by mutating epitopes, 
since dozens of epitopes all across the genome would have to be mutated simultaneously. 
Furthermore, the T-cells responses in the context of a RhCMV infection differ significantly from 
the T-cell response seen with other vaccine approaches. RhCMV 68-1 does not induce canonical 
MHC class I restricted epitope normally seen in SIV infection or after vaccination with DNA or 
common vaccine vectors, but it introduces a collection of very unique and never before described 
responses [278]. About 2/3 of the epitopes presented to CD8+ T-cells are actually presented by 
MHC class-II molecules, violating an immunological dogma in which MHC class I presents to 
CD8+ T-cells and MHC class-II presents to CD4+ T-cells. The remaining 1/3 of epitopes are 
presented by MHC-class I, but not by classical HLA molecules, but by the non-classical HLA-E 
molecules (Hansen, Sacha and Picker, unpublished data). These molecules are known to present 
signal sequences of classical MHC class I alleles to NK-cells to counteract the “missing self” 
recognition and thereby preventing NK-cell mediated killing. In addition, some of the epitopes 
presented either on MHC class-I or class-II molecules are presented in all or almost all tested 
animals. This would not be that surprising in inbred mouse strains, but rhesus macaques represent 
an outbred population with a wide array of MHC haplotypes, and it should be impossible for an 
outbred population with different MHC alleles to present the same epitopes. We termed theses 
widely presented epitopes “supertopes”. In the context of MHC-II, these promiscuous epitopes can 
be presented by multiple different MHC class-II alleles (Sacha et al, unpublished data). In the 
context of MHC class I, the non-polymorphic nature of HLA E permits the universal presentation 
of the same peptides (Hansen, Sacha and Picker, unpublished data). In addition, deletion of the 
US11 protein from the vaccine backbone further increases the number of epitopes presented, since 
the deletion of this MHC class-I evasion gene now enables the presentation of canonical epitopes 
recognized by T cells in SIV infected animals, but not elicited in the context of US11-containing 
RhCMV. All theses different responses can be either generated or inhibited depending on the 
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makeup of the vaccine backbone. As mentioned above, canonical T cell responses can be generated 
by the deletion of US11, whereas MHC class-II restricted epitopes only appear in the absence of a 
functional pentameric complex. Supertopes and HLA-E responses are inhibited by simultaneously 
expressing functional UL128 and UL130 proteins, possibly due to their chemokine activity 
(Hansen, Malouli, Früh and Picker, unpublished data). Taken together, we are now able to generate 
custom vaccine vectors generating exactly the immune responses needed for a specific target 
pathogen. To date, it is not clear which of the aforementioned unique T-cell responses generated 
by CMV vector are responsible for the protection of our animals in the vaccine studies, but in 
ongoing studies we will determine the optimal vector combinations to fight SIV infections, which 
will hopefully further increase the effectiveness of our vaccine platform. 
 We conclude that our new and innovative approach might help save the lives of millions 
of peoples suffering from infectious diseases like HIV and Tb. Protecting the exposed population 
from these pathogen is a challenging task, but we are confident, that our vaccine platform will 
provide new hope to contain and hopefully eradicate HIV. Further steps have to be undertaken 
before human testing can begin, but our animal results show that we are able to not only enable 
vaccinated animals to control the viral infection, but also enable them to clear the virus altogether 
suggesting that our approach might be beneficial for already HIV positive individuals ultimately 
curing HIV. 
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Supplementary Material 
Supplemental Figure 1: Alignment of ORFs Rh08, Rh13.1, Rh61/Rh60, Rh67.1, Rh72, Rh152/Rh151, Rh164, 
Rh194 and Rh197 from RhCMV 68-1 (BAC), RhCMV 68-1 and RhCMV180.92. The amino acid sequences of 
the Rh08 (A), Rh13.1 (B), Rh61/Rh60 (C), Rh67.1 (D), Rh72 (E), Rh152/Rh151 (F), Rh164 (G), Rh194 (H) and 
Rh197 (I) from our BAC derived RhCMV 68-1 sequence discussed in this paper and from the two fully sequenced 
RhCMV strains 68-1 (AY186194) and 180.92 (DQ120516) (A-F and H-I) or RhCMV isolate CNPCR (EF990255) 
(G) were aligned using a CLUSTAL W (1.83) multiple sequence alignment. 
Supplemental Figure 1A: Alignment of ORF Rh08 from RhCMV 68-1 (BAC), RhCMV 68-1 
and RhCMV180.92 
 
 
 
 
 
 
Rh08 (RL11 family) 
 
 
68-1_BAC_        MNAYHTLISCLCFFILYAYITESTRVVTLQYVYNVSIGENVTLSKPDNLSFQLHSWFCNN 
68-1_Virus_      MNAYHTLISCLCFFILYAYITESTRVVTLQYVYNVSIGENVTLSKPDNLSFQLHSWFCNN 
180.92           MNAYHTLISCLCFFILYAYITESTRVVTLQYVYNVSIGENVTLSKPDNLSFQLHSWLCNN 
                 ********************************************************:*** 
 
68-1_BAC_        RASACNNPIMKLCEETAGNNKPNSYTRFQNNCHPPTFTCNTTGLYLYNVQETDPTTYTLT 
68-1_Virus_      RASACNNPIMKLCEETAGNNKPNSYTRFQNNCHPPTFTCNTTGLYLYNVQETDPTTYTLT 
180.92           RASACNNPIMKLCEETAGNNKPNSYTRFQNNCHPPTFTCNTTGLYLYNVQDTDPATYTLT 
                 **************************************************:***:***** 
 
68-1_BAC_        QRAGNGNITDRNTTYIIHFITSTTPPPVTNYICNLSSTSCTNTSNYQL------------ 
68-1_Virus_      QRAGNGNITDRNTTYIIHFITSTTPPPVTKLHMQFIFNQLHKHKQLPTIAT--------- 
180.92           QRAGNGNITDRNTTYIIHFITSTTPPPPLQTTYAIYLQPVAQTHATTNYSYITITLTVIT 
                 ***************************  :    :      :                   
 
68-1_BAC_        ---------------------------------------- 
68-1_Virus_      ---------------------------------------- 
180.92           LILFMLGAGYLKHRRSLKHYKQNTHKCTSLGESRYPESSI 
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Supplemental Figure 1B: Alignment of ORF Rh13.1 from RhCMV 68-1 (BAC), RhCMV 68-
1 and RhCMV180.92 
 
 
 
 
 
 
 
 
Rh13.1 (RL13) 
 
68-1_BAC_        MTKYTCFRSMSACGIFMLLINLALACDSQCACNSSCGFAYNVTHVSGYEHSNVTLHTSIS 
68-1_Virus_      MTKYTCFRSMSACGIFMLLINLALACDSQCACNSSCGFAYNVTHVSGYEHSNVTLHTSIS 
180.92           MTKYTCFRSMSACGIFMLLINLALACDPQCACNSSCGFAYNVTHVSGYEHSNVTLHTSIS 
                 ***************************.******************************** 
 
68-1_BAC_        HSNISHMNVGYWIRYNYPVNSYTICTVSGNNVASTKHNGWFFECNGTSLTLHNLNADHTG 
68-1_Virus_      HSNISHMNVGYWIRYNYPVNSYTICTVSGNNVASTKHNG--------------------- 
180.92           HSNISHMNVGYWIRYNYPVNSYTICTVSGNNVASTKHNGWFFECNGTSLTLHNLNADHTA 
                 ***************************************                      
 
68-1_BAC_        SYLFKNLLGLMEHYTVTVLPIPQPPAPQVTTVTNCSLTFFSEHLWRNATTRIITTTTQST 
68-1_Virus_      ------------------------------------------------------------ 
180.92           SYLFKNLL---------------------------------------------------- 
                                                                              
 
68-1_BAC_        STTTTRTTKPTTTTHRTTAGRVSTPTPEESSTSTTTEESTTTTWPPGRPKFISKYSLNSR 
68-1_Virus_      ------------------------------------------------------------ 
180.92           ------------------------------------------------------------ 
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Supplemental Figure 1C: Alignment of ORFs Rh61/Rh60 from RhCMV 68-1 (BAC), 
RhCMV 68-1 and RhCMV180.92 
 
 
 
Rh61/Rh60 (UL36) 
 
 
68-1_BAC_        MSYRLMSGMDDLRDTLMAYGCIAVRAQDPASLYTFVDQECGTKLHLAWPDNGYIQLRPRT 
68-1_Virus_      MSYRLMSGMDDLRDTLMAYGCIAVRAQDPASLYTFVDQECGTKLHLAWPDNGYIQLRPRT 
180.92           MSYRLMSGMDDLRDTLMAYGCIAVRAQDPASLYTFVDQECGTKLHLAWPDNGYIQLRPRT 
                 ************************************************************                                                             
 
68-1_BAC_        LMGPFSSKYYDVCCQGKYVCCNELMEPFGVVELSKLGFYQLVMMIGRSGAIYCYEETEKC 
68-1_Virus_      LMGPFSSKYYDVCCQGKYVCCNELMEPFGVVELSKLGFYQLVMMIGRSGAIYCYEETEKC 
180.92           LMGPFSSKYYDVCCQGKYVCCNELMEPFGVVELSKLSFYQLVMMIGRSGAIYCYEETEKC 
                 ************************************.*********************** 
 
68-1_BAC_        VYCLAPDMKSFIQLGLRRCDYLQKMELYQEPVIDCDEIIKELMIFNWDVDRISDVVAKNG 
68-1_Virus_      VYCLAPDMKSFIQLGLRRCDYLQKMELYQEPVIDCDEIIKELMIFNWDVDRISDVVAKNG 
180.92           VYCLAPDMKSFIQLGLRRCDYLQKMELYQEPVIDCDEIIKELMIFNWDVDRISDVVAKNG 
                 ************************************************************ 
 
68-1_BAC_        YRVYDIRDPLGEQVDSHFALWSSDSAVANFQDTSFSLMSPSGLRSFEIMVRCVARIVCVN 
68-1_Virus_      YRVYDIRDPLGEQVDSHFALWSSDSAVANFQDTSFSLMSPSGLRSFEIMVRCVARIVCVN 
180.92           YRVYDIRDPLGEQVDSHFALWSSDSAVANFQDTSFSLMSPSGLRSFEIMVRCVARIVCVN 
                 ************************************************************ 
 
68-1_BAC_        QLLGVLGCFRKEKK---------------------------------------------- 
68-1_Virus_      QLLGVLGCFRKEKNEFLVRLYVLVDKFGTIYGFDPALNSIYRLAENMRMFTCMMGKKGYR 
180.92           QLLGVLGCFRKEKNEFLVRLYVLVDKFGTIYGFDPALNSIYRLAENMRMFTCMMGKKGYR 
                 *************:                                               
 
68-1_BAC_        ------------------------------------------------------------ 
68-1_Virus_      NHRHDRRRTAIVRLEKVPYCMHGEEPSDPMIMFNDDSEDEKPPKTEADVVVGIYEAIKAD 
180.92           NHRHDRRRTAIVRLEKVPYCMHGEEPSDPMIMFNDDSEDEKPPKTEADVVVGIYEAIKAD 
                                                                              
 
68-1_BAC_        ------------------------------------------------------------ 
68-1_Virus_      IRFGVDMMMRDSSVTQKFWPQHLEALSDSPLLPSLIYDMEDVRSKMLGNIADMRAFDMSF 
180.92           IRFGVDMMMRDSSVTQKFWPQHLEALSDSPLLPSLIYDMEDVRSKMLGNIADMRAFDMSF 
                                                                              
 
68-1_BAC_        --------------------------------------------------- 
68-1_Virus_      VGLAEDNDSDREETVRGYLFDDTVCTRCVSSRRLRLFRSGRGMGRARVSYV 
180.92           VGLAEDNDSDREETVRGYLFDDTVCTRCVSSRRLRLFRSGRGMGRARVSYV 
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Supplemental Figure 1D: Alignment of ORF Rh67.1 from RhCMV 68-1 (BAC), RhCMV 68-
1 and RhCMV180.92 
 
 
 
 
 
 
 
 
 
 
 
 
Rh67.1(UL41a) 
 
 
68-1_BAC_        MMLLWCNASFTELRQNYFLPCPWLVGVGCFVLGLFLLIFACLMKTVWSRKKYHHLLTTDE 
68-1_Virus_      MMLLWCNASFTELRQNYFLPCPWLVGVGCFVLGLFLLIFACLMKTVWSRKKYHHLLTTDE 
180.92           MMLLWCNASFTELRQNYFLPCPWLVGVGCFVLGLFLLIFACLMKTVWSRKKYHHLLTTDE 
                 ************************************************************ 
 
68-1_BAC_        EEEDIVCEKKPLSTKDIEF 
68-1_Virus_      EEEDIVWEKKPLSTKDIEF 
180.92           EEEDIVWEKKPLSTKDIEF 
                 ****** ************ 
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Supplemental Figure 1E: Alignment of ORF Rh72 from RhCMV 68-1 (BAC), RhCMV 68-1 
and RhCMV180.92 
 
   Rh72(UL45) 
 
 
68-1_BAC_        MAQASLRNTGAGGLEAVMQEGSEGGDGGTEENGVEAMEVATSSPDAEQQQAQQQQQQPQV 
68-1_Virus_      MAQASLRNTGAGGLEAVMQEGSEGGDGGTEENGVEAMEVATSSPDAEQQQAQQQQQQPQV 
180.92           MAQASLRNTGAGGLEAVMQEGSEGGDGGTEENGVEAMEVATSSPDAEQQQAQQQQQQPQV 
                 ************************************************************ 
 
68-1_BAC_        GVHACWSLADQGTATSCRPDASSSLVQHMPAMNTVQLLMGKKCHCHGRWGKFRFCGVPDP 
68-1_Virus_      GVHACWSLADQGTATSCRPDASSSLVQHMPAMNTVQLLMGKKCHCHGRWGKFRFCGVPDP 
180.92           GVHACWSLADQGTATSCRPDASSSLVQHMPAMNTVQLLMGKKCHCHGRWGKFRFCGVPDP 
                 ************************************************************ 
 
68-1_BAC_        VKHVEDRATLWRDIDSASRQSGIRGAYRLFQMLMRYGPALIRQIPRSDLLIGRFYLKVNW 
68-1_Virus_      VKHVEDRATLWRDIDSASRQSGIRGAYRLFQMLMRYGPALIRQIPRSDLLIGRFYLKVNW 
180.92           VKHVEDRATLWRDIDSASRQSGIRGAYRLFQMLMRYGPALIRQIPRSDLLIGRFYLKVNW 
                 ************************************************************ 
 
68-1_BAC_        LRESRNALNYTSSMCEGPLRDFVMRHSEDLPKILADITRYLDLAGCWGFYGAIVLTDKVS 
68-1_Virus_      LRESRNALNYTSSMCEGPLRDFVMRHSEDLPKILADITRYLDLAGCWGFYGAIVLTDKVS 
180.92           LRESRNALNYTSSMCEGPLRDFVMRHSEDLPKILADITRYLDLAGCWGFYGAIVLTDKVS 
                 ************************************************************ 
 
68-1_BAC_        RQIYGQDESLGGIFLRISMAITLAIVSSPCARVYRFHMDCRHKYEVLESVVKRCRDGQLS 
68-1_Virus_      RQIYGQDESLGGIFLRISMAITLAIVSSPCARVYRFHMDCRHECEVLESVVKRCRDGQLS 
180.92           RQIYGQDESLGGIFLRISMAITLAIVSSPCARVYRFHMDCRHECEVLESVVKRCRDGQLS 
                 ******************************************: **************** 
 
68-1_BAC_        LTPFSMSNIGFVELPQYDYLISCDLYSREVDWLALHKWLYENLTRGVSLSINVTRFNVEA 
68-1_Virus_      LTPFSMSNIGFVELPQYDYLISCDLYSREVDWLALHKWLYENLTRGVSLSINVTRFNVEA 
180.92           LTPFSMSNIGFVELPQYDYLISCDLYSREVDWLALHKWLYENLTRGVSLSINVTRFNVEA 
                 ************************************************************ 
 
68-1_BAC_        ISVIRCIGGFCDMIREKEVHRPIVRIFVDLWDVAAIRVLNFVLKETDIIGIHYAFNIPSV 
68-1_Virus_      ISVIRCIGGFCDMIREKEVHRPIVRIFVDLWDVAAIRVLNFVLKETDIIGIHYAFNIPSV 
180.92           ISVIRCIGGFCDMIREKEVHRPIVRIFVDLWDVAAIRVLNFVLKETDIIGIHYAFNIPSV 
                 ************************************************************ 
 
68-1_BAC_        LMKRYRAQDSHYSLFGRTVSRKLSECGNEFAFEKEYVRYETTVPKVTVKASEFMRNMLFC 
68-1_Virus_      LMKRYRAQDSHYSLFGRTVSRKLSECGNEFAFEKEYVRYETTVPKVTVKASEFMRNMLFC 
180.92           LMKRYRAQDSHYSLFGRTVSRKLSECGNEFAFEKEYVRYETTVPKVTVKASEFMRNMLFC 
                 ************************************************************ 
 
68-1_BAC_        ALKGKCALVFVHHIVKYSVLTGNMPLPPCLGPDMASCHFGESDLPLQRLSINLTRCLFTR 
68-1_Virus_      ALKGKCALVFVHHIVKYSVLTGNMPLPPCLGPDMASCHFGESDLPLQRLSINLTRCLFTR 
180.92           ALKGKCALVFVHHIVKYSVLTGNMPLPPCLGPDMASCHFGESDLPLQRLSINLTRCLFTR 
                 ************************************************************ 
 
68-1_BAC_        TDDDVLCRDNVVLGNTRRYFDMQVLRTLVTEAVVWGNARLDALIRSGDWPLESAICKMRS 
68-1_Virus_      TDDDVLCRDNVVLGNTRRYFDMQVLRTLVTEAVVWGNARLDALIRSGDWPLESAICKMRS 
180.92           TDDDVLCRDNVVLGNTRRYFDMQVLRTLVTEAVVWGNARLDALIRSGDWPLESAICKMRS 
                 ************************************************************ 
 
68-1_BAC_        LNIGVTGLHTVLMRLGFTYFASWDLIERIFENMYYAALRTSVDLCKSGLPPCEWFDRTIY 
68-1_Virus_      LNIGVTGLHTVLMRLGFTYFASWDLIERIFENMYYAALRTSVDLCKSGLPPCEWFDRTIY 
180.92           LNIGVTGLHTVLMRLGFTYFASWDLIERIFENMYYAALRTSVDLCKSGLPPCEWFDRTIY 
                 ************************************************************ 
 
68-1_BAC_        KEGKFIFELYRKPHLSLPVAQWETLRTEMQEYGVRNAQLLSIAADEETAFLWNVTPSIWA 
68-1_Virus_      KEGKFIFELYRKPHLSLPVAQWETLRTEMQEYGVRNAQLLSIAADEETAFLWNVTPSIWA 
180.92           KEGKFIFELYRKPHLSLPVAQWETLRTEMQEYGVRNAQLLSIAADEETAFLWNVTPSIWA 
                 ************************************************************ 
 
68-1_BAC_        ARDRIVDEETVLPVSPPSDECYFPTVMQKHLKVPIINYAWIEHHDEVKAKSITQGTVQRA 
68-1_Virus_      ARDRIVDEETVLPVSPPSDECYFPTVMQKHLKVPIINYAWIEHHDEVKAKSITQGTVQRA 
180.92           ARDRIVDEETVLPVSPPSDECYFPTVMQKHLKVPIINYAWIEHHDEVKAKSITQGTVQRA 
                 ************************************************************ 
 
68-1_BAC_        DVPSCVFQRAAELQADVEMASVNVSMFVDQCVPLPFYYESSMTPDLLMKRMLKWYHLRCK 
68-1_Virus_      DVPSCVFQRAAELQADVEMASVNVSMFVDQCVPLPFYYESSMTPDLLMKRMLKWYHLRCK 
180.92           DVPSCVFQRAAELQADVEMASVNVSMFVDQCVPLPFYYESSMTPDLLMKRMLKWYHLRCK 
                 ************************************************************ 
 
68-1_BAC_        VGVYKYCAS 
68-1_Virus_      VGVYKYCAS 
180.92           VGVYKYCAS 
                 ********* 
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Supplemental Figure 1F: Alignment of ORFs Rh152/Rh151 from RhCMV 68-1 (BAC), 
RhCMV 68-1 and RhCMV180.92 
 
 
 
Rh152/Rh151 (UL119/UL118) 
 
68-1_BAC_        MLGTGHVLALAAAVLIAQQVIGGTSTTTAANTTSTTTAPSTSTVTSSATSVTTSLTSSSA 
68-1_Virus_      MLGTGHVLALAAAVLIAQQVIGGTSTTTAANTTSTTTAPSTSTVTSSATSVTTSLTSSSA 
180.92           MLGTGHVLALAAAVLIAQQVIGGTSTTTAANTTSATTAPSTSTVTSSPTSVTTSVASSSA 
                 **********************************:************.******::**** 
 
68-1_BAC_        AASSVTSSNAASSSTSGTATSTATSTQKTSTSNSSTDTGTQTTSSNTTTAPATTESATTS 
68-1_Virus_      AASSVTSSNAASSSTSGTATSTATSTQKTSTSNSSTDTGTQTTSSNTTTAPATTESATTS 
180.92           TASSVTSSSAAASTTSGTVTSTSK---------SSTDSSTQTTSSNTTTAPATTESATTS 
                 :*******.**:*:****.***:.         ****:.********************* 
 
68-1_BAC_        SNASDNSTTENSTVTTTADTT----------SDTSTAATSTTANKPRVPDIYVTCESAYS 
68-1_Virus_      SNASDNSTTENSTVTTTADTT----------SDTSTAATSTTANKPRVPDIYVTCESAYS 
180.92           SNASENSTTENSTVTTNATDSNATTDTTTAETTITAATNITTTTKPRVPDIYVTCESAYS 
                 ****:***********.*  :          :  ::*:. **:.**************** 
 
68-1_BAC_        YNYLVLQTTCQIHNMSHAQNVSRDLISIECFEQVGCDGNLTSIGSVTTSNTSHGMLYNIT 
68-1_Virus_      YNYLVLQTTCQIHNMSHAQNVSRDLISIECFEQVGCDGNLTSIGSVTTSNTSHGMLYNIT 
180.92           YNYLVLQTTCQIHNMSHAQNVSRDLISIECFEQVGCDGNLTSIGSVTTSNTSHGMLYNIT 
                 ************************************************************ 
 
68-1_BAC_        TQTFTMYRQAPNVTTQYSCRFIATGQTLNKSWEFLVMPIKAVFASPTNDSMIQLRVLVND 
68-1_Virus_      TQTFTMYRQAPNVTTQYSCRFIATGQTLNKSWEFLVMPIKAVFASPTNDSMIQLRVLVND 
180.92           TQTFTMYRQAPNVTTQYSCRFIATGQTLNKSWEFLVMPIKAVFASPTNDSMIQLRVLVND 
                 ************************************************************ 
 
68-1_BAC_        HPCTNETVYSSSKAFVYFGNTNHSSHKVQNITRHNQSLWEYIFHFTNHDLPNTAHMKILL 
68-1_Virus_      HPCTNETVYSSSKAFVYFGNTNHSSHKVQNITRHNQSLWEYIFHFTNHDLPNTAHMKILL 
180.92           HPCTNETVYSSSKAFVYFGNTNHSSHKVQNITRHNQSLWEYIFHFTNHDLPNTAHMKILL 
                 ************************************************************ 
 
68-1_BAC_        GDRYSVSTHVFIKRDPDEWPIIGTLGYIVLAFLLFMLFALLYITYVLMRQRNP------- 
68-1_Virus_      GDRYSVSTHVFIKRDPDEWPIIGTLGYIVLAFLLFMLFALLYITYVLMRQRNPWAYRRLD 
180.92           GDRYSVSTHVFIKRDPDEWPIIGTLGYIVLAFLLFMLFALLYITYVLMRQRNPWAYRRLD 
                 *****************************************************        
 
68-1_BAC_        ------------- 
68-1_Virus_      EEKPYPVPYFKQW 
180.92           EEKPYPVPYFKQW 
Supplementary Material                             178 
 
Supplemental Figure 1G: Alignment of ORF Rh164 form RhCMV 68-1 (BAC), RhCMV 68-
1 and RhCMV CNPRC 
 
 
 
Rh164(UL141) 
 
68-1_BAC_        MSYTVRFRKGFGRVSEEAETVQLLAEGQEGADSADAESASKRTIHDGPLRVKACTPVSAP 
68-1_virus_      MSYTVRFRKGFGRVSEEAETVQLLAEGQEGADSADAESASKRTIHDGPLRVKACTPVSAP 
clinical         MSYTVRFRKGFGRVSEEAETVQLLAEGQEGADSADAESASKRTIHDGPLRVKACTPVSAP 
                 ************************************************************ 
 
68-1_BAC_        RAAMWVRRAMVAITIVMVSLTPRVRGGSIDHTMWDECYEHNSPAPLIMPIGSQVTVPCAF 
68-1_virus_      RAAMWVRRAMVAITIVMVSLTPRVRGGSIDHTMWDECYEHNSPAPLIMPIGSQVTVPCAF 
clinical         RAAMWVRRAMVAITIVMVSLTPRVRGGSIDHTMWDECYEHNSPAPLIMPIGSQVTVPCAF 
                 ************************************************************ 
 
68-1_BAC_        LPHSWPMVSIRARFCQSEYGGYELKINATNGTVVDDDLTYRLINASWKFHDLAISHYVTL 
68-1_virus_      LPHSWPMVSIRARFCQSEYGGYELKINATNGTVVDDDLTYRLINASWKFHDLAISHYVTL 
clinical         LPHSWPMVSIRARFCQSEYGGYELKINATNGTVVDDDLTYRLINASWKFHDLAISHYVTL 
                 ************************************************************ 
 
68-1_BAC_        TMNISDNTTGMFDCVLRNATHGFLMTRFTIVTQIETLHRLGDPDCAPKLGFHADGKKIWS 
68-1_virus_      TMNISDNTTGMFDCVLRNATHGFLMTRFTIVTQIETLHRPGDPDCAPKLGFHADGKKIWS 
clinical         TMNISDNTTGMFDCMLRNATHGFLMTRFTIVTQIETLHRPGDPDCAPKLGFHADGKKIWS 
                 **************:************************ ******************** 
 
68-1_BAC_        AEYNEWQRHQCGTFYGFDRLYYYLAASNQSNTKPPCPPSEPDRCWPVLQQYVLDGDCFRS 
68-1_virus_      AEYNEWQRHQCGTFYGFDRLYYYLAASNQSNTKPPCPPSEPDRCWPVLQQYVLDGDCFRS 
clinical         AEYNEWQRHQCGTFYGFDRLYYYLAASNQSNTKPPCPPSEPDRCWPVLQQYVLDGDCFRS 
                 ************************************************************ 
 
68-1_BAC_        QNFRREPPLPTEKTPVPIFVIDWQWVSLGLTMMVIGGVCLGLVLVVRCACGEMCRNRERF 
68-1_virus_      QNFRREPPLPTEKTPVPIFVIDWQWVSLGLTMMVIGGVCLGLVLVVRCACGEMCRNRERF 
clinical         QNFRREPPLPTEKTPVPIFVIDWQWVSLGLTMMVIGGVCLGLVLVVRCACGEMCRNRERF 
                 ************************************************************ 
 
68-1_BAC_        QKKMNAYRPMSTHFMRPPGYEELYSVVDDESDSGYFEKEDRSESYNDLVDENVYDEVAVP 
68-1_virus_      QKKMNAYRPMSTHFMRPPGYEELYSVVDDESDSGYFEKEDRSESYNDLVDENVYDEVAVP 
clinical         QKKMNAYRPMSTHFMRPPGYEELYSVVDDESDSGYFEKEDRSESYNDLVDENVYDEVAVP 
                 ************************************************************ 
 
68-1_BAC_        PLYSKIKRRL 
68-1_virus_      PLYSKIKRRL 
clinical         PLYSKIKRRL 
                 ********** 
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Supplemental Figure 1H: Alignment of ORF Rh194 form RhCMV 68-1 (BAC), RhCMV 68-
1 and RhCMV180.92 
 
 
 
 
 
 
 
Rh194(US14) 
 
68-1_BAC_        MPFAPRLQPFTVHRPPAPMIQLDLDERSSLSWLRQHLPLASVYLCLLFVIAVCICSYGAF 
68-1_Virus_      MPFAPRLQPFTVHRPPAPMIQLDLDERSSLSWLRQHLPLASVYLCLLFVIAVCICSYGAF 
180.92           MPFAPRLQPFTVHRPPAPMIQLDLDERSSLSWLRQHLPLASVYLCLLFVIAVCICSYGAF 
                 ************************************************************ 
 
68-1_BAC_        KSQFHCMVFNTEICRMEPAFILIIVPVLLMFVWNMFDHRQDDMIHMGNGLLYIVVFACIG 
68-1_Virus_      KSQFHCMVFNTEICRMEPAFILIIVPVLLMFVWNMFDHRQDDMIHMGNGLLYIVVFACIG 
180.92           KSQFHCMVFNTEICRMEPAFILIIVPVLLMFVWNMFDHRQDDMIHMGNGLLYIVVFACIG 
                 ************************************************************ 
 
68-1_BAC_        FTLISFCTDGITAGLSLLFTATFFLTCSGLALWSSRPLPSKCRYVATLVSTFLLLLFYFG 
68-1_Virus_      STLISFCTDGITAGLSLLFTATFFLTCSGLALWSSRPLPSKCRYVATLVSTFLLLLFYFG 
180.92           STLISFCTDGITAGLSLLFTATFFLTCSGLALWSSRPLPSKCRYIATLVSTFLLLLFYFG 
                  *******************************************:*************** 
 
68-1_BAC_        QLSHSVMRNGLSIILHGSMGIIIWENIYITKFNLTMKHVVSACIVYVDILIVMYYMYVYL 
68-1_Virus_      QLSHSVMRNGLSIILHGSMGIIIWENIYITKFNLTMKHVVSACIVYVDILIVMYYMYVYL 
180.92           QLSHSVMRNGLSIILHGSMGIIIWENIYITKFNLTMKHVVSACIVYVDILIVMYYMYVYL 
                 ************************************************************ 
 
68-1_BAC_        LTPSLWTLDPHKMLTGVSQLWNGSFNRTFCSPSSVYG 
68-1_Virus_      LTPSLWTLDPHKMLTGVSQLWNGSFNRTFCSPSSVYG 
180.92           LTPSLWTLDPHKMLTGVSQLWNGSFNRTFCSPSSVYG 
                 ************************************* 
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Supplemental Figure 1I: Alignment of ORF Rh197 form RhCMV 68-1 (BAC), RhCMV 68-
1 and RhCMV180.92 
 
  
Rh197 (US14) 
 
68-1_BAC_        MVSKMVTKLTNHVIWLNRSIHVWSVYGWLAFQVSITVLVYGLVRCQQYLFDTCAQEPVRQ 
68-1_Virus_      MVSKMVTKLTNHVIWLNRSIHVWSVYGWLAFQVSITVLVYGLVRCQQYLFDTCAQEPVRQ 
180.92           MVSKMVTKLTNHVIWLNRSIHVWSVYGWLAFQVSITVLVYGLVRCQQYLFDTCAQEPVRQ 
                 ************************************************************ 
 
68-1_BAC_        IMITSPALVFIQESYINRVIRKVSLWKNCGVALFCVIHIAFSHVWFSGCVATWTVIQSWI 
68-1_Virus_      IMITSPALVFIQESYINRVIRKVSLWKNCGVALFCVIHIAFSHVWFSGCVATWTVIQSWI 
180.92           IMITSPALVFIQESYINRAIRKGSLWKNCGVALFCVIHIAFSHVWFSGCVATWTVIQSWI 
                 ******************.*** ************************************* 
 
68-1_BAC_        ATFCLFILMIYVSDGSNWKPFIERQVLSDMLCAGALAANCFVHSVTQPSVTLWWIAQTLY 
68-1_Virus_      ATFCLFILMIYVSDGSNWKPFIERQVLSDMLCAGALAANCFVHSVTQPSVTLWWIAQTLY 
180.92           ATFCLFILMIYVSDGSNWKPFIERQVLSDMLCAGALAANCFVHSVTQPSVTLWWIAQTLY 
                 ************************************************************ 
 
68-1_BAC_        IIGTVGFMNAMCLQLSNVRRQQRSNERAMSISLLLYCIFHLVHYNNVIMWSFP------- 
68-1_Virus_      IIGTVGFMNAMCLQLSNVRRQQRSNERAMSISLLLYCIFHLVHYNNVIMWSFPWKAEDPW 
180.92           IIGTVGFMNAMCLQLSNVRRQQRSNERAMSISLLLYCIFHLVHYNNVIMWSFPWKAEDPW 
                 *****************************************************        
 
68-1_BAC_        - 
68-1_Virus_      L 
180.92           L 
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Supplemental Figure 2: List of all predicted ORFs in the fully sequenced RhCMV strains 68-1 and 180.92 and 
the partial sequence for the ULb’-region from RhCMV CNPRC. The sequences of the two fully sequenced 
genomes for RhCMV 68-1 and 180.92 and the partial sequence for RhCMV CNPRC were analyzed for potential 
ORFs by entering the sequences into NCBI’s Open Reading Frame Fonder (ORF Finder). As a cutoff point we selected 
ORFs ≥300bp. The three different sequences are listed next to each other and the predicted ORFs are in the order they 
would be found in a low passage isolate. The nomenclature used for the different sequences was chosen according to 
their original publication, so the nomenclature for 68-1 is based on Hansen et al. (30), the nomenclature for 180.92 is 
based on Rivailler at al. (63) and the nomenclature for RhCMV CNPRC is based on Oxford et al.(50). ORFs not 
annotated by the original authors were named using the nomenclature created by Hansen et al. 
RhCMV strain 68-1 RhCMV strain 180.92 
RhCMV low passage isolate 
(ULb' region, partial sequence) 
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     Rh00 1 37 480 444      
     Rh00.1 2 164 637 474      
Rh00.2 3 864 1223 360 Rh00.2 2 866 1225 360      
Rh01 2 1040 2566 1527 RhRL1 1 1042 2568 1527      
Rh02 1 1486 2037 552 Rh02 3 1488 2039 552      
Rh02.1 3 2280 2606 327 Rh02.1 2 2282 2608 327      
Rh03 2 2618 3082 465 Rh03 1 2620 3084 465      
Rh04 -2 2703 3401 699 Rh04 -2 2705 3403 699      
Rh03.1 3 2751 3053 303 Rh03.1 2 2753 3055 303      
Rh03.2 1 3088 3465 378 Rh03.2 3 3090 3467 378      
Rh05 3 3528 4349 822 Rh05 2 3530 4351 822      
Rh06 3 4710 5198 489 Rh06 2 4712 5356 645      
Rh07 3 5325 5906 582 Rh07 3 5343 5921 579      
Rh08 1 5881 6396 516 Rh08 1 5896 6558 663      
Rh08.1 2 6578 7000 423 Rh08.1 3 6600 7148 549      
Rh09 -1 6724 7029 306           
Rh10(1) -1 8521 9027 507 Rh10(1) -2 8555 9061 507      
Rh10(2) -2 9267 9845 579 Rh10(2) -3 9301 9906 606      
Rh11 3 9462 9902 441 Rh11 1 9496 9936 441      
Rh10(3) -3 9806 10126 321 Rh10(3) -3 9979 10302 324      
Rh12 2 11225 11920 696 Rh12 1 11260 11952 693      
Rh13 -1 11233 11547 315 Rh13 -1 11268 11582 315      
     Rh13.1 1 12148 12534 387      
Rh14 2 12506 13087 582 Rh14 1 12538 13113 576      
Rh15 -1 12556 12879 324 Rh15 -1 12588 12911 324      
Rh16 -1 12937 13458 522 Rh16 -3 13165 13488 324      
Rh17 1 13525 14625 1101 Rh17 1 13555 14652 1098      
Rh18 -2 13557 13922 366 Rh18 -1 13587 13949 363      
Rh19 1 14707 15642 936 RhUL7 1 14734 15681 948      
Rh20 1 15700 16293 594 Rh20 3 15708 16337 630      
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     Rh21(1) 3 16371 16712 342      
Rh21 1 16327 17004 678 Rh21(2) 2 16580 17038 459      
Rh22 2 17111 17818 708 Rh22 3 17145 17852 708      
Rh23 1 17716 18411 696 RhUL11 2 17750 18445 696      
Rh24 2 18428 18817 390 Rh24 3 18462 18851 390      
Rh25 2 18896 19570 675 Rh25 3 18930 19604 675      
Rh26 3 19554 20402 849 Rh26 1 19588 20436 849      
Rh27 3 20547 21152 606 Rh27 1 20581 21186 606      
Rh28 1 21154 21777 624 Rh28 2 21188 21811 624      
Rh29 2 21854 23239 1386 Rh29 2 21887 23245 1359      
Rh30 -3 23315 23638 324 Rh30 -2 23321 23632 312      
Rh31 3 23355 24662 1308 Rh31 3 23361 24671 1311      
Rh32 -2 23577 24029 453 Rh32 -1 23583 24035 453      
Rh33 3 24942 25838 897 RhUL14 1 24949 25860 912      
Rh34 -2 26718 27041 324 Rh34 -2 26726 27049 324      
Rh35 3 26778 27101 324 Rh35 2 26786 27109 324      
Rh36 1 27826 29172 1347 RhUL20 2 27833 29179 1347      
Rh37 -1 29275 29640 366 RhUL21a -2 29282 29647 366      
Rh38 3 29898 30251 354 Rh38 1 29905 30258 354      
Rh39 -2 29916 30380 465           
Rh40 -3 30731 31669 939 RhUL23 -2 30737 31675 939      
Rh41 3 31416 31796 381 Rh41 3 31422 31802 381      
Rh42 -1 31726 32652 927 RhUL24 -3 31732 32658 927      
Rh43 1 32719 34476 1758 RhUL25 1 32725 34485 1761      
Rh44 -1 34537 35283 747 RhUL26 -3 34546 35295 750      
Rh45 1 34897 35328 432 Rh45 1 34909 35340 432      
Rh46 -3 35237 36976 1740 RhUL27 -2 35249 36988 1740      
Rh47 -3 37064 38077 1014 RhUL28 -2 37076 38089 1014      
Rh48 2 37289 37786 498 Rh48 2 37301 37798 498      
Rh49 3 38190 38588 399 Rh49 3 38202 38600 399      
Rh50 -2 38208 39218 1011 RhUL29 -1 38220 39230 1011      
Rh51 -3 38351 38755 405 Rh51 -2 38363 38767 405      
Rh52 3 38925 39395 471 Rh52 3 38937 39407 471      
Rh53 -3 39548 39979 432 Rh53 -2 39560 39991 432      
Rh54 1 39865 41487 1623 RhUL31 1 39877 41499 1623      
Rh55 -3 41498 43615 2118 RhUL32 -2 41510 43627 2118      
Rh56 3 43983 44972 990 RhUL33 3 43995 44981 987      
Rh57 3 45177 45977 801 RhUL34 3 45186 46043 858      
Rh58 2 45491 45877 387 Rh58 2 45500 45886 387      
Rh59 3 46098 47870 1773 RhUL35 2 46106 47878 1773      
Rh60 -2 47988 49151 1164 RhUL36 -2 47996 49159 1164      
Rh61 -3 49115 49480 366           
Rh62 -2 49578 50396 819 RhUL37(1) -1 49587 50405 819      
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Rh63 3 50598 50981 384 Rh63 3 50607 50990 384      
Rh64 -3 50702 51583 882 rhUL38 -2 50711 51592 882      
Rh65 2 50768 51133 366 Rh65 2 50777 51142 366      
Rh66 -1 51625 51930 306 RhUL37(2) -3 51634 51939 306      
Rh67 -1 52255 52785 531 Rh67 -3 52264 52794 531      
Rh68 -2 53229 53621 393 RhUL42 -1 53238 53627 390      
Rh69 -1 53605 54606 1002 RhUL43 -3 53611 54612 1002      
Rh70 -1 54730 55902 1173 RhUL44 -3 54736 55908 1173      
Rh71 1 55132 55608 477 Rh71 1 55138 55614 477      
Rh72 -1 56143 58692 2550 RhUL45 -3 56149 58698 2550      
Rh73 1 56404 56829 426 Rh73 1 56410 56835 426      
Rh74 2 58181 58483 303 Rh74 2 58187 58489 303      
Rh75 -1 58711 59583 873 RhUL46 -3 58717 59589 873      
Rh76 2 59582 62458 2877 RhUL47 2 59588 62464 2877      
Rh77 -2 62052 62357 306 Rh77 -1 62058 62363 306      
Rh78 1 62479 69012 6534 RhUL48 1 62485 69018 6534      
Rh78.1 2 62978 63370 393 Rh78.1 2 62984 63376 393      
Rh79 1 69181 69846 666 Rh79 1 69187 69852 666      
Rh80 -1 69295 70764 1470 RhUL49 -3 69301 70770 1470      
Rh81 -3 70754 71629 876 RhUL50 -2 70760 71638 879      
Rh82 -2 71655 71990 336 RhUL51 -1 71664 71999 336      
Rh83 3 72069 73724 1656 RhUL52 3 72078 73733 1656      
Rh84 -3 72179 72484 306 Rh84 -2 72188 72493 306      
Rh85 1 73717 74583 867 RhUL53 1 73726 74592 867      
Rh86 -1 74128 74559 432 Rh86 -3 74137 74568 432      
Rh87 -3 74561 77668 3108 RhUL54 -2 74570 77677 3108      
Rh88 2 77489 77866 378 Rh88 2 77498 77875 378      
Rh89 -3 77687 80251 2565 RhUL55 -2 77696 80266 2571      
Rh90 2 79376 79822 447 Rh90 2 79322 79837 516      
Rh91 -2 80217 82523 2307 RhUL56 -1 80232 82538 2307      
Rh91.1 -1 81220 82587 1368 Rh91.1 -3 81235 82602 1368      
Rh92 -3 82670 86161 3492 RhUL57 -2 82685 86176 3492      
Rh93 -3 87380 87694 315           
Rh94 2 87758 88315 558           
Rh94.1 -2 87846 88319 474 Rh94.1 -1 87858 88331 474      
Rh95 -3 88049 88750 702 Rh95 -2 88061 88762 702      
Rh96 3 88116 89006 891 Rh96 3 88128 89018 891      
Rh96.1 1 88186 88560 375 Rh96.1 1 88198 88572 375      
Rh97 -2 90525 92858 2334 RhUL69 -1 90537 92867 2331      
Rh98 1 91522 91830 309 Rh98 1 91531 91839 309      
Rh99 3 92073 92855 783 Rh99 3 92082 92864 783      
Rh100 -3 92792 95644 2853 RhUL70 -2 92801 95539 2739      
Rh99.1 2 94067 94390 324 Rh99.1 2 94076 94399 324      
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Rh100.1 3 95610 96248 639 RhUL71 2 95552 96256 705      
Rh101 -1 96316 97347 1032 RhUL72 -1 96324 97355 1032      
Rh102 1 97342 97656 315 RhUL73 3 97350 97664 315      
Rh103 -3 97637 98806 1170 RhUL74 -3 97645 98814 1170      
Rh104 -3 99023 101185 2163 RhUL75 -3 99031 101193 2163      
Rh105 2 101318 102202 885 RhUL76 1 101326 102210 885      
Rh106 3 101871 103658 1788 RhUL77 2 101879 103666 1788      
     Rh106.1 -2 101975 102358 384      
Rh107 3 103785 104924 1140 RhUL78 2 103793 104932 1140      
Rh108 -3 105020 105820 801 RhUL79 -3 105028 105828 801      
Rh109 3 105819 107663 1845 RhUL80 2 105827 107671 1845      
Rh110 -1 107776 109422 1647 RhUL82 -1 107784 109430 1647      
Rh111 -1 109552 111171 1620 RhUL83a -1 109560 111179 1620      
Rh112 -2 111240 112868 1629 RhUL83b -2 111248 112879 1632      
Rh113 3 112041 112487 447 Rh113 2 112052 112498 447      
Rh114 -1 112990 114528 1539 RhUL84 -1 112998 114533 1536      
Rh115 2 113051 113419 369 Rh115 1 113059 113424 366      
     Rh115.1 -3 113125 113484 360      
Rh116 3 114270 114728 459 Rh116 2 114275 114733 459      
Rh117 -3 114443 115369 927 RhUL85 -3 114448 115374 927      
Rh118 -3 115430 119461 4032 RhUL86 -3 115435 119466 4032      
Rh119 3 115995 116309 315 Rh119 2 116000 116314 315      
Rh120 -2 116922 117656 735 Rh120 -2 116927 117661 735      
Rh121 2 117836 118309 474 Rh121 1 117841 118314 474      
Rh122 1 119476 122022 2547 RhUL87 3 119481 122027 2547      
Rh123 1 122035 123237 1203 RhUL88 3 122040 123242 1203      
Rh124(1) -2 123234 124181 948 RhUL89(1) -2 123239 124186 948      
Rh125 3 123897 124469 573 Rh125 2 123902 124477 576      
Rh126 1 124501 124803 303 RhUL91 3 124509 124820 312      
Rh127 2 124697 125401 705 RhUL92 1 124705 125418 714      
Rh128 3 125367 126932 1566 RhUL93 2 125384 126949 1566      
Rh128.1 2 125528 125848 321 Rh128.1 1 125545 125865 321      
Rh129 1 126808 127848 1041 RhUL94 3 126825 127865 1041      
Rh124(2) -2 127845 128768 924 RhUL89(2) -2 127862 128785 924      
Rh130 1 128767 130047 1281 RhUL95 3 128784 130061 1278      
Rh131 3 130044 130433 390 RhUL96 2 130058 130447 390      
Rh132 3 130491 132323 1833 RhUL97 2 130505 132331 1827      
Rh133 -2 131142 131456 315 Rh133 -2 131150 131464 315      
Rh134 2 132374 134044 1671 RhUL98 1 132382 134052 1671      
Rh135 -1 132886 133287 402 Rh135 -1 132894 133295 402      
Rh136 -3 133325 133918 594 Rh136 -3 133333 133926 594      
Rh137 1 133981 134436 456 RhUL99 3 133989 134444 456      
Rh138 -3 134603 135673 1071 RhUL100 -3 134611 135681 1071      
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Rh139 1 135862 138036 2175 RhUL102 3 135870 138044 2175      
Rh140 -1 138058 138813 756 RhUL103 -1 138066 138821 756      
Rh141 -3 138740 140707 1968 RhUL104 -3 138748 140715 1968      
Rh142 3 140544 143123 2580 RhUL105 2 140552 143131 2580      
Rh142.1 2 140693 140995 303 Rh142.1 1 140701 141003 303      
Rh142.2 -2 142185 142514 330 Rh142.2 -2 142193 142522 330      
Rh142.4 -2 142776 143243 468           
     Rh142.3 2 143999 144301 303      
Rh143 1 146491 146958 468 RhUL111a 3 146505 146966 462      
Rh144 1 147820 148620 801 RhUL112(1) 1 147838 148629 792      
Rh145 3 148719 149600 882 RhUL112(2) 3 148728 149609 882      
Rh146 -3 149714 150457 744 RhUL114 -2 149723 150466 744      
Rh147 -2 150420 151196 777 RhUL115 -1 150429 151205 777      
Rh148 -1 151207 152277 1071 RhUL116 -1 151503 152066 564      
Rh147.1 2 151808 152299 492 Rh147.1 1 151594 152088 495      
Rh149 -3 151952 152416 465 Rh149 -3 151726 152205 480      
Rh150 -2 152259 153407 1149 RhUL117 -2 152048 153196 1149      
Rh149.1 3 153243 153545 303 Rh149.1 2 153032 153334 303      
Rh151 -2 153432 154031 600 RhUL119(1) -2 153221 153820 600      
Rh152 -1 154111 154782 672 RhUL119(2) -1 153900 154574 675      
Rh153 -2 154260 154577 318           
     Rh151.1 1 154123 154524 402      
Rh154 -1 154831 155427 597 Rh154 -1 154623 155219 597      
Rh155 -3 155429 155977 549 Rh155 -3 155221 155769 549      
Rh156(1) -1 156229 157689 1461 RhUL122 -1 156027 157757 1731      
Rh156(2) -2 158214 159383 1170 RhUL123 -3 158017 159192 1176      
Rh156.1 1 159898 160200 303 Rh156.1 2 159707 160009 303      
Rh156.2 2 160052 160495 444 Rh156.2 3 159861 160307 447      
Rh156 -2 161559 162053 495 Rh157.1 -3 161371 161865 495      
Rh157 1 161947 162489 543 Rh157.3 -1 161571 162098 528      
Rh157.3 -3 161966 162286 321 Rh157 2 161759 162337 579      
Rh157.2 3 162081 162404 324 Rh157.2 1 161893 162198 306      
     RhUL128(1) -1 162726 163052 327 RhUL128(1) -1 722 1048 327 
     RhUL128(2) -1 163293 163631 339 RhUL128(2) -2 1288 1626 339 
     rhUL130 -3 163675 164364 690 RhUL130 -1 1628 2359 732 
Rh160 3 165417 166082 666 rhUL132 -3 165406 166071 666 RhUL132 -2 3403 4068 666 
Rh159 1 164371 165351 981      RhUL148 -3 4134 5114 981 
Rh158 1 163705 164166 462      RhUL147 -3 5319 5780 462 
Rh158.1 2 163289 163654 366      RhUL146 -1 5831 6175 345 
          RhUL146b -3 6738 7064 327 
          Rh161.1 -3 7188 7520 333 
Rh161 -2 167130 167570 441      Rh161.2 -3 7602 8117 516 
Rh162 -2 167655 167960 306      RhUL145 -3 8202 8507 306 
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Rh163 -2 168378 168893 516      RhUL144 -3 8925 9440 516 
Rh163.1 3 168912 169268 357      Rh163.1 3 9459 9815 357 
Rh164 -1 169096 170388 1293      RhUL141 -2 9643 10935 1293 
Rh165 -1 170857 171288 432      Rh165 -1 11396 11827 432 
Rh165.1 1 170872 171312 441      Rh165.1 2 11411 11851 441 
Rh166 -2 171333 171857 525      Rh166 -2 11872 12396 525 
Rh166.1 1 171772 172080 309      Rh166.1 2 12311 12619 309 
Rh167 -1 171988 172491 504 Rh167 -1 166137 166766 630 Rh167 -1 12527 13030 504 
Rh168 -3 172745 173401 657 Rh168 -3 167020 167676 657      
Rh168.1 2 173495 173926 432 Rh168.1 1 167773 168204 432      
Rh169 -3 173501 174064 564 Rh169 -3 167779 168342 564      
Rh170 -2 174198 174764 567 Rh170 -2 168476 169042 567      
Rh171 -2 174768 175607 840 Rh171 -2 169046 169885 840      
Rh172 -2 175806 176336 531 Rh172 -3 170083 170613 531      
Rh171.1 3 175839 176213 375 Rh171.1 1 170116 170490 375      
Rh173 -2 176388 177515 1128 Rh173 -3 170665 171786 1122      
Rh174 -2 178695 179774 1080 Rh174 -2 172913 173992 1080      
Rh175 2 180470 180922 453 Rh175 1 174688 175140 453      
Rh176 -1 180619 181260 642 Rh176 -1 174837 175478 642      
Rh177 -3 181226 181669 444 Rh177 -3 175444 175887 444      
Rh178 -2 181320 182060 741 Rh178 -2 175538 176278 741      
     Rh178.2 -3 176224 176544 321      
Rh178.1 3 182280 182642 363 Rh178.1 2 176498 176932 435      
Rh178.3 2 182609 182971 363 Rh178.3 1 176827 177189 363      
Rh179 3 183231 183746 516 Rh179 2 177449 177964 516      
Rh180 -3 183347 183670 324 Rh180 -3 177565 177888 324      
Rh181 -1 183766 184272 507 RhUS1 -3 177988 178623 636      
Rh180.1 2 184121 184447 327 Rh180.1 2 178343 178735 393      
Rh182 -3 184502 185092 591 Rh182 -1 178725 179315 591      
Rh183 1 185590 185952 363 Rh183 1 179818 180180 363      
Rh184 -1 185617 186159 543 Rh184 -3 179845 180387 543      
Rh185 -3 187133 187645 513 Rh185 -1 181392 181904 513      
Rh186 -3 187934 188638 705 Rh186 -1 182193 182897 705      
Rh187 -3 188879 189559 681 Rh187 -1 183138 183821 684      
Rh188 -2 189657 190031 375 Rh188 -3 183913 184287 375      
Rh189 -1 190318 191163 846 RhUS11 -2 184574 185416 843      
Rh190 -2 191367 192149 783 RhUS12 -2 185621 186403 783      
Rh191 -1 191524 191856 333 Rh191 -1 185778 186110 333      
Rh192 -2 192207 192971 765 RhUS13 -2 186461 187225 765      
Rh193 -3 192977 193462 486 Rh193 -3 187231 187716 486      
Rh194 -1 193084 193917 834 Rh194 -1 187338 188171 834      
Rh195 -3 194048 194791 744 Rh195 -3 188302 189045 744      
Rh196 -3 194864 195622 759 RhUS14 -3 189118 189876 759      
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Rh197 -3 195728 196453 726 Rh197 -3 189982 190707 726      
     Rh196.1 -2 190262 190576 315      
Rh198 -2 196431 197255 825 RhUS17 -2 190685 191509 825      
Rh199 -1 197605 198216 612 RhUS18 -2 191615 192415 801      
Rh200 -2 198336 199121 786 Rh200 -3 192535 193320 786      
Rh201 -2 199182 199943 762 RhUS20 -3 193381 194142 762      
Rh202 -3 199991 200677 687 RhUS21 -1 194190 194876 687      
Rh203 -1 200797 202521 1725 RhUS22 -2 194996 196720 1725      
Rh204 -2 202680 204548 1869 RhUS23 -3 196879 198750 1872      
Rh205 3 202743 203504 762 Rh205 1 196942 197706 765      
Rh206 -3 202979 203326 348 Rh206 -1 197178 197528 351      
Rh208 3 204333 204650 318 Rh208 1 198535 198852 318      
Rh209 -3 204572 206002 1431 RhUS24 -1 198774 200204 1431      
Rh210 2 205019 205594 576 Rh210 3 199221 199796 576      
Rh211 -3 206363 208156 1794 RhUS26 -1 200565 202358 1794      
Rh212 -1 206818 207132 315 Rh212 -2 201020 201334 315      
Rh213 2 206909 207424 516 Rh213 3 201111 201626 516      
Rh214 2 208328 209314 987 Rh214 3 202530 203516 987      
Rh215 2 209660 210673 1014 Rh215 3 203862 204875 1014      
Rh216(1) 2 210809 211138 330 Rh216 3 205011 206012 1002      
Rh216(2) 1 211078 211809 732           
Rh217 -2 211704 212006 303 Rh217 -2 205907 206209 303      
Rh218 1 211882 212901 1020 Rh218 3 206085 207104 1020      
Rh219 -1 212671 212976 306 Rh219 -1 206874 207179 306      
     RhUS28(1) 3 207249 207635 387      
Rh220 1 213046 214497 1452 RhUS28(2) 2 207794 208711 918      
Rh220.1 -2 213093 213440 348           
Rh221 3 214653 215978 1326 RhUS29 1 208867 210192 1326      
Rh222 1 215128 215451 324 Rh222 2 209342 209665 324      
Rh223 1 215896 216717 822 Rh223 2 210110 210931 822      
Rh224 -2 216579 217196 618 Rh224 -3 210793 211410 618      
Rh225 1 216793 217278 486 RhUS31 2 211007 211492 486      
Rh226 1 217405 217965 561 RhUS32 2 211619 212179 561      
Rh227 -3 217463 217879 417 Rh227 -1 211677 212093 417      
Rh228 1 218098 218403 306 Rh228 2 212312 212623 312      
Rh228.1 -2 218655 219032 378 Rh228.1 -1 212880 213257 378      
Rh229 -2 219051 219506 456 Rh229 -1 213276 213731 456      
Rh230 -1 219127 221214 2088 RhTRS1 -3 213352 215439 2088      
Rh231 -2 220326 220631 306 Rh231 -1 214551 214856 306      
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Supplemental Figure 3. Comparison of host proteins contained in WT and ∆pp65ab virions. A) The total number 
of host proteins found in RhCMV WT and Δpp65ab virions and the overlapping proteins found in both samples are 
shown. B) All peptides and proteins found in WT and Δpp65ab virions as shown here separated into either host or 
viral proteins dependent on their origin. C) Host proteins with a minimum abundance of 0.25mol% of the total amount 
of host proteins were ranked by abundance into two groups, proteins that had significant abundance in WT virions 
and were not found in Δpp65ab virions (upper panel) and host proteins that were found in both virions, but with at 
least two fold higher abundance in the WT. D) Similar to C), host proteins were ranked by abundance, but only proteins 
are shown that were either present in Δpp65ab virions and not in the WT (upper panel) or host proteins that were 
found in both virions, but with at least two fold higher abundance in Δpp65ab. 
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Supplemental Figure 4. ∆pp65ab establishes primary and secondary infections and protects against super-
infection with ΔUS2-11.. A) Two RhCMV sero-negative male RM (RM1 and RM2) were infected s.c with 107 PFU 
of ∆pp65ab at day 1. CD4+ (blue) and CD8+ (red) T-cell responses were monitored in broncho-alveolar lavages (BAL) 
by intracellular cytokine staining (ICCS) at the indicated days using overlapping peptides of pp65ab and IE1/2) On 
day 659 the two animals were inoculated s.c. with 107 PFU of ∆US2-11gag (green dotted line) and the T cell response 
to SIVgag was measured in addition. Note the absence of a T cell response to SIVgag or pp65 and a lack of boosting 
of responses to IE1. C) On day 876, the two RM were inoculated with 107 PFU of WTgag (black dotted line) and the 
T cell response was monitored by ICCS. Note the appearance of de novo responses to SIVgag and pp65 and a boosting 
of the T cell response to IE1. D) On day 1107 the two RM were inoculated with 107 PFU of ∆pp65ab-rtn (blue dotted 
line). Using overlapping 15mer peptides a de novo response to SIVrev/tat/nef was detectable indicating super-
infection. Also note a boosting of the IE1 response but not of pp65 or SIVgag-specific responses.  
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Supplemental Figure 5. T cells induced by heterologous prime/boost vaccination with pp65b do not protect 
against super-infection with ∆US2-11. Three CMV-negative RM were vaccinated with 1mg of pND/pp65b and 
boosted with MVApp65b at 6 and 12 weeks after the initial vaccination (black). As controls three CMV-negative RM 
were vaccinated with the parental pND plasmid not expressing any antigen and boosted with WT MVA at 6 and 12 
weeks after the initial vaccination (green). At 18 weeks after the initial DNA vaccination both groups of animals were 
challenged with 107 PFU of ∆US2-11gag. The left two panels show the specific T-cell responses to pp65 whereas the 
right two panes show specific T-cell responses to SIV gag. T-cells were isolated from broncho-alveolar lavages (BAL). 
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Supplemental Figure 6. Pp65b-specific T cells induced in naïve RM after DNA prime and MVA boost 
vaccination show mostly effector memory (TEM) phenotype at the time of RhCMV ∆U∆V challenge. T cells were 
isolated from peripheral blood drawn from the three RM described in Figure 6 (Supplemental Figure 3) at the times 
indicated above each dot plot.  The memory phenotype of the total pp65b response was determined by flow cytometry 
using the cell surface markers CD28 and CCR7 as previously described [353]. 
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